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Executive Summary  
 
Background and objectives 
 
HIV is a significant contributor to child mortality in low and middle income 
countries.
1,2
 In Sub-Saharan African countries more than a thousand children are 
newly infected with HIV daily.
3
 Despite the rapid scale-up of services to prevent HIV 
transmission from mother-to-child (PMTCT services) in this region, poor service 
utilisation remains a major barrier. South Africa is signatory to the UNGASS 
declaration of commitment to provide universal access to antiretroviral (ARV) 
treatments for PMTCT, and to the UNAIDS target to eliminate mother-to-child 
transmission of HIV (MTCT) by 2015.
4,5
 Even though effective packages of 
interventions have been introduced to enable the virtual elimination of mother-to-
child transmission (eMTCT), the effectiveness of these interventions is ultimately 
influenced by the coverage of PMTCT services and retention rates as women 
progress through a cascade of PMTCT preventive, treatment and care services.  
 
Few studies evaluate the coverage of PMTCT cascade services and gaps in PMTCT 
programmes nationally.
6-8
 Although several targets have been set for PMTCT 
programmes, available data (routine programme data) used for tracking the 
achievement of these targets have limited validity. Thus in most high HIV prevalence 
countries (including South Africa), there is a lack of strong evidence on progress 
towards achievement of international targets. This study aimed to (i) measure 
national and provincial uptake of antenatal and early postpartum PMTCT cascade 
services and missed opportunities at each step of the PMTCT cascade services in 
South Africa, (ii) the study also aimed to explore health facility and individual level 
factors that explain geographical variations in the risk of mother-to-child HIV 
transmission and (iii) the last objective of the study assessed reasons for missed 
opportunities of early infant HIV diagnosis (EID) services. This is the first national 
study that provides estimates of uptake of antenatal and perinatal PMTCT cascade 
services using a national and provincial level representative sample.   
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Methods   
 
Two quantitative studies were carried out in randomly-selected facilities within all 
nine provinces of South Africa. First, a situational assessment of these randomly 
selected  facilities was undertaken using key informant (health care personnel) 
interviews and record reviews to ascertain guidelines and procedures for early 
identification of HIV-exposed infants (HEI), the coverage of early infant diagnosis 
services, the human resource capacity of the health system, and existing linkage and 
referral system for antenatal and postnatal PMTCT services. This was followed by 
the South African national PMTCT survey (SAPMTCTE) which involved a 
collection of infant blood samples and maternal interview data from mother-infant 
pairs (infants age 4-8weeks) attending six weeks immunisation service points in the 
selected facilities. Interviews were conducted with mothers to assess antenatal and 
peripartum PMTCT services received and maternal intention to request for infant 
HIV testing at six weeks immunisation visits. Data on gestational age at birth, infant 
birth weight and HIV status was extracted from the road-to-health-card (RtHC).  
 
The HIV status of mothers was determined from maternal report or enzyme 
immunoassay (EIA) test conducted on infants dried blood spots (DBS). A weighted 
analysis (weighted for sample size realisation and population live births) was 
performed to assess uptake of services along the PMTCT cascade. Mothers who 
either self-reported an HIV-positive status or had an EIA positive infant were 
classified as HIV-positive mothers. Perinatal ARV regimen coverage was calculated 
from the total number of HIV-positive mothers who received maternal 
azidothymidine (AZT) or HAART for any duration during pregnancy plus infant 
nevirapine (NVP)/AZT received at birth. Descriptive methods were used to analyse 
national availability of EID services and approaches for identifying HEI at the six 
weeks immunisation visit. Logistic regression assessed key factors influencing 
maternal intention to receive EID. Logistic regression was also used to explore 
individual, health facility and provincial level factors that explain variability in 
mother-to-child-transmission rates.  
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Results  
 
The study shows high (97.7%) uptake of antenatal HIV testing but substantial loss to 
follow-up on subsequent key steps along the PMTCT cascade. The study findings 
indicate that high attrition challenges the South African PMTCT programme with 
10.4% of mothers at six week visit reporting not to know their HIV-positive status; 
not receiving CD4 count test / test result  and dropout at referral for HAART 
accounting for a total of 22.6%  and 10% missed opportunities for HAART treatment 
respectively..  In total, 78% of all (known and unknown) HIV-exposed infants 
received both maternal and infant antiretrovirals (i.e. maternal AZT or HAART for 
any duration during pregnancy plus NVP/AZT at birth).  
 
Uptake of PMTCT cascade services varied between provinces - provincial uptake of 
CD4 count and maternal and infant ARVs (i.e. maternal AZT/HAART and infant 
NVP) ranged from 54%-89% and 65%-88%, respectively. Transmission rates also 
varied geographically ranging from 1.4% to 5.9%. Multivariate analysis of factors 
explaining geographical variations in mother-to-child-transmission rates identified 
two health system factors that are predictors of geographical variations observed in 
mother-to-child transmission, these are: low (<80%) provincial PMTCT cascade 
coverage (AOR 1.7, 95% CI 1.2 -2.6), and shortage of (≤2 health-care personnel 
doing VCT) health-care-personnel doing VCT (AOR 2.2, 95% CI 1.1 -4.3). Other 
significant factors associated with transmission include low (<2.5kg) birth weight, 
ARV regimens (receiving both maternal AZT/HAART and infant NVP v.s. receiving 
maternal only, infant only or no antiretrovirals (ARV)) and any breastfeeding. 
Achievement of the UNGASS universal PMTCT coverage target (≥80%) was 
associated with significantly lower (<3%) transmission rate. 
 
Our assessment of infant HIV testing services at immunisation service points 
indicates the majority (68%) of facilities in South Africa offer targeted testing that 
relies on maternal notification of infant HIV-exposure or the road-to-health-card 
(RtHC) to identify HIV-exposed infants for six weeks infant testing.  However, both 
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the RtHC and maternal reporting were poorly utilised. The HIV-exposure prevalence 
(32%) at six-week immunisation visits reported in our cross-sectional survey was 
similar with the HIV prevalence (29%) reported for pregnant women in the 2009 
antenatal survey.  Only 35% of known HIV-positive mothers intended to report their 
HIV-exposure at six week immunisation visit, and only 55% had RtHC that reflected 
their HIV-status. Thus facilities that use targeted approach  potentially missed 
opportunities of early testing on significant percentage (38%) of HEI.  Since the 
study offered provider-initiated counselling and testing to all infants, few of the 
infants actually missed HIV testing. In our study when PICT was offered to all 
mothers at six weeks immunisation visit, 95% of mothers agreed to give an infant 
blood sample for testing and to receive results. In regression analysis, poor maternal 
reporting for EID was associated with feeling discriminated, missing maternal/infant 
antiretrovirals, and inadequate knowledge about HIV transmission. 
 
Conclusion  
 
This assessment shows that South Africa is on track to meet the UNGASS universal 
access target (≥80%) for maternal and infant antiretroviral regimens. Contrary to 
previous reports (based on routine programme data), our study shows that ARV 
regimen coverage in South Africa is lower than the UNAIDS 90% effective ARV 
regimen target. Despite this, in three provinces that achieved the UNGASS (≥80% 
ARV regimen coverage) target, average transmission rate was significantly lower 
(<3%).  
 
The study demonstrates variations in mother-to-child transmission rates were directly 
related to variations in uptake of the PMTCT cascade services and gaps in health 
systems infrastructure (particularly human resource shortage). Geographical 
variations in human resource distribution and subsequent differences in uptake of 
PMTCT services contributed to significant geographical differences in mother-to-
child transmission. Strengthening the health system and reducing leakage at key 
dropout points /steps of the PMTCT cascade should be prioritized in order to 
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maximize the effectiveness of the PMTCT programme. The study identifies 
knowledge of HIV status, CD4 count, HAART initiation and early infant HIV 
diagnosis as key dropout points. The lack of on-site CD4 count service, gaps in 
courier and transportation systems and the CD4 count requirement for initiation of 
HAART are mentioned in the literature as the major barriers for low coverage of 
CD4 count and delay in HAART initiation. In light of the significant number (22.6%) 
of  HIV-positive mothers in this study whose eligibility for HAART was not assessed 
(and thus HAART was not initiated), this study supports the adoption of the WHO 
Option B treatment guideline in South Africa which removes the CD4 count 
requirement for initiation of HAART. However, though the adoption of the WHO 
Option B treatment guideline has removed the CD4 count requirement, there is still a 
need to improve access to HAART treatment (e.g. by emphasising on decentralisation 
of HAART initiation through nurse initiated HAART treatment) as dropouts at 
antiretroviral  referral points could pose major challenge for HAART initiation. Our 
findings on EID services indicate relying on identification of HEI for EID services 
through maternal request for testing or documentation on the RtHC contributes to 
lower uptake of EID services. Immunisation service points should give provider-
initiated counselling and testing (with maternal or infant HIV antibody testing to 
identify the HIV exposure status of infant) to six weeks mother-infant pairs with 
undocumented/unknown HIV status.   
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DEFINITIONS  
 
 Acceptability of PMTCT service: the degree to which the PMTCT service meets 
the social and cultural needs and standards of the community, which in turn 
influences uptake of PMTCT service. 
9
 
 
Access (to health services): the perceptions and experiences of people as to their 
ease in reaching health services or health facilities in terms of location, time, and ease 
of approach.
10
 
 
Affordability refers to the direct (doctor’s fees, travel and medical costs) and indirect 
costs (e.g. absenteeism from work) that affect access to service.
11
  
 
Availability of service - we use this term in particularly to refer to the delivery (or 
availability) of services at peripheral level health care units (i.e. primary health care 
units).
10
 
 
Caregiver  
The person who feeds and looks after the child most of the week. This includes 
parents, legal guardians, family members, nannies, or friends who routinely feed, 
bath, change nappies, or in particular reference to this study, bring child for routine 
health services. 
Coverage: the extent of interaction between the service and the people for whom it is 
intended. Coverage is not to be limited to a particular aspect of service provision, but 
ranges from resource allocation to the achievement of the desired objective.
12
 
Early (six weeks) HIV Transmission rate amongst HIV-exposed infants 
Number of DNA PCR positive infants and EIA (enzyme immunoassay) positive 
infants divided by the number of EIA positive infants at 4-8 weeks. 
 
Effective ARV regimen coverage 
Effective coverage is defined as the magnitude of the realised health gain from the 
intervention relative to the potential health gain possible with the optimal 
performance of the providers for a given health system. 
 
Mother-infant pairs are considered as they received effective ARV regimen if eligible 
mothers (CD4 ≤350) received HAART and non-eligible mothers received ARV 
prophylaxis from 14 weeks (or earlier if receiving HAART) of pregnancy through 
delivery. Infants should receive daily dose of nevirapine for at least 6 weeks (not 
breastfeeding) or as long as breast milk is given. (See definition of total ARV regimen 
coverage) 
 
Health care personnel 
Health care providers and health care workers. 
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Health care provider 
Any person providing health services in terms of any law, including in terms of the: 
 Allied Health Professions Act, 1982 (Act No.63 of 1982) 
 Health Professions Act, 1974 (Act No. 56 of 1974) 
 Nursing Act, 2005 (Act No. 33 of 2005) 
 Pharmacy Act, 1974 (Act No. 53 of 1974) and 
 Dental Technicians Act, 1978 (Act No. 19 of 1979) 
 
Health care worker 
Any person who is involved in the provision of health services to a user, but does not 
include a health care provider. This includes lay counsellors and community 
caregivers. 
 
HIV-exposed infant 
An infant born to an HIV-positive mother and/or having a positive HIV antibody test 
result using DBS EIA.  
 
HIV-infected infant 
An HIV-exposed infant having a positive HIV DNA PCR result. 
 
HIV-uninfected infant 
An HIV-exposed infant having a negative HIV DNA PCR result.       
 
HIV-positive mother 
Defined for this survey as mothers whose infants have a positive DBS EIA.  
 
HIV status unknown  
Refers to people (including children) who have not taken an HIV test or who do not 
know the result of their test. 
 
Infant 
A child from birth to 12 months of age. 
 
Mother-to-child transmission (MTCT) 
Transmission of HIV from an HIV-positive woman during pregnancy, delivery or 
breastfeeding to her child. The term is used because the immediate source of the 
infection is the mother, and does not imply blame on the mother. 
 
MTCT Rate 
Defined for this survey as a numerator of HIV-positive infants (PCR positive) and 
denominator of HIV-exposed infants (infant EIA antibody positive).  
 
PMTCT-cascade   
For the purpose of this study, PMTCT cascade is defined as the following 
interventions: maternal HIV-testing and receiving result; if mother is HIV-positive: 
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receiving CD4 count test, and CD4 count test result; and appropriate ARV 
prophylaxis/treatment for mother and infant.  
 
Quality of PMTCT  service 
Quality of PMTCT service refers to the degree to which PMTCT services are 
provided with high standard and excellence as set in PMTCT protocols/ guidelines, to 
ultimately increase the likelihood of desired health outcomes for mother-infant pairs.  
 
Total ARV regimen coverage  - Maternal azidothymidine (AZT) or HAART 
received for any duration during pregnancy plus infant nevirapine (NVP)/AZT 
received at birth (maternal and infant ARV prophylaxis/ HAART) was considered as 
a marker for total perinatal ARV regimen coverage. 
 
Universal access/coverage –Particularly for this thesis, this term is  defined as ≥80% 
total ARV regimen (maternal AZT or HAART received for any duration during 
pregnancy and infant NVP/AZT taken at birth) coverage.  
 
Uptake of PMTCT services   
Uptake refers to utilisation of PMTCT service by mother-infant pairs. For this study 
the following PMTCT cascade uptake measures are defined (of which the receiving of 
both maternal and infant ARV is considered as the perinatal PMTCT cascade 
coverage): 
 
Uptake of maternal antenatal HIV testing - refers to the proportion of mothers   
interviewed at six weeks immunisation visit who reported receiving antenatal   HIV 
testing.  
 
Uptake of maternal HIV test result: refers to the proportion of  interviewed 
mothers who reported receiving antenatal HIV test result.   
 
Uptake of maternal CD4 testing result - refers to the proportion of  infant EIA 
positive or reported positive mothers who had CD4 count test and received  result 
during antenatal period. 
 
Uptake of maternal ARV prophylaxis - refers to the proportion of infant EIA 
positive or reported positive mothers who reported receiving antiretroviral 
prophylaxis  during pregnancy. 
 
Uptake of maternal HAART - refers to the proportion of infant EIA positive or 
reported positive mothers with CD4 count ≤350 who reported receiving ARV 
treatment during pregnancy. 
 
Uptake of Infant ARV prophylaxis - refers to the proportion of infant EIA positive 
or reported positive mothers whose infant received ARV prophylaxis immediately 
after delivery  
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Uptake of Maternal and infant ARV/total ARV regimen coverage   - refers to the 
proportion of infant EIA positive or reported positive mothers who reported both 
mother and infant received ARVs (i.e. maternal ARV/HAART and infant ARV 
prophylaxis) 
 
Utilization (of health services): experience of people as to their receipt of health 
care services of different types. 
10
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Chapter 1: INTRODUCTION, AIM AND OBJECTIVES  
 
1.1. Introduction  
 
HIV is a significant contributor of child morbidity and mortality in developing 
countries.
1,2
 An estimated 390 000 children aged less than 15 years old globally were 
newly infected with HIV in 2010; over 90% of them through mother-to-child 
transmission.
13
 In sub-Saharan African countries more than a thousand children are 
newly infected with HIV every day. Without treatment, about half of these infected 
children will die before their second birthday.
14 
The risk of MTCT without any 
intervention ranges from 15% to 30% in non-breastfeeding population and 25% to 
35% in breastfeeding population with breastfeeding till 6 months.
15
 With specific 
interventions in non-breastfeeding populations, the risk of MTCT can be reduced to 
less than 2%, and to 5% or less in breastfeeding populations.
16,17
 
 
International policies emphasise on a four-pronged approach to prevent mother-to-
child transmission, which includes: 1) Primary prevention of HIV infection among 
women of childbearing age; 2) Preventing unintended pregnancies among women 
living with HIV; 3) Preventing HIV transmission from a woman living with HIV to 
her infant; and 4) Providing appropriate treatment, care and support to mothers living 
with HIV and their children and families.
4
 
 
In 2001, at the United Nations General Assembly Special Session (UNGASS), 
countries committed themselves for a universal coverage of PMTCT programmes and 
to halving of HIV infection in children by 2010. 
4
 South Africa is one of the signatory 
countries to the UNGASS Declaration. Since this declaration, South Africa has taken 
several steps to scale-up PMTCT interventions: 
 The PMTCT programme was piloted in 2001 in 18 pilot sites. This was followed 
by full scale-up of the programme in all primary health care centres across all 
nine provinces. The programme started with single dose nevirapine (NVP) for 
mothers at the onset of labor and to their new-born within 72 hours after birth.  
The PMTCT programme package also included antenatal voluntary counselling 
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and testing, infant feeding counselling, provision of free formula milk for women 
who choose not to breastfeed and infant rapid antibody testing at 12-18 months. 
In 2005, PCR testing at 6 weeks was added in the package of care for the PMTCT 
programme.
18
  
 In 2008, the PMTCT guidelines were revised to include the initiation of AZT at 
28 weeks with single dose NVP at the onset of labor for mothers with CD4 count 
greater than 250 cells/µl, and initiation of maternal HAART for mothers with 
CD4 count less than or equal to 250 cells/µl or with stage IV disease. In addition, 
single dose nevirapine and 7 days AZT was  recommended for HEI immediately 
post-delivery.
18  
 In April 2010, the Department of Health revised the PMTCT guideline to 
incorporate new protocols in line with the WHO 2010 (Option A) guideline. The 
new protocol recommended initiation of AZT at 14 weeks to pregnant mothers 
with CD4 count above 350 cells/µl, with nevirapine during labour and single dose 
of Tenofovir (TDF) + Emtracitabine (FTC) during or immediately post-delivery. 
For women with CD4 cell counts less than or equal to 350 cells/µl provision of 
maternal HAART is recommended. Infant NVP is given daily for at least 6 weeks 
(if on HAART or not breastfeeding) or until one week after cessation of 
breastfeeding. Immediate (irrespective of CD4 count) initiation of ARV treatment 
is recommended for HIV-infected infants diagnosed.
19 
 Recently, in April 2013, South Africa adopted the WHO Option B treatment 
guideline. This guideline recommends  initiation of HAART for all HIV-positive 
pregnant mothers (regardless of CD4 count) as soon as possible after diagnosis 
until one week after cessation of breastfeeding, unless mother requires treatment 
for her own health in which case treatment will continue for life.
20 
 
In 2011, UNAIDS recommitted countries to eliminate new HIV infections among 
children by 2015.
5 
The achievement of the UNAIDS goal relies on a successful 
implementation of a set of PMTCT interventions called the PMTCT cascade.
15 
In 
sub-Saharan African countries despite the rapid scale-up of PMTCT services, poor 
service utilisation remains a major barrier for prevention of mother-to-child 
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transmission.
21
 This study analyses coverage, uptake and quality of ‘the PMTCT 
cascade service’– defined as - a  sequence of steps needed to deliver preventive, 
treatment and care services to HIV-infected mothers and their infants to prevent 
mother-to-child HIV transmission and infant mortality.   
 
The paper is organized in 5 sections. The first chapter gives a general introduction to 
the problem, context and rationale of the study and presents the research questions, 
aims and objectives of the study. The second chapter reviews existing literature. The 
third chapter elaborates on methods and materials used. Chapter four presents the 
results of the study in three sub-sections in the form of manuscripts for publication. 
Finally, chapter five presents the conclusion and recommendations of the study. 
 
1.2. Conceptual framework of the research  
 
In order for PMTCT programmes to be successful, a number of steps have to be 
undertaken (fig 1). In particular all pregnant women should receive:  
(1)  Antenatal care  
(2) Good quality antenatal HIV counselling and testing including receipt of HIV test 
results; 
If HIV-positive: 
(3) CD4 cell count  
(4) Effective maternal and infant ARV regimen; 
(5) Appropriate infant feeding counselling;  
(6) Continuity of care, including follow-up counselling; continuous support for 
optimal infant feeding (regardless of feeding choice) and linkages to other services, 
such as neonatal and child health care, as well as HIV care and treatment, and;  
(7) Infant PCR testing at or before 6 weeks (linked with the first immunisation), after 
cessation of breastfeeding, and a rapid test at 18-months.
22
  
Loss at one or more of these PMTCT cascade steps diminishes effectiveness of the 
PMTCT programme.  
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Several factors could influence uptake of the PMTCT cascade services including 
health system factors that affect service uptake, user-related/ individual factors and 
broader socio-cultural factors.  Health system/structure issues such as staffing level, 
availability and cost of antiretrovirals, capacity of health personnel to prescribe 
appropriate regimens, loss of laboratory specimens being transported from facility to 
laboratory (or loss of result back to facility); shortage of supplies (in facilities), 
failure to follow‐up mother or infants’ status, and giving wrong information/sub-
optimal quality of counselling could lead to loss /dropout from the PMTCT cascade. 
Individual factors such as mothers’ knowledge of PMTCT, socioeconomic and 
demographic characteristics, pregnancy history, as well as broader socio-cultural 
factors such as fear of stigma, lack of interest, cultural, family and social barriers are 
factors that influence successful completion of the PMTCT cascade services. 
3,23-26
 
 
Figure 1: The PMTCT cascade 
 
 
1.3. Problem statement and motivation for the study  
 
The achievement of high coverage and uptake of services along the PMTCT cascade 
is crucial for national and international mother-to-child transmission elimination 
Since 04/2010: initiation of HAART for CD4<350 ; if 
CD4>350 -> AZT at 14 wks 
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goals. South Africa has set targets to achieve above 95% uptake of PMTCT services 
along the cascade, by year 2015.
27
 Available data is limited to track progress towards 
achievement of these targets.  Routine programme data obtained from the district 
health information system (DHIS) does not provide information about the proportion 
of women who move successfully through each step of the PMTCT cascade. This is 
because, DHIS provides aggregated data and lacks a system (unique identifier) to 
link follow-up and repeat services given to mother-infant pairs. Hence, routine 
programme data (DHIS) cannot be used for measuring loss to follow-up of mother-
infant pairs at each level in the PMTCT cascade. Furthermore, DHIS data is paper-
based in most provinces of South Africa and relies on accurate documentation of 
information at facility level, followed by accurate transcription and transfer of this 
data to district, provincial and national levels. Studies indicate often, due to 
inadequate monitoring of data collation, the quality of the DHIS data is poor, 
resulting in questionable validity.
21,28
 A study that compared PMTCT data submitted 
to DHIS with data on PMTCT registers (for  reports in the same time period) in 3 
large districts of KZN indicated that data elements for key PMTCT indicators was 
not reported in 49.7% of the time and were “inaccurate” 87% of the time.28 The same 
study further reports that the primary site for a breakdown in accurate transfer of data 
is during the tallying and collation of data from the PMTCT registers. Therefore, 
DHIS data currently has limited usefulness to measure PMTCT programme 
effectiveness and uptake of PMTCT services along the cascade.  
 
A small number of periodic surveys are conducted in South Africa to gather data on 
health and HIV related indicators (table 1).  The national antenatal survey, conducted 
annually in the 52 districts of  South Africa, provides  measures of HIV prevalence 
among pregnant women at district, provincial and national level.
29
 The Human 
Science Research Council (HSRC) national HIV prevalence, incidence and 
behaviour and communication survey measures HIV prevalence in the general 
population and among children. The 4
th
 round of the HSRC survey gathered more 
data on access to health services and health status of infants and their mothers. This 
data is not fully released yet. In the last three consecutive HSRC surveys (2002, 
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2005, and 2008), the sample size of infants participating in the study was not 
adequate  to allow  HIV prevalence (or mother-to-child HIV transmission) 
measurement among infants. Also no data on PMTCT service related indicators  was  
collected in the last three consecutive HSRC surveys. 
30
  The demographic health 
survey (DHS) and the general household survey (GHS)   gather national data on 
general health indicators, but no PMTCT related data is gathered in either survey. 
31,32
  
Our study is the first study globally that attempts to provide a national estimate of 
uptake of services along the PMTCT cascade using a national and provincial level 
representative sample. The study aims to give a baseline national and provincial level 
estimate of uptake of PMTCT services that can be used for tracking progress towards 
achievement of national and international targets.   
 
Table 1:National surveys assessing maternal and child Health and /or HIV related indicators 
National 
surveys 
assessing 
maternal 
and child 
Health and 
/or HIV 
key maternal and 
child measures 
assessed 
HIV 
variables 
assessed sample size 
geographi
cal unit 
where 
estimates 
are made 
periodicit
y of 
survey 
ANC 
national 
survey
29 
Syphilis prevalence 
among pregnant women 
HIV 
prevalence 
among 
pregnant 
women 
large sample 
size (33446 
pregnant 
women) 
National, 
provincial 
and district 
level Annual 
the HSRC 
South 
African 
National 
HIV 
Prevalence, 
Incidence, 
Behaviour 
and 
Communicat
ion 
Survey
30 
 
 
Hospitalization history 
and health status of 
children 
HIV 
prevalence   
among 
children; 
HIV 
testing 
among 
reproducti
ve age; 
HIV 
knowledge 
and 
behaviour 
Not adequate 
sample size 
for measuring 
MTCT among 
infants 
(sampled 
3988 total 
children  in 
2002); 
 National  
Conducte
d every 3 
years 
(2002, 
2005, 
2008) 
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SA DHS  
2003
31 
Neonatal, infant, and 
child  mortality ; 
Vaccinations ; 
Prevalence and 
treatment of acute 
respiratory infection, 
and diarrhoea; Feeding 
practices; 
Maternal mortality 
ratio; Antenatal care; 
Tetanus toxoid 
vaccination; Iron 
tablets/anti-malarial 
drugs; Place of delivery; 
Assistance during 
delivery; Characteristics 
of delivery; Delivery 
complications; 
Problems in accessing 
health care; fertility 
preferences ; 
contraception use; Use 
of smoking tobacco 
knowledge 
of 
HIV/AIDS 
and sexual 
behaviour 
among 
youth and 
adult 
large sample 
sizes (7756 
households) 
National 
(designed 
to give 
results by 
province, 
race and  
urban/rural
) 
conducted  
every 5 
years 
the GHS
32 
 Teenage pregnancy, 
Health service 
utilization and quality  none 
 Large sample 
size (>25000 
households) 
 National, 
provincial 
and district 
level Annual 
 
The study was conducted at six weeks immunisation visit targeting 4-8 weeks old 
infants brought for six weeks immunisation. Hence, we measure uptake of PMTCT 
services for services provided during pregnancy and early postpartum (4-8 weeks of 
infant age) period, whilst we do not assess PMTCT services provided during the late 
(> 4-8weeks) postnatal period. 
 
The study has two components: a situational assessment preceding the main survey 
that aimed to assess the coverage of early infant HIV diagnosis service and capacity 
of health system to provide EID services. This was followed by a PMTCT survey 
which entailed collection of infant blood samples and maternal interview data from 
mother-infant pairs (infant age 4-8weeks) attending 6 weeks immunisation service.  
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1.4. Research questions 
1) What is the national uptake of antenatal and perinatal services along the PMTCT 
cascade? Are there dropout points along the PMTCT cascade?  Is South Africa on 
track to achieve international targets? 
2) What are the health facility and individual level factors that explain geographical 
variations in mother-to-child transmission rate in South Africa?  What influence 
does PMTCT service coverage have on transmission rate? 
3) What are the challenges and gaps in implementing early infant diagnosis services 
at six weeks immunisation visits of primary health care facilities in South Africa? 
What percentage of facilities provide EID services at immunisation service 
points? What approach do facilities use to identify HIV-exposed infants from six 
weeks immunisation visits? What are the factors that influence maternal intention 
for receiving six weeks EID service? 
 
1.5. Aim and specific objectives 
 
1.5.1. Aim 
 To assess uptake, and quality of PMTCT services in South Africa  
 
1.5.2. Specific objectives of the study 
1. Determine national uptake of antenatal and perinatal PMTCT cascade services 
and missed opportunities for PMTCT services 
2. Determine health facility and individual level factors that explain geographical 
variations in mother-to-child transmission. 
3. Determine reasons for low uptake of  early infant diagnosis services in South 
Africa 
 
1.6. Significance of the study  
 
This study provides the first national (for South Africa) baseline estimate of uptake of 
services along the PMTCT cascade at a provincial and national level.  These results 
can be used to track progress towards achievement of national targets set for steps 
within the PMTCT cascade. The study highlights gaps/missed opportunities along the 
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PMTCT cascade that policy makers, managers and health facility staff could use to 
plan and prioritize strategies to address identified gaps in the coverage and uptake of 
the PMTCT programme.   
 
The situational analysis component provides a comprehensive assessment of gaps and 
challenges in the implementation of EID services within the routine primary health 
care system. This component reports on provision of EID services at six weeks 
immunisation visits and analyses challenges and gaps in identifying and offering EID 
services to HIV-exposed infants at six weeks immunisation visits.  Given that 
PMTCT has been a high priority in the international and national response against 
HIV/AIDS, this study can give baseline data that can be used to monitor the impact 
of resources channelled into PMTCT interventions to increase uptake and quality of 
PMTCT services.   
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Chapter 2: LITERATURE REVIEW  
 
2.1. Burden of HIV infection in women and children and mother-to-child 
transmission  
 
HIV/AIDS is a leading cause of morbidity and mortality among women of 
reproductive age (15-49) worldwide.
13
 According to UNAIDS estimate half of the 34 
million people living with HIV globally are women of reproductive age.
3
 Women in 
sub-Saharan African countries constitute more than half (59%) of the people living 
with HIV/AIDS in the region.
3
 The HIV prevalence trend among pregnant women in 
sub-Saharan African countries has showed little or no decline in the past 15 years.
3 
 
 
HIV infection in children accounts for a significant proportion of child morbidity and 
mortality worldwide. 
1,2,33
 In 2010 an estimated 390,000 children (under 15 years) 
contracted new HIV infections globally.
3
  Although significant progress has been 
made in recent years, reducing new infant HIV infections from the peak of 560,000 
in 2002/03 to 390,000 in 2010, the rate of the decline particularly in sub-Saharan 
African countries is not sufficient enough to eliminate new infant HIV infections 
worldwide.
3
 The global plan to eliminate new HIV infections among infants requires 
reduction of the number of new infections to below 5% (<43,000 new infections) by 
2015.
5
  
  
HIV is one of the leading causes of death among children in Southern African 
countries. 
1,2,33
  In 2009, death due to HIV among children under 5 years was 
estimated to be 162,000 globally.
33
 HIV/AIDS related child (under 5 years) mortality 
rate in 2009 in the African region is estimated at 198 per 100,000 population.
34
 The 
Millennium Development Goals aim to reduce the death due to HIV among children 
by half in order to reach to the global target of reducing HIV related child deaths to 
below 81,000 by 2015.
3,35
 
 
There is significant variation within regions in HIV prevalence trends among 
children and women of reproductive age group. In high income countries, the advent 
of highly active antiretroviral therapy, caesarean section, the utilisation of 
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appropriate technology, and better resource allocation has enabled the virtual 
elimination of mother-to-child transmission of HIV, reducing transmission rates to 
<2%. In most resource-rich countries infant HIV infection is a sentinel health 
event.
36,37
 For instance, in the US, only about 67 infants were born HIV-infected in 
2005.
36
 Whilst in developing countries mother-to-child transmission is cause for 
significant proportion of infant morbidity and mortality.
37
 According to UNAIDS 
estimate, 90% of the 1,800 new infant HIV infections and 1,400 HIV related 
illnesses occurring among children everyday occur in the developing world.
38 
 
 
In South Africa three times as many young women (13.6%) aged 15 to 24 years are 
living with HIV as young men (4.5%).
13
 According to the 2011 antenatal survey, the 
overall national HIV prevalence among antenatal women aged 15-49 years is 
29.5%.
29
 According to the antenatal survey findings, the HIV prevalence over the last 
three surveys has stabilised around this level. In 2008 2009, and 2010 the HIV 
prevalence was 29.3% , 29.4%  and 30.2% respectively. 
29
 However, there are 
variations in HIV prevalence rates across provinces. In 2011, the Northern Cape 
reported the lowest estimate of 17.0% while KwaZulu-Natal had the highest 
antenatal HIV prevalence in the country at 37.4%.
29
 Mpumalanga has shown an 
increase in HIV infection from 35.1% in 2010 to 36.7% in 2011. 
29
  
 
Based on the above figures (antenatal HIV prevalence of 29%), it is estimated that 
close to 300,000 babies in South Africa are born exposed to HIV. 
29
 Without access 
to a programme to prevent mother-to-child transmission of HIV, around 90,000 
(approximately 30%) of these babies will be HIV-infected every year by age six 
weeks.
15
 Routine PCR testing laboratory data for infants aged <2 months indicates 
mother-to-child transmission in 2009 was 11% nationally, ranging between 8.1% (in 
Western Cape) and 13.1% (in Limpopo).
39
 With the estimated 11% mother-to-child 
transmission rate, annually 33,000 infants become HIV-infected perinatally. The 
2010 report from routine district health information system estimates a slightly 
higher (40,000) number of HIV-infected children.
3
 With comprehensive PMTCT 
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interventions the neonatal infection rate could be reduced to less than 5% (<15,000), 
thus saving between 18,000 and 25,000 lives annually.  
2.2. Global PMTCT targets and strategies  
 
Prevention of mother-to-child transmission programmes influence the achievement 
of three MDG goals declared by the global health community: MDG 4 aims to 
reduce the mortality rate among children under 5 by two thirds; MDG 5 aims to 
reduce the maternal mortality ratio by three quarters; and MDG 6 targets to halt and 
begin to reverse the spread of HIV.
35
 The 2001 UNGASS declaration also commits 
the 189 WHO signatory countries to reduce the proportion of infants infected with 
HIV by half in 2010 and to ensure universal access (greater than 80% coverage) to 
effective antiretroviral treatment, voluntary counselling and testing and provision of 
continuum of care.
4
 Achieving these targets require adequate resource allocation and 
an emphasis on provision of high quality PMTCT services. 
 
In 2005 an ambitious target was set by a high-level global partners forum in Abuja to 
attain an HIV-free and AIDS-free generation worldwide.
40
 The United Nations 
General Assembly High-level Meeting on AIDS in June 2011 further endorsed this 
goal by adopting the political declaration on HIV/AIDS to eliminate new HIV 
infections among children by 2015.
5
  Twenty two countries (India and 21 countries 
in sub-Saharan Africa) with a high burden of MTCT have been identified as priority 
countries for intensified support to achieve the UNAIDS HIV elimination goal. 
5
 
With the endorsement of the new infant HIV infection elimination goal, countries 
target to increase coverage of PMTCT services to  ≥95%.5,41 
 
In order to achieve the MDG and UNAIDS goals, the UNGASS four pronged 
strategy is recommended which includes the following comprehensive PMTCT 
services: (i) primary prevention programmes to avoid HIV infection among women 
in reproductive age; (ii) provision of an integrated reproductive health programme, 
including provision of family planning to avoid unintended pregnancies; (iii) the 
routine offer of HIV counselling and testing at antenatal clinic, enrolment into 
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PMTCT programme and provision of ARV treatment/prophylaxis and postnatal 
follow-up/support for infant feeding; and (iv) treatment and care of HIV-infected 
infants and their mothers.  
  
All four components of the UNGASS strategies need to be implemented in order to 
achieve   the PMTCT goals.  However current evidence shows PMTCT programmes 
are usually focused on the third and fourth prongs of UNGASS strategies and often 
neglect the first two prongs that are very crucial for elimination of new infant HIV 
infections. For instance, the 2009 UNAIDS report for low and middle income 
countries indicate whilst the coverage of antiretroviral medications for prevention of 
mother-to-child transmission has increased from 15% in 2005 to 53% in 2009, the 
contraceptive prevalence in sub-Saharan African countries remains low at 25%.
13
 
Emphasising the need for a comprehensive programme, a demographic model 
developed by Mahy et al, indicates even if effective antiretroviral treatments are 
provided using the 2010 WHO guidelines to 90% of HIV-positive mothers 
worldwide, the number of new infant infections cannot be reduced to elimination 
level by 2015, unless all four UNGASS prongs are implemented and the following 
progress is achieved: new HIV infections among reproductive women is reduced by 
half, unmet family planning needs are eliminated, the duration of breastfeeding is 
limited to 12 months and coverage of effective antiretrovirals  is increased to 90%.
42
 
 
2.3. Review of previous and current PMTCT antiretroviral guidelines  
 
The first WHO recommendation to use short course ARV regimens to prevent 
mother-to-child transmission programme was issued in 2000 after evidence showing 
provision of short course ARV prophylaxis for HIV-positive pregnant mothers and 
their new born could result in a two to three fold reduction in mother-to-child 
transmission rates.
43-45 
Following this finding, WHO recommended provision of 
azidothymidine (AZT) alone or in combination with lamivudine (3TC) or single dose 
nevirapine (sdNVP) to HIV-positive pregnant mothers for prevention of mother-to-
child transmission.
45
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Most PMTCT programmes in developing countries were launched with the 
affordable and simple regimen single dose nevirapine (sdNVP) given at labour to the 
mother and to the infant within 72 hours after birth. However although sdNVP was 
less expensive and easy for scale up at national level, studies that examined the 
efficacy of sdNVP identified that single dose NVP only target transmission during 
labour and delivery and does not prevent antenatal and postnatal transmission; whilst 
dual therapy (AZT +sdNVP) given from 28 weeks of pregnancy till after 1 week of 
child birth was found more efficacious in preventing antenatal and early postnatal 
transmission.
16,46-48
 Exposure to single dose maternal and infant NVP was also 
associated with increased occurrence of viral resistance. The HIVNET 012 study 
detected viral strains resistant to NVP at 6–8 weeks postpartum among 25% of 
women who received sdNVP.
49
 The SAINT study in South Africa found a 67% rate 
of NVP resistance at four weeks postpartum among women who had received two 
doses of NVP.
50
 Other studies showed adding up to a week of postpartum tail of 
twice-daily AZT/3TC to sdNVP might reduce the risk of resistance.
51
  
 
Following the above findings the WHO guideline was updated twice in 2004 and 
2006.
52,53
 The 2004 revised guideline recommended to give maternal AZT from 28 
weeks of gestational age and a one week infant prophylaxis in addition to sdNVP in 
order to prevent antenatal, labour and early postnatal transmission. The 2006 revised 
guideline added a one week maternal postpartum AZT for the mother in addition to 
the regimens recommended in the 2004 guideline. The 2006 guideline also 
recommended lifelong ART for women with CD4 counts ≤200 cells/µl or stage 3 or 
4 clinical diseases.  
 
Although these guidelines that recommended initiation of ARV prophylaxis from 28 
weeks were distributed in 2004 to all national authorities, several years later many 
developing countries did not have adequate infrastructure to shift from sdNVP 
treatment to combination therapy for prevention of mother-to-child transmission.
52
  
The WHO guidelines also suggested countries consider readiness of their health 
system infrastructure before implementing the dual therapy guideline. Therefore, in 
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many sub-Saharan African countries sdNVP continued to be used as an interim 
measure while steps were being taken to enable more effective regimens to be 
delivered. 
52
  Currently, although many countries have shifted to a combination 
therapy for prevention of mother-to-child transmission, reports from low and middle 
income countries indicate significant health system and infrastructural problems still 
challenge the successful implementation of the PMTCT programme.
24,25,54
 
 
In most provinces of South Africa sdNVP was the antiretroviral choice of treatment 
for prevention of mother-to-child transmission until 2008. In 2008 the national 
guideline was reviewed in accordance with the WHO 2006 guideline and 
recommendation was made to provide AZT from 28 weeks until delivery and 7 days 
infant post-exposure ARV and single dose NVP for HIV-positive pregnant mothers 
and their infants.
18
  
 
Single dose nevirapine still continues to be used in some settings in developing 
countries. In 2010, thirty three countries globally reported that sdNVP was given for 
PMTCT mothers.
3
 However, the overall percentage of women globally receiving 
sdNVP has significantly reduced from 49% in 2007 to 11% in 2010.
3
 The 2010 
WHO guideline states that sdNVP should be phased out from all countries.
20
   
 
The new WHO guideline released in 2010 recommends two options (Option A or 
Option B) for prevention of mother-to-child transmission. Option A recommends 
initiation of HAART for all women who have CD4 cell counts of ≤350 cells/ µl, 
irrespective of WHO clinical staging, and for all women in WHO clinical stage 3 or 
4, irrespective of the CD4 cell count.  HIV-infected pregnant women who do not 
need HAART for their own health are recommended to start ARV prophylaxis from 
as early as 14 weeks of gestation (second trimester) or as soon as possible thereafter. 
For infants receiving breast milk, daily administration of infant NVP is 
recommended from birth (within 6−12 hours) or as soon as feasible thereafter, until 1 
week after all exposure to breast milk has ended or, if breastfeeding stops before the 
age of 6 weeks, for a minimum of 4 to 6 weeks following birth.
20
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Option B recommends provision of HAART to all HIV-infected pregnant women 
irrespective of CD4 count or clinical stage starting from as early as 14 weeks of 
gestation (or as soon as possible thereafter) until delivery, or, if breastfeeding, until 
one week after all infant exposure to breast milk has ended. In this option, 
irrespective of the mode of infant feeding, it is recommended that maternal HAART 
should be coupled with daily administration of NVP (or twice-daily AZT) to the 
infant from birth (within 6−12 hours) or as soon as feasible thereafter until 4 to 6 
weeks of age.
20
   
 
Recently WHO announced Option B+ as an alternative treatment option for 
preventing mother-to-child transmission. This option recommends initiation of 
lifelong HAART to all HIV-positive pregnant mothers irrespective of CD4 count or 
clinical staging.
55
 The evidence base on ethics, medical safety, economic and 
programme feasibility of Option B+ is sparse.
56
 Currently most African countries 
have adopted either Option A or Option B treatment guidelines, whilst Malawi, and 
more recently Rwanda, have adopted Option B+ treatment guideline.
57,58
 The new 
WHO guidelines are believed to be a major paradigm shift for PMTCT. The 
effectiveness of these options however remains to be assessed in operational settings 
rather than in clinical trials settings.   
 
2.3.1. Current evidence on efficacy of antiretroviral regimens and rates of 
mother-to-child transmission  
 
Prior to the adoption of the WHO 2006 guidelines, published scientific evidence and 
guidelines (particularly from Africa and Asia) focused on prevention of mother-to-
child transmission occurring during labour and delivery. Whilst recently, with 
increasing evidence showing greater contribution of breastfeeding for mother-to-
child transmission, more studies are exploring the efficacy of antiretrovirals  for 
prevention of  postnatal transmission.  
 
Available evidence shows high transmission rate is associated with incident 
infections or untreated (not receiving antiretroviral prophylaxis/treatment) infections. 
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Transmission with incident infections (new infections occurring during pregnancy or 
breastfeeding) are estimated to be as high as 30% during peripartum and 28% 
postnatally within 6 months of maternal infection if no antiretroviral treatment is 
received.
59
 Based on a number of randomized and non-randomized studies the 
peripartum (in-utero and intrapartum) transmission rates when no 
prophylaxis/treatment is given from several reports ranges from 15.3%-25.5%.
43,47,59-
62
 The  Petra study conducted in Tanzania, South Africa and Uganda in a 
breastfeeding population reported 15.3% transmission rate at 6 weeks postpartum in 
the placebo (not received any prophylaxis or treatment) arm of the study.
60
 Other 
studies conducted in formula feeding populations in US and France, and Thailand 
reported 25.5% and 18.9% in-utero transmission rates respectively among groups 
that did not receive any prophylaxis/treatment.
43,61
 In two studies conducted in 
breastfeeding populations in Cote d’Ivoire the transmission rate at 4-6 weeks in the 
placebo arm (group not receiving any prophylaxis or treatment) of the studies were 
21.7% and 21.8%, respectively.
47,62
  
 
Several studies that assess the efficacy of different types of antiretroviral regimens 
confirm that significant reductions in MTCT can be achieved by providing effective 
ARV regimens. These studies assess the efficacy of HAART in comparison with 
ARV prophylaxis at different levels of CD4 count, the best timing for initiation of 
treatment and efficacy of maternal based versus infant based antiretroviral 
treatments/prophylaxis.
63
 
64
 
65,66
 The Kesho Bora study was a randomized control 
trial that assessed the efficacy of HAART given from 28-36 weeks of gestation until 
cessation of breastfeeding for mothers with higher CD4 count (200-500 cells/µl).
63
 
The study found a 4.1% and 5.8% reduction in HIV transmission and HIV-free 
survival rate respectively at 12 months by providing HAART to women with CD4 
count 200-500 cells/µl compared to providing AZT and sdNVP prophylaxis for 
women with the same CD4 count. This study was the first randomised controlled 
trial that provided evidence on the PMTCT benefit of initiating HIV-positive 
pregnant women with HAART even though they do not need it for their own health. 
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Similarly, the MTCT-plus study compared cohorts of HIV-infected women initiated 
on HAART at 24 weeks with women who were initiated on ARV prophylaxis at 28 
weeks.
67
 The women who were initiated on HAART had CD4 count ≤200 cells/ µl 
whilst those received ARV prophylaxis had CD4 count >200 cells/ µl. This study 
found a lower perinatal transmission rate (3.3%) among those who received HAART 
compared to those who received short course ARV prophylaxis with higher (>200 
cells/ µl) CD4 count (5.7%). The results from this study suggest that the effect of 
ARV prophylaxis is lower compared to HAART irrespective of initiation of ARV 
prophylaxis at higher CD4 count level.  
 
The Kisumu study is another study that initiated HAART for all breastfeeding HIV-
positive mothers at 34 weeks of gestation till 6 months postpartum (breastfeeding 
cessation) reported that initiating HAART at higher CD4 count prevents transmission 
more effectively.
68
 This study reported a lower (5.5%) transmission rate at 12 months 
among mothers with CD4 count >250 cells/ µl compared to mothers with CD4 count 
≤ 250 cells/µl (6.7%) despite both groups receiving HAART. 
 
Other studies indicate that duration of HAART is an important predictor of 
transmission. An observational study published by the Kesho Bora study group that 
assessed efficacy of antiretroviral treatment initiated during pregnancy for women 
with advanced (stage 4 or with <200 CD4 cells/ µl) HIV disease stage found that  
antiretroviral initiated at late stage of pregnancy (median time 7 weeks till delivery) 
among women with advanced HIV-1 disease resulted in a higher HIV transmission 
risk (7.5% transmission at 18 month) compared to ARV prophylaxis given to women 
with higher CD4 count (>500 cells/ µl) during pregnancy and delivery (5.8%  
transmission rate at 18 month).
64 
The study highlighted adequate viral suppression 
will be difficult to achieve at delivery with a short duration of HAART provided to 
women with advanced HIV-1 disease, thus recommended to initiate HAART as early 
as possible for women with advanced HIV-1 disease. 
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Similarly, the Dream study which analysed the HIV transmission rate among a 
cohort of mothers who received lifelong HAART from 14 weeks (<350 cells/ µl) or 
from 25 weeks (<350 cells/ µl) till weaning concluded that short duration of prenatal 
HAART (<30 days) is strongly associated with higher (AOR:2.4) infant HIV-1 
transmission and/or death at 6 months postpartum compared to HAART initiated 30 
days prior to delivery. Thus the study highlighted the importance of early initiation 
of HAART for women eligible to receive HAART.
69
  
 
Other studies compared lifelong maternal HAART with infant ARV prophylaxis 
given for the duration of breastfeeding for prevention of postnatal transmission.
65,66
 
The BAN study which compared maternal triple antiretroviral prophylaxis with 
infant nevirapine prophylaxis suggests that both (maternal and infant ARV) 
interventions reduced the risk of transmission equally, however infant nevirapine was 
more advantageous as it is low cost and has manageable toxic effects.
65
  
 
The above and other studies illustrate the benefit of extended duration of HAART 
and initiation of HAART at higher CD4 counts. Transmission rates reported from the 
above studies varied due to different duration of treatment and disease stage.  The 
transmission rates among women who received HAART in the MTCT-plus study 
was much lower (3.3% early transmission and 1.9% late postnatal transmission) 
compared to women who received HAART in the Kisumu (5.5% at 12 month) and 
the Kesho Bora studies (3.3% at 6 weeks and 5.6% at 12 months) mainly due to 
varied duration of treatment.  
 
According to reports from several studies, including ones mentioned above, perinatal 
transmission rates can be reduced to 9.4% - 12.3% with single dose 
Nevirapine.
47,65,70,71
 The SWEN study conducted in Ethiopia, India and Uganda 
reported a six weeks cumulative transmission rate of 9.4% for women receiving 
single dose nevirapine (in the control group).
70
 A multi-centred random controlled 
trial study in South Africa reported 12.3% transmission at 8 weeks among those who 
received single dose nevirapine.
71
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The peripartum transmission rate is significantly lower (ranging from 2.3% to 5.3%) 
when dual therapy is provided per the WHO 2006 guideline.
16,47,59,67
 A randomised 
controlled trial conducted in Thailand during 2001-2003 reported peripartum 
transmission rate of 2.3% among formula fed infants who received dual therapy 
(maternal and infant AZT and NVP).
16
 The ANRS Ditrame study conducted in a 
predominantly breastfeeding population in Cote d’Ivoire reported a six weeks 
transmission rate of 5.3% among those who received maternal and infant AZT and 
sdNVP.
47
 In the same study the addition of maternal 3TC reduced six weeks 
transmission to 4.7%. Another study in Cote d’Ivoire among primarily formula-fed 
population reported a four weeks transmission rate of 3.1% among those who 
received maternal AZT +3TC+sdNVP and infant AZT and sdNVP.
67
 The low 
transmission rate in this group was also due to the high CD4 count of mothers, as all 
mothers had CD4 count >350 cells/ µl.  
 
The Kesho Bora study showed that with provision of ARV prophylaxis from 14 
weeks of gestation for mothers with CD4 count 350-500 cells/ µl, and with extended 
postnatal ARV regimen for infants until one week after breastfeeding the 
transmission rate at 6 weeks could be lowered to 2.9%.
63
 In the same study among 
mothers who received dual prophylaxis (AZT and sdNVP per the WHO 2006 
guideline) with CD4 count 350-500 cells/ µl the peripartum transmission rate was 
3.4%.   
 
Postnatal transmission rates with no postnatal antiretroviral provision are estimated 
to be 1.57% and 0.51%  per  month of any breastfeeding for CD4 count ≤350 cells/ 
µl and CD4 count >350 cells/ µl, respectively.
59
 Initiating HAART for those with 
CD4 count ≤350 cells/ µl during pregnancy could reduce the risk of postnatal 
transmission to 0.16% per month of breastfeeding.
59
  For mothers with CD4 count 
above 350 cells/ µl, provision of infant NVP using Option A WHO guideline or 
providing maternal HAART using WHO Option B guideline could reduce postnatal 
transmission to 0.2% per month of breastfeeding.
59
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The above transmission rate reports in the context of antiretroviral treatment and 
prophylaxis are measured in clinical trial settings rather than at operational settings. 
Hence the operational effectiveness of currently recommended antiretroviral 
regimens remains to be assessed at a programmatic level. 
 
2.3.2. Maternal and infant adverse events and drug resistance 
 
Antiretroviral treatment provision for HIV-positive women requires careful 
consideration of the balance between the mother's health needs, the need to reduce 
transmission, and the adverse effects of antiretroviral treatments. Few studies report 
adverse effects and drug resistance of antiretroviral treatment in the perinatal and 
postnatal periods.  
 
In the MTCT-plus study drug related maternal adverse events were more common 
among women who received HAART compared to women received short course 
ARV prophylaxis.
67
 The adverse events reported in women who were on HAART 
included grade 3 or 4 adverse events attributed to HAART, mucocutaneous rash 
attributed to NVP, grade 4 liver toxicity attributed to NVP, and severe anaemia 
attributed to AZT.  But none of these adverse events were fatal. In the same study, 
infant birth weight was low among infants whose mothers received HAART 
compared to infants exposed to maternal ARV prophylaxis. 
 
The Kesho Bora observational (cohort) study reported a higher rate of low birth 
weight but lower ARV related toxicity among women and children exposed to 
HAART compared to those exposed to short course ARV prophylaxis.
64
 In this 
study, low birth weight was twice as high in the HAART group compared to the 
ARV prophylaxis group, although this was not significantly different which was 
stated in the paper as due to sample size limitation. The lack of significant difference 
could also be due to  lack of actual difference in birth weight between the two groups 
comapred (i.e. the difference noted could be due to chance alone).  Mothers in both 
the Kesho Bora and the MTCT-plus studies were on HAART because they were at 
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advanced stage of the disease; hence it is not known whether the cause for low birth 
weight is exposure to HAART or due to the mothers advanced disease stage. Other 
studies report hematologic abnormalities on infants were observed in the ARV 
prophylaxis group more than in the HAART group.
72
 
 
Development of drug resistance is another concern in the provision of antiretroviral 
treatment for prevention of mother-to-child-transmission. A secondary analysis from 
the Kisumu study reports occurrence of drug resistance mutation among 67% of 
HIV-positive infants whose mothers received a NVP based or nelfinavir based triple 
ARV regimen from 34 weeks throughout the breastfeeding period.
68
 The study 
reports ingestion of antiretroviral drugs through breast milk may have contributed to 
the emergence of HIV drug resistance mutations and recommend while a 
combination ART treatment is a successful PMTCT intervention, selection of less 
resistant ARV drugs  and early infant diagnosis to identify HIV-positive infants 
before they develop drug resistance  is crucial. Similarly, the PACTG P1030 study 
reports a quarter of a cohort of  HIV-infected infants were infected with drug-
resistant HIV after taking nevirapine (NVP)-containing PMTCT  regimens.
73
  
 
Given, the WHO Option B treatment recommendation to provide HAART until 
cessation of breastfeeding and to stop HAART after cessation of breastfeeding for 
mothers with high CD4 count, the impact of interrupting HAART after termination 
of breastfeeding has been assessed by few studies. A secondary analysis of the Kesho 
Bora randomized controlled study shows interrupting prolonged HAART 
prophylaxis among mothers with CD4 count >350 cells/ µl had no effect on HIV-1 
progression following cessation of HAART compared to women in the ARV 
prophylaxis group.
72
 In the same study, the women in the HAART group had lower 
disease progression during the time they were on HAART compared to the ARV 
prophylaxis group. Adverse events in mothers and infants were similar in both the 
HAART and ARV prophylaxis group. A similar finding was reported in the Dream 
study. In the Dream study, HAART interruption following extended PMTCT use was 
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associated with improved health parameters in the first 3 years following 
interruption.
69
 Both studies suggest that interruption of HAART with cessation of 
breastfeeding does not lead to any adverse effect or deterioration of health.   
 
In summary, results from the above studies indicate that highly active antiretroviral 
treatment has higher efficacy compared to antiretroviral prophylaxis at any CD4 
count level. Duration of treatment and initiating HAART at higher CD4 count 
provided more advantage to achieve lower transmission rates. Whilst more side 
effects were documented with initiation of HAART, the studies have showed that 
side effects were not fatal and no side effect was reported by stopping HAART after 
cessation of breastfeeding. However more studies are needed in order to understand 
the safety of highly active antiretroviral treatment as countries rollout the new 
(Option B and B+) treatment guidelines. 
2.3.3. Biomedical and Health System risk factors for MTCT  
 
Transmission rates are affected by a number of factors including viral, maternal, 
obstetrical, fetal and infant factors. Maternal and viral related factors include: lower 
CD4+ counts, advanced  clinical stage, high maternal viral load, procedures during 
pregnancy that cause placental/amniotic sac inflammation, long duration of ruptured 
membranes, procedures during delivery (episiotomy), mode of delivery (vaginal 
delivery) and viral genotype (HIV type C) are reported as factors that increase the 
risk of mother-to-child transmission.
47,59,67,74-82
 There is limited evidence on the 
effect of viral geno type on transmission,  although a few studies suggest viral geno 
type as a probable risk factor of transmission.
75
  The strong link between viral load 
and transmission is reported in several studies.
77,80,81
  In a New York study women 
with detectable level of viral load had almost six times higher risk of transmission than 
those who had undetectable viral load.81  Transmission rates are also higher in incident 
(new infection during pregnancy or breastfeeding) maternal infections.
59
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Elective caesarean section has been shown to be a protective factor in some prospective 
studies 74,76  In a study by Newell transmission rate was 3.8 times higher in children 
born before 34 weeks of gestation.
78
 The risk of transmission in breastfeeding also 
varies. Mixed-feeding, the presence of infection - breast conditions such as mastitis, 
oral thrush, nipple cracks - increase MTCT risk during breastfeeding.
79,82
 Exclusive 
breastfeeding with postnatal maternal HAART reduces transmission significantly.
59
 
 
Whilst there are studies that assess the association between socio-economic (SES), 
cultural, demographic and health system factors and coverage of services, few 
studies assess the association between these health system and socioeconomic factors 
and transmission rates.
a
 Stringer et al. report failed coverage of nevirapine was 
associated with younger maternal age (<20), and fewer antenatal visits (2 or 3).
7
 In a 
study in Lusaka, non-adherence to NVP was associated with home delivery or 
hospital delivery showing the impact of poor integration of PMTCT service at 
hospital and community level.
83
 In the same study poor infant health status was also 
associated with poor adherence to NVP. However, these studies do not assess the 
direct relationship between SES/health system factors and transmission.  
 
Few studies report significantly influential SES factors on transmission. A study in 
Kenya report neither socioeconomic status nor cultural factors (disclosure/stigma) 
were associated with transmission.
84
 A study in South Africa reported maternal age 
of > 25 years as significant risk factor for transmission.
85
 A study  in Rwanda  
showed unmarried status carried higher risk of undisclosed HIV status, and 
undisclosure of HIV status was independent risk factors of transmission 
86
 
 
Other studies show the link between knowledge of HIV, education, adherence to 
treatment and MTCT using a combination of theoretical and empirical evidences.
87,88
 
Wenger et al. report a good level of understanding about HIV by the patient, a belief 
                                               
a Key words used in Medline search: risk factors and  transmission, socioeconomic status and transmission, 
health systems and transmission, risk factors and   infant HIV infection,  socioeconomic status and   infant 
HIV infection, health systems and   infant HIV infection, nevirapine coverage and risk factors. 
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that HAART is effective and prolongs life and recognition that poor adherence may 
result in viral resistance and treatment failure, could impact favourably upon mothers 
ability to adhere to treatment.
89
  
 
The link between adherence to treatment and transmission rate was demonstrated by 
Boateng et al.
90
 No study could be found that assess the impact of health system 
factors (including PMTCT service coverage and health infrastructure) on 
transmission rate.  Modelling studies however illustrate transmission rates that can be 
achieved with different levels of PMTCT services coverage. According to these 
studies higher (>90%-95%) PMTCT service cascade coverage is required in order to 
reduce transmission rates to virtual elimination level.
41,42
 
 
2.4. Coverage of PMTCT services – the PMTCT cascade  
 
2.4.1. PMTCT service coverage globally 
 
Antenatal HIV testing 
The latest UNAIDS data (2010) indicate nearly two thirds (65%) of pregnant women 
in low and middle income countries do not receive antenatal testing.
3
 The antenatal 
testing coverage in Eastern and Southern African countries is slightly higher (most 
southern African countries have above 80% coverage) compared to east, south and 
south-east Asia which had 18%  and 30% antenatal testing coverage in 2009 and 
2010, respectively.
3
   
 
UNAIDS reports in 2010 approximately 68% of the estimated total number of 1.49 
million pregnant women living with HIV know their HIV-positive status.
3
  Countries 
that have implemented innovative strategies to improve the antenatal testing 
coverage have shown significant progress in increasing their antenatal testing 
coverage. Rwanda is one of these countries which has substantially improved 
antenatal testing rates from 16% in 2003 to 80% in 2009 through using a family 
centred approach and male involvement.
3,91
 Reports indicate most countries (98 out 
119 UNAIDS reporting countries) have now adopted policies on provider-initiated 
counselling and HIV testing for all pregnant women.
3
 However although the policy 
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exists on paper, a number of pregnant women visiting antenatal clinic in sub-Saharan 
African countries miss antenatal testing  due to gaps in translation of policy.
3
 
 
Uptake of antiretrovirals 
 
In 2010 the coverage of effective maternal antiretroviral (both prophylaxis and 
therapy excluding sdNVP only regimen) for prevention of mother-to-child 
transmission globally was 48%.
3
 Additionally 11% of pregnant women received 
single dose nevirapine which was no longer recommended.
3
  The UNAIDS target is 
to increase maternal antiretroviral coverage to above 90% by 2015. In addition, with 
the updated WHO 2010 guideline, 90% of women are expected to be covered with 
postnatal maternal or infant antiretroviral treatment or prophylaxis during the 
breastfeeding period.  
 
The number of HIV-positive women assessed for eligibility of HAART in 2010 was 
45% globally. Thirty four percent (34%) of eligible women received HAART.
3
  In 
developing countries infrastructural gaps (such as lack of on-site CD4 count service, 
gaps in courier and transportation systems) and poor referral and tracking systems 
remain as major  reasons for  low coverage of HAART.
54,92,93
  
 
Uptake of Early infant diagnosis(EID) services and cotrimoxazole 
 
In 2010 from 65 countries reporting on EID coverage, 28% of infants were reported 
to have been tested for HIV in the first two months of life.
3
 Southern African 
countries including South Africa (68%), Lesotho (78%), Namibia (62%), Swaziland 
(54%) and Botswana (53%) reported above 50% coverage of services to diagnose 
early infant HIV infection.
3
  Coverage of ARV therapy among HIV-infected children 
was 23% in 2010.
3
 
 
Both early infant diagnosis and paediatric ARV initiation 
services need more attention globally in order to achieve the UNAIDS target to 
provide early ARV treatment for all HIV-infected infants by 2015. In addition, 
cotrimoxazole coverage was 13% and 23% in 2009 and 2010 respectively, also 
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showing poor coverage of this essential drug for prevention of opportunistic 
infections among uninfected HIV-exposed infants.
3 
 
 
2.4.2. National PMTCT service coverage in South Africa   
 
Limited reliable national data exists on the coverage of PMTCT cascade services in 
South Africa. The national accelerated plan sets national targets to achieve 95% 
coverage on the following PMTCT indicators by 2011: 95% HIV testing rate (among 
pregnant women), 95% ARV (dual prophylaxis both for infant and mother) 
prophylaxis coverage, and 95% six weeks PCR testing (and initiation of 
cotrimoxazole) coverage.
94
 DHIS data reports current national aggregated uptake of 
these PMTCT indicators, and had limitations as explained in section 1.3 above. 
Given these caveats the following data are currently available. 
 
 
Antenatal HIV testing and HIV prevalence among antenatal women   
According to DHIS data antenatal attendance rate in South Africa is high, at 94%, 
and antenatal HIV testing rate has impressively increased from 49.9% in 2005/06 to 
86.7% in 2008/09.
95,96
  
 
Uptake of CD4 count and ARV prophylaxis  
The DHIS data on uptake of CD4 cell count testing and receipt of results is 
incomplete with data missing and of unreliable quality (with reports above 100% 
coverage), hence there is limited data on national uptake of CD4 count services. 
 
According to the 2009 DHIS report, there has been an overall increase in the uptake 
of ARV prophylaxis/treatment from a national uptake of 65% in 2006/07 to 83% in 
2009. However, according to the UNICEF country progress report, in the same year 
37% of women received single-dose nevirapine only, despite a change in national 
policy that includes short course AZT from 28 weeks.
96-98
 The same report indicates 
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only 56% of HIV-exposed infants received ARV prophylaxis to prevent mother-to-
child transmission of HIV.
98
  
 
Uptake of Early infant diagnosis services 
Routine data on uptake of EID services comes from the DHIS and from the National 
Health Laboratory Services (NHLS). DHIS reports the number of babies who are 
PCR tested at six weeks after birth as a proportion of estimated live births to HIV-
positive women. However this is a new indicator that was only introduced into DHIS 
data in 2008, and there is no national figure yet due to differences in the denominator 
used between provinces (Western Cape province use a birth cohort register to track 
cohort data for mother-infant pairs while other provinces estimate the denominator) 
and missing data. NHLS data indicates that uptake of EID services for infants age 
<2months has increased from 31.4% in 2008 to 51.4% in 2010.
39
  However both data 
use number of live births as a denominator, hence do not reflect the true PCR testing 
that would be measured if actual cohorts of infants were tracked. Similar to this, the 
antenatal HIV testing rate, and the uptake of CD4 count and ARV indicators are 
measured using proxy denominators rather than actual tracking of data for mother-
infant pairs starting at antenatal visit.  
 
Although inadequate, due to limited data availability, these uptake indicators have 
been used nationally and internationally to track countries progress towards 
achievement of national and international goals. However, a critical indicator for the 
impact of the PMTCT programme is the proportion of women who successfully go 
through and complete the PMTCT cascade.   
 
2.5. Challenges in the PMTCT programme 
 
2.5.1. Dropout /attrition from the PMTCT cascade   
 
HIV-positive pregnant mothers and children born from HIV-positive mothers require 
PMTCT follow-up services starting from first antenatal visits in early pregnancy till 
18-months of infant’s age. Although many countries are moving towards national 
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coverage of services for PMTCT, loss to follow-up during antenatal, delivery and 
postnatal periods remain a major challenge. According to a recent review by 
Khalembo and Zgambo (2012), cumulative losses in sub-Saharan African PMTCT 
programmes are estimated to range from 20% to 28% during antenatal care, about 70% 
at four months postpartum and close to 81% at six months after birth.
99
 The same 
study reports very few children under the age of one get diagnosed with HIV and 
receive treatment. Similarly, a four-country African study of HIV-positive mothers 
showed half of the children exposed to HIV during pregnancy and childbirth did not 
receive nevirapine at the time of delivery.
7
  
 
A number of community- and provider-related operational and cultural reasons for 
loss to follow-up are documented in the literature.
100-106
 These include: fear of 
stigma, discrimination, household conflict/divorce on disclosure of HIV status; lack 
of support from husbands; not being prepared for HIV testing; social and cultural 
taboos; long waiting times at the antenatal clinics; and inability to afford transport 
costs related to the long distances to hospitals. 
 
In South Africa the PEARL study reports 17.6% of all mothers who were dispensed 
with maternal nevirapine did not take (ingest) the nevirapine.
7
 The study reports 
younger mothers and those who made fewer visits to the health facility before giving 
birth were significantly less likely to have taken the dose of nevirapine, and their 
infants were less likely to have received a dose of nevirapine after birth.  A 
descriptive study conducted by Jones SA, Sherman, G and  Varga, A in the 
Coronation Women and Children's Hospital South Africa reports socioeconomic 
factors such as poverty, geographical relocation and a lack of paternal support affect 
the capacity of families to comply with the PMTCT follow-up programme.
107
 
Women’s education also plays a major role in accepting and honouring PMTCT 
follow-up visits. Two studies from Malawi and Ethiopia report mothers who were 
less educated were less likely to attend PMTCT follow-up services.
108,109
 At health 
facility level, lack of functional community based organizations (CBOs) working 
with PMTCT and paediatric HIV programmes is often reported as a major  barrier in  
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tracking lost to follow-up mothers and infants. On the contrary, good coordination 
between the health care facilities and the community and computerised tracking 
systems are reported to enable tracing loss to follow-up mother-infant pairs – yet  in 
most developing countries these best practices are not implemented widely.
110
  
 
The above and other research evidence adequately show provider related gaps and 
social barriers that influence the performance of PMTCT follow-up programmes. 
These identified gaps remain to be addressed in most sub-Saharan African countries.  
 
 
2.5.2. Health systems constraints 
 
Health services in sub-Saharan African countries face severe resource constraints to 
run a successful PMTCT programme. Lack of health care infrastructure, limited 
human resource, and competing public health priorities within limited health care 
budgets remain major challenges in the implementation of the PMTCT programmes 
in sub-Saharan African countries.
24,25
  
 
The capacity of health care facilities is a major determinant factor for provision of 
PMTCT services. In resource-rich countries, one of the promoting factors for low 
transmission rates is the high coverage of PMTCT services that are ensured through 
usage of appropriate technology, adequate human resources, and uninterrupted 
supply of antiretrovirals. Availability of such resources in high income countries has 
enabled implementation of innovative interventions such as universal antenatal 
testing, integrated MCWH and PMTCT services and computerised tracking systems. 
In developing countries, although internationally recommended interventions, such 
as universal testing are adopted at policy level, their consistent implementation is 
challenged by health systems constraints such as shortage of human resources.
3,24
 
The literature recommends strategies such as geographical redistribution of 
professional health care personnels, task shifting and capacity building, which could 
be used to curb the human resource shortage problems in sub-Saharan African 
countries.
23
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On the other hand, the literature shows inaccessible or non-functional health facilities, 
and long distances are major impediments for pregnant women to access PMTCT 
programmes.
111 
 There also exists lack of clarity regarding positioning of PMTCT 
within the health service delivery context.  Whilst there exist different integration 
models to provide PMTCT interventions as part of existing facility and community 
based MCWH (maternal, new-born and child health ) programmes, challenges such 
as severe shortage of human, logistical and technical resources, as well as funding 
weaknesses interfere with the full implementation of integrated PMTCT 
programmes.
26
  
 
 
2.5.3. Access to Antiretroviral drugs and decentralisation of HAART services   
 
Although inadequate, some progress has been made in increasing the coverage of 
antiretroviral treatment in developing countries. Thus far providing antiretroviral 
prophylaxis to pregnant women living with HIV has prevented more than 350 000 
children from acquiring HIV infection globally since 1995.
3
 Approximately 85% of 
these new infant infections averted were from sub-Saharan African countries.
3 
As of 
December 2010 the antiretroviral coverage among people in need of treatment in low 
and middle income countries was 47%.
3
 Women represented 53% of people who 
received HAART and 51% of those who are in need of HAART.
3
 Overall a 27% 
increase of HAART coverage is observed in low and middle income countries 
between 2009 and 2010.
3
 The number of health facilities providing HAART 
treatment in 2010 also increased by 22% since 2009 in sub-Saharan African 
countries, this represented an average number of 484 people receiving antiretroviral 
therapy per health facility in sub-Saharan African countries compared to 297 
globally.
3 
 
South Africa has the largest antiretroviral (HAART) treatment  programme in the 
world, with about 1.8 million people estimated to be taking antiretrovirals by April, 
2011.
112
 antiretroviral services are also available in more than 2552 approved 
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facilities countrywide.
112
 Roughly 50% of individuals in need of HAART were 
receiving treatment in South Africa in 2011.
3,113
  
 
However, with the new (2010) WHO guideline that recommends initiation of ARV 
treatment for all mothers (Option B) or for mothers with CD4 count below 350 cells/ 
µl (Option A), the number of mothers that need to go on HAART  increased by about 
50%, and HAART spending (drugs, tests, service delivery costs) is expected to grow 
from around $3.3 billion  to $9.5 billion by 2015.
114
 In South Africa it is estimated 
that with the new South African adult and adolescents treatment guideline 
implementation in 2010 (eligibility at ≤350 for pregnant women and TB/HIV co-
infected; early paediatric treatment; and immediate treatment  for adults with CD4 
≤200 cells/µl for all others) people who are in need of treatment will increase from 
1.5 million in 2010/11 to about 3.2 million by 2016/17.
115
  
 
In order to meet the increasing demand of antiretrovirals, WHO promotes a public 
health approach to HAART delivery.
23
 In this approach, standardised simplified 
treatment protocols, decentralised service delivery, negotiating drug prices, and 
selection of less costly ARV treatment are recommended. Task shifting is also 
recommended as a vital step for simplifying and enabling expanded provision of 
HAART.
116
 
. 
 
2.6. Methodologies to measure MTCT and PMTCT Services Cascade  
 
Prospective follow-up cohort study  
Although there is no national study conducted to determine transmission and 
coverage of services along the PMTCT cascade, there is research conducted to 
estimate transmission and coverage of PMTCT cascade services in selected sites, 
using different approaches (methods) to establish the coverage of PMTCT cascade.   
 
The most rigorous but expensive approach, which was used by the Good Start study, 
is a prospective home based follow-up of a cohort of mother infant pairs - at three 
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purposively selected sites -  recruited during the antenatal or immediate post-delivery 
period. The Good Start study conducted a medical record review at delivery and 
followed mother-infant pairs at 3,5,7,9,12,16,20,24,28,32 and 36 weeks post-
delivery.
117 
Blood samples were collected at 3, 24 and 36 weeks. This type of method 
has high internal validity and gives robust estimates of the PMTCT cascade, as well 
as 9-month outcome measures of infant HIV-free survival rates. However, the cohort  
approach is resource-intensive, time consuming, and is not always generalizable at 
country level due to the limited representativeness of the cohort, bias due to loss to 
follow-up and the  “Hawthorne” effect118 (subjects improve or modify their 
behaviour simply in response to being followed, since investigators would be 
ethically bound to provide cohort participants with the best possible care e.g. referral 
of mother and infants for HIV care and treatment), members of the cohort could thus 
be poorly representative of the population as a whole. In addition, prospective 
approaches, although ideal, are not practical for routine monitoring in most 
developing countries given their expense and complexity. 
 
Facility based cord blood surveillance plus a population based survey  
The PEARL study used a facility-based process data and cord blood surveillance 
plus a structured evaluation and a community-based survey to assess coverage of the 
PMTCT cascade and transmission rates.
7,21,119
 The PEARL study recommends the 
modification of the Demographic and Health Survey (DHS) to include gathering of 
data on maternal HIV history, PMTCT programme enrolment, interventions 
received, infant feeding practices and household child mortality.  This 
recommendation has been argued to be challenging due to requirements of sample 
size larger than currently allocated sample sizes for DHS. 
 
The facility based component of the PEARL study involved a collection of umbilical 
cord blood sample from 43 randomly selected facilities in 4 African countries aiming 
to measure antiretroviral prophylaxis coverage. The study defined coverage of 
antiretrovirals for preventing mother-to-child transmission as the proportion of 
mother–infant pairs with confirmed nevirapine ingestion. Maternal ingestion was 
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confirmed by the presence of nevirapine in the cord blood, and infant ingestion was 
confirmed by reviewing relevant documentation. This study assessed maternal 
adherence to nevirapine by testing umbilical cord specimens. The study found 27% 
of mothers did not adhere to the treatment prescribed.
7
 The results from this study 
however could only represent mothers who deliver at institutions. This approach is 
likely too costly and complex for country wide implementation.   
 
Facility based surveys 
Surveys with retrospective information gathering are another approach to collect 
PMTCT cascade and transmission data.
6
 This approach needs shorter study periods, 
and in areas with high immunisation attendance rate, population level representative 
outcomes could be reported from facility-based surveys conducted at 6 weeks 
immunisation visits. 
6
 Retrospective gathering of information may introduce recall 
bias, unless recall periods are short. The results from facility based surveys will not 
represent infants who do not attend or who died before 6 weeks immunisation visits. 
In research settings, conducting a national facility based survey could have high cost, 
but if facility based surveys could be incorporated into routine 6 weeks immunisation 
services, this method will be most cost-effective. Facility-based surveys are not also 
ideal for measuring longer term postnatal outcomes due to high loss to follow-up rate 
often occurring due to societal barriers, distance, financial and time commitment 
needed from participants  to attend regular facility-based follow-up visits. 
Community based studies (e.g. home visits) are more appropriate for follow-up 
studies as participants can be visited in their home/or at other nearest/convenient 
location.    
 
In conclusion, the main difference among the three methodologies discussed in this 
section is with their study population (facility-based versus population-based) and 
study design (cross-sectional versus cohort).  Whilst each method has its own 
advantages and limitations (explained above), in countries with high immunisation 
coverage, cross-sectional facility based surveys may be the most efficient method for 
evaluating PMTCT programmes for the early postpartum period.
120
 Nonetheless, 
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cross-sectional studies conducted to date are limited to certain geographical areas and 
do not provide estimates of the national coverage of the PMTCT cascade.
6,121
 Thus, a 
national study is required to monitor progress towards achievement of national and 
international targets set to reduce mother-to-child transmission rates.  
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Chapter 3: METHODOLOGY 
 
3.1.  Study components and study design 
Two quantitative studies were carried out in randomly selected facilities within the 
nine provinces of South Africa. First, a cross-sectional facility-level situational 
assessment was undertaken in 680 selected facilities using key informant (health care 
provider) interview and record review methods to assess the coverage of EID services 
and the capacity of the health system to provide PMTCT and EID services.  
 
Following the situational assessment, a facility based cross-sectional survey 
(SAPMTCTE survey) was conducted to gather caregiver interviews and infant blood 
samples from caregiver/mother-infant pairs (4-8 weeks infants) attending six weeks 
immunisation (1st DTP Dose) visits in sampled facilities. The HIV status of the 
infants was determined based on the approach recommended by Rollins et al.
6
 – HIV 
antibody testing was performed on infant blood samples (dried blood spots) to screen 
for the presence of maternal HIV antibody, which was a marker for HIV-exposure of 
infant, this was followed by DNA PCR test for those infants who are HIV-exposed.   
This study design was field tested and proven to be effective in the South African 
context. 
6,121
 The high attendance rate (>95%)
122
  of six weeks (DTP1) immunisation 
services in South Africa provided an opportunity to provide estimates that closely 
represent all 4-8 weeks old infants. Antenatal and PMTCT histories and infants blood 
samples were collected from all infants visiting six weeks immunisation regardless of 
whether the mother and/or infant received any PMTCT interventions. This method 
was relatively rapid to undertake compared to longitudinal study designs.  
 
The combined data from the two study designs ((i) facility level situational 
assessment and (ii) the six weeks individual level PMTCT survey) enabled this study 
to examine the effect of health service measures (i.e. service availability, guidelines 
for service provision, human resource and other infrastructure) on service utilisation 
(uptake/coverage of services) and PMTCT outcomes (transmission rates). 
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3.2.Sample size, sampling design and justification thereof   
 
Facility sampling, sample size and sample frame 
 
A two-stage stratified sampling method was used to select sample facilities for both 
studies. In the first stage, target facilities (Primary sampling units - PSUs) for both 
the situational assessment and PMTCT survey were randomly sampled using a 
probability proportional to size sampling methodology. The sampling frame 
comprised all public primary health clinics (PHCs) and community health centres 
(CHCs) throughout the country. Three thousand three hundred ninety (3390) CHCs 
and PHCs reportedly administering 1st DTP doses in the South African national 
district health information system (DHIS 2007) were eligible for inclusion in the 
sampling frame.
123
 Satellite and mobile clinics were excluded as they only operate for 
a few hours a week. Private facilities and public hospitals were not primary sites for 
immunisations therefore they were not included in the sampling frame.  
 
Facilities in the sampling frame were stratified into four groups based on the 2007 
DHIS data and the 2009 antenatal HIV prevalence estimates: small facilities with 
<130 annual immunisation (DTP1) coverage, medium size facilities with 130 -300 
annual immunisation (DTP1) coverage, large (annual immunisation/DTP 1 coverage 
>= 300) facilities with antenatal HIV prevalence below 29% (the national HIV 
prevalence estimate), and large facilities (>= 300 annual immunisation 
/DTP1coverage) with antenatal HIV prevalence above or equal to 29%. 
123,124
  
 
This sample size was calculated to enable providing a national and provincial level 
estimate of transmission rates and PMTCT cascade coverage. The sample size of 
medium and large facilities was determined based on antenatal HIV prevalence and 
transmission rate estimates using the following methodology:  
1. The overall infant HIV prevalence  of each province was estimated using  the 
antenatal HIV prevalence data, the transmission rate estimates from two 
KwaZulu-Natal (KZN) surveys (estimates of transmission rates for SdNVP and 
no treatment were taken from  Rollins
6
  while the transmission rate for Dual 
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Therapy comes from the recent KZN survey
125
) and the coverage of ARV 
prophylaxis in each province from DHIS report. (Appendix I)   
2. In the next step precision levels were specified. The first sample size calculations 
were based on a fixed relative precision of 30% across all provinces. The Western 
Cape Province had the lowest estimated infant HIV prevalence (with 1.9% infant 
HIV prevalence at six weeks).  Specifying a 30% relative precision for Western 
Cape led to a sample size of nearly 4000 infants for this province alone. The 
numbers for the other provinces are also indicated in the table (appendix I). This 
approach resulted in an imbalance in field work effort required. The biggest effort 
would be required in the province with the lowest expected prevalence. It was felt 
that given the low infant HIV prevalence in Western Cape a larger relative 
precision would be acceptable. For the Western Cape Province it was felt that a 
+1% precision would be adequate for public health purposes. With this precision, 
the upper limit of the 95% confidence interval was around 3% and this equates to 
a relative precision of 51%. For the provinces with a higher expected prevalence a 
reasonable precision was needed. In Gauteng province infant HIV prevalence is 
estimated at 8.2% and therefore a higher precision was required to monitor this 
transmission. A+2% precision was decided to be reasonable. The precision 
required and specified for the nine provinces thus vary from +1% to +2%. In 
general provinces with a higher prevalence had a lower (better) relative precision. 
The relative precision implemented in each province is indicated in the table 
(Appendix I). The benefit of this is that better equity in sample size is achieved 
between provinces.  
3. Sample size was calculated using nQuery Advisor Version 7 software  for 
specified precision levels for each province (Appendix I)  
4. Sample size was doubled using design effect of 2  to take into account for the 
clustering effect at facility level (Appendix I)   
5. Based on the above calculation of sample size, for the six weeks PMTCT survey a 
total sample size of 12200 infants nationally and 700-1800 infants provincially 
was required.  
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6. The sample size calculated for the province (700-1800 infants) was allocated 
proportionally (population proportionate to size) between the strata (medium, 
large and large and high prevalence strata) in each province.  
7. For each stratum, using immunisation data from DHIS, the median number of  
children expected in a fixed time period (3-4 weeks) was calculated. This number 
was then used to determine the number of clinics that need to be sampled in each 
stratum in each province to obtain the number of children specified in Appendix 
I. 
8. Clinics were then randomly sampled proportional to size (PPSSYS) within each 
stratum using the detailed information of the sampling frame. The method 
operates under the without-replacement-type selection as described in Lehtonen 
(1994).
126
 This sampling method was implemented in excel.  
 
The sampling design of each province is given in Appendix I. It contains the 
summarised information from the sampling frame and the number of facilities and the 
number of infants sampled to provide the sample size required.  
 
Provincial sample size adjustment and justifications  
 
In three provinces the following sample size adjustments were made: 
Eastern Cape has a large number of medium sized facilities (130-300 immunisations 
per annum) therefore requiring that a substantial number of these facilities be 
sampled. This would lead to an unfeasible sampling burden in this province. For this 
reason we oversampled facilities in the larger stratum and under sampled facilities in 
the smaller stratum. This oversampling fraction is 6%.  
Mpumalanga used the same sampling strategy described for the Eastern Cape 
Province. The oversampling fraction was 7%  
Northern Cape has the largest geographical coverage in the country and has 
enormous distance between facilities. Hence, taking into account our logistical 
capacity, decision was made to limit the number of facilities sampled in each of the 
stratum, and in compensation for the reduced number of facilities, the duration of 
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time spent in each facility for data collection was increased to a median number of 4 
weeks.  
 
Based on this, nationally, 580 facilities (34-79 provincially) were selected from 
medium and large size facilities for inclusion in the situational assessment and 
SAPMTCTE survey (Appendix I). For the situational assessment, an additional 100 
facilities (10-20 facilities per province) were randomly sampled from small (< 130 
immunisation) facilities, thus the total number of facilities sampled for situational 
assessment were 680 facilities. Small facilities were not included in the six weeks 
PMTCT survey as it was not logistically feasible, hence 580 facilities were planned 
to be visited for the six weeks survey.   
 
3.3.Situational assessment 
 
The situational assessment was conducted between January and May 2010 on 580 
facilities that were sampled for the situational assessment and PMTCT survey and an 
additional 100 facilities sampled for situational assessment only as described in the 
previous section. The second stage sampling in the situational assessment was the 
selection of key informants. Three health workers and a district information officer 
were purposefully selected from each facility for key informant interviews as follows: 
one clinic manager (or representative manager in the absence of a manager), one 
immunisation nurse and one child health (IMCI) nurse who were on duty at the time 
of the assessment, and the health information officer of the district (where available 
each facility’s information officer) were interviewed in each facility using structured 
questionnaires (appendix II). In facilities that had more than one immunisation 
nurse/IMCI nurse on duty, one nurse from each unit was randomly (simple random 
sampling) selected. A self-administered structured questionnaire was used to obtain 
quantitative data from respondents. The questionnaire was adapted from previously 
tested tools (Doherty, Besser and Donohue (2003) and Doherty and McCoy D et al. 
(2005)).
127,128
 Participants were interviewed face-to-face by trained fieldworkers. A 
four days training was given for field workers using standard manuals (SOPs).  The 
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questionnaire was piloted in two clinics prior to field work. Data was collected over a 
one month period in each province.  
 
Both open ended and close ended questions were used to collect the data. The 
questionnaire had four sections: a section for facility managers, a section for 
immunisation nurses, a section for IMCI nurses, and a section for district information 
officers.  
Topics covered in the questionnaire include:  
Organization of the health system for identifying HIV-exposed infants, infant HIV 
testing, transportation of HIV-related maternal and infant blood specimens, postnatal 
maternal HIV testing and linkages to HIV-related care. This included:  
- human resources for EID and PMTCT services;  
- distribution of PMTCT/ARV services;  
- procurement and stock control of supplies for infant HIV testing;  
- systems that exist for routine transport of DBS specimens;  
- communication / referral systems for HIV-related care;  
- Current policies and procedures relating to EID ; 
- Attitudes of maternal, child and women health (MCWH) staff towards early 
infant diagnosis and, 
- Community involvement   
Data on quarterly immunisation numbers and quarterly uptake of antiretrovirals was 
extracted from record reviews.  
 
 Written, signed, informed consent was collected from each facility 
manager/immunisation nurse/information officer and child health nurse participated 
in the situational assessment. The information sheet for participants was prepared in 
English language describing the purpose of the study, confidentiality of data, and 
benefit of conducting the situational assessment. The information sheet explained that 
data reporting will be aggregated, at a strata and provincial level. Hard copy 
questionnaires (Appendix I) were used for data collection of the situational 
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assessment. The data was captured on excel and was transferred to STATA SE 
(version 12, Texas, 77845 USA) for analysis.  
 
Descriptive analysis, including frequency tables, ranges and cumulative numbers 
were used for analysing data.  During data analysis the following variables were 
created: 
Approaches for early infant HIV diagnosis (EID) were categorized as follows:  
- Universal HIV testing: offering testing to all infants visiting for six weeks 
immunisation service regardless  of prior maternal HIV status 
- Targeted Testing: HIV-testing of  known HIV-exposed infants    
- Provider-initiated counselling and testing (PICT) for undocumented and uncertain 
HIV status infants: is defined as the routine provision of HIV testing to six weeks 
immunisation infants whose HIV status is unknown  or uncertain.  
 
The implementation and effectiveness of the above three EID service approaches was 
examined using service utilisation data from the six weeks PMTCT survey (this is 
discussed in detail in chapter 4 - Paper 3). 
 
3.4.The six weeks PMTCT survey 
 
3.4.1. Study population 
 
The study population for the six weeks PMTCT survey was infants aged 4-8 
completed weeks and their caregivers/mothers  visiting Public Clinics and CHC 
(primary sampling units) for administering 1st DTP dose to the infant.  
3.4.2. Sample size and sampling 
 
The desired sample size of the six weeks survey was the collection of 12200 maternal 
interviews and infant blood samples from mother-infant pairs visiting the selected 
580 facilities for this component of the study.  The sample size allocated for each 
stratum was divided equally for each facility in the stratum giving a self-weighted 
sample. The second stage sampling for this component of the study was the sampling 
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of mother-infant pairs from each facility. A fixed number (i.e. the allocated sample 
size for each facility) of mother/caregiver-infant pairs were consecutively or 
randomly (depending on the size of the facility) selected from each facility over a 
planned three to four weeks recruitment period. The sample size allocated for each 
facility was the median number of infants expected within the sampling window (3-4 
weeks) across the population of facilities within the stratum as determined from the 
detailed information of the sampling frame (appendix I). 
 
3.4.3. Participant inclusion and exclusion criteria for survey 
 
Participant inclusion criteria 
 
Infants were eligible for participation in the study if they are in the age range 4-8 
completed weeks, attending clinic for 1st DTP immunisation and mother/caregiver 
consents to participation (consent for maternal or caregiver interview and/or infant 
DBS). Orphaned children brought to the clinic by caregivers who consent to 
participation in the study (consent was taken from caregiver for interview and/or 
infant DBS) were included. The PMTCT cascade analysis included all mothers with 
interview data regardless of infant DBS collection and HIV test.  
 
Participant exclusion criteria 
 
The following were exclusion criteria:  severely ill infants needing emergency 
medical care or urgent referral to the next level of care e.g. infants who were 
vomiting or have convulsions, or are lethargic or unconscious or have severe 
pneumonia or severe dehydration. For the PMTCT cascade, caregivers (other than 
mothers) were excluded from analysis as PMTCT programme data for mothers 
cannot be obtained from caregivers (other than mothers) interview.  
3.4.4. Data collection 
 
Data collectors (trained field workers) recruited mothers/caregivers from the 
clinic/CHC waiting room during immunisation days. The data collectors introduced 
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themselves and the study verbally and in written form using a standardised 
information sheet. If the mother agreed to the interview, the nurse and the participant 
moved to a private location in the clinic/CHC. After the participants understand the 
purpose of the study, expectation from the subject, the long and short term benefits 
and risks of the study, the right to refuse to participate or withdraw, and the 
confidentiality of all information taken from the participants, written signed informed 
consent (Appendix II) was obtained from each eligible caregiver/mother. Interviews 
were conducted with mothers using full questionnaire, and a shortened version of the 
questionnaire (PMTCT questions were excluded from caregivers’ questionnaire) was 
used for caregivers, legal guardians and fathers. The questionnaire was adapted from 
several validated tools (Rollins et al., 2007 & 2009; HSRC, undated; Nyblade & 
MacQuarrie, 2006; Tlebere et.al., 2007; Jackson et al. 2007).
6,117,125,129
 
130,131
 Mothers 
were asked questions regarding utilisation of specific HIV-prevention services 
including HIV testing; receipt of HIV test results; if HIV-positive: CD4 count testing; 
receiving antiretroviral prophylaxis or highly active antiretroviral treatment 
(HAART) and intention to test infant at six weeks immunisation.  Printed pictures of 
samples of antiretrovirals were showed to mothers, following antiretroviral questions, 
to assist them to identify the antiretrovirals they (or their infant) received. Data on 
gestational age at birth, infant birth weight and HIV status was extracted from the 
road-to-health-card (RtHC).  
 
3.4.5. Laboratory tests 
 
Blood specimens were collected from infants for HIV testing after mothers/caregivers 
were given pre-test counselling by the study nurse and agreed for infant testing. All 
specimens were tested in one accredited central laboratory, National health laboratory 
(NHLS), Johannesburg. Blood samples were sent from clinics to the central 
laboratory using the routine transportation system used by facilities. A serologic test, 
an enzyme immunoassay (EIA) (Greenscreen HIV 1/2 Ab EIA version 2, Bio-Rad 
Laboratories, France), was used to determine presence of HIV-antibody in collected 
specimens. All antibody positive and 10% of antibody negative specimens were 
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retested using a second enzyme immunoassay (EIA) (Vironostika HIV Uni-form II 
plus O, Marcy-L’Etoile, France). Discordant results were checked using Western 
blot. Specimens with one or two EIA result were tested using a qualitative 
deoxyribonucleic acid (DNA) polymerase-Chain- Reaction (PCR) test to determine 
infant HIV infection.  EIA positive result indicated HIV-exposure of infant, and a 
PCR positive result showed HIV infection of infant.  
 
3.4.6. Data management and analysis  
 
Data collection for the PMTCT survey was done using electronic questionnaires 
(Appendix II) that were loaded on low cost mobile phones using the Mobile 
Researcher software management solution. This reduced cost and time needed for 
data capturing and data cleaning. 
 
Analysis of the PMTCT cascade data was started by observing the sample realisation 
in each stratum of each province. The sample realisation was established and the 
sampling weights were adjusted to reflect the sample size realisation. A formal 
survey analysis was done which included the specification of the different sampling 
stages and the finite number of PSU’s involved. A weighted analysis was performed 
for each province as well as estimating the national uptake of PMTCT services 
(PMTCT cascade). Unweighted cell counts are presented where it is important to 
show the sample size in each category.  District level analysis could not be done as 
the sample size was not adequate for providing district level estimates. 
 
Definition of Service coverage terms 
- Acceptability of PMTCT service: the degree to which the PMTCT service meets 
the social and cultural needs and standards of the community, which in turn 
influences uptake of PMTCT service. 
9
 
- Access (to health services): the perceptions and experiences of people as to their 
ease in reaching health services or health facilities in terms of location, time, and 
ease of approach.
10 
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- Affordability refers to the direct (doctor’s fees, travel and medical costs) and 
indirect costs (e.g. absenteeism from work) that affect access to service.
11
  
- Availability of service - we use this term in particularly to refer to the delivery 
(or availability) of services at peripheral level health care units (i.e. primary 
health care units).
10
 
- Coverage: the extent of interaction between the service and the people for whom 
it is intended. Coverage is not to be limited to a particular aspect of service 
provision, but ranges from resource allocation to the achievement of the desired 
objective.
12
 
 
- Uptake is used to refer to utilisation of services. Uptake was calculated for the 
following PMTCT cascade indicators using maternal report data:  
1) Percentage of mothers who received ANC HIV testing   
2) Percentage of mothers who received antenatal HIV test result   
3) Percentage of reported HIV-positive or infant EIA positive mothers who 
had CD4 count test (and received CD4 count result)  
4) Percentage of reported HIV-positive or infant EIA positive mothers who 
took ARV prophylaxis/HAART during pregnancy  
5) Percentage of HIV-exposed infants (from maternal report or EIA result) 
who received ARVs immediately after delivery, and  
6)  Percentage of mothers who had intention to test infant at six weeks 
immunisation visit.  
The final outcome that represents the coverage of the perinatal PMTCT cascade is the 
receiving of maternal AZT or HAART for any duration during pregnancy and infant 
NVP/AZT taken at birth.  
- Utilization (of health services): experience of people as to their receipt of health 
care services of different types. 
10
 
- Universal access/coverage –Particularly for this thesis, this term is  defined as 
≥80% total ARV regimen (maternal AZT or HAART received for any duration 
during pregnancy and infant NVP/AZT taken at birth) coverage.  
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Multivariate analysis using both situational assessment and six weeks survey data  
 
A logistic regression model was fitted to compare transmission differences between 
provinces that achieved universal coverage (≥80% ARV regimen coverage) of ARV 
regimens and provinces that did not achieve universal coverage. The auxiliary 
information obtained through the six weeks questionnaire and the situational 
assessment facility level data were combined and analysed using the survey analysis 
framework. This framework takes into account the sampling weights the survey 
design and the cluster sampling of participants. The following variables were 
considered in adjusting this model: from individual level factors, marital status, 
maternal age, education, socioeconomic status, planned pregnancy, number of life 
time pregnancy, gestational age at birth, infant birth weight, and history of child 
sickness (sickness treated at a clinic or a hospital level) since birth; and at facility 
level, human resources, referral system, availability of on-site ARV clinic, task 
shifting and community involvement were included. All estimates are reported with 
95% confidence limits. Detail data analysis step is presented in chapter 4 (paper 2). 
 
A second logistic model was fitted to examine individual level factors influencing 
maternal intention to receive EID at six-week visit among known HIV-positive 
mothers. Variables used for adjusting this model are presented in chapter 4 (paper 3). 
 
Data imputation  
 
All variables included in the final model of the multivariate analysis were imputed 
using multivariate imputation by chained equation (MICE) method. Variables that 
closely explain the missing variables were specified and STATA SE 12 was used in 
performing the multiple imputations. This method creates multiple imputation for 
each missing data and accounts for uncertainties introduced with imputed missing 
data at analysis stage by running a series of regression models which are conditional 
upon other variables in the data.  
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3.4.7. Informed consent 
 
Written, signed, informed consent was obtained from each eligible caregiver/mother 
(see Information Sheet and Consent form in Appendix II). Informed consent was 
prepared in the preferred language of the participants. The information sheet was 
written in plain lay words to be easily understood by participants and has a SMOG 
score of <8. The Flesch-Kincaid Grade Level is 4.7 meaning that the consent form is 
easy to read by an average student in the 4-5th grade (around 9-11 years old). In the 
PMTCT study, pre-test counselling was given to all mothers, following which 
mothers were requested for consent to collect heel prick blood sample with an option 
to know the HIV test result of the infant. Mothers who agreed to infant testing were 
given confidential linked (names were written on lab forms) testing. Confidentiality 
of identifying information was assured by limiting the number of people who have 
access to identifying information. The national laboratory technicians (NHLS) who 
process the testing of the blood specimen were the only parties who had access to 
infant identifying information (the laboratory technicians had access to identifying 
information as they were responsible for returning of results to the health facility). 
These laboratory technicians had no access to interview data collected from mothers. 
Mothers could refuse if they did not want to have the infant HIV test result. For 
mothers who refused to have named infant HIV results, anonymous testing was 
offered, in which case specimens were collected without taking infants/mothers 
name, but a barcode was used for data linking.  If infant was brought by caregiver 
other than mother, they were given an option for anonymous testing, however if 
caregivers indicated the mother/guardian is interested to know the HIV status of the 
infant, confidential linked testing was given and appointment card was sent to the 
mother to collect the infant result at 10-14 weeks. Results were returned through the 
routine system. A confidential Study ID (BARCODE) was given to each participant 
consent form and questionnaire for the purpose of data linking and audit, and to 
provide the infants blood test results. Data collectors were properly trained and 
carried identification. The data collectors ensured that the prospective subject is 
provided with all the necessary information about the study, and that participation in 
the study is not influenced by coercion, undue influence or intimidation. Care was 
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taken to ensure that HIV-infected mothers who refuse the study understand that their 
infant should still be tested and can be tested without participating in the study.  
 
All aspects of the project were carried out according to strict standard operating 
procedures (SOPs). Detailed instruction was written explaining the step-by-step 
process of: recruitment of caregiver/mother-infant pairs, informed consent procedure 
(and confidentiality), interview (interpretations of questions), process of blood 
sample collection and transportation, referral of mothers/infants to receive the 
necessary care, monitoring the field data collection process and data management and 
an analysis.  
 
3.5. Ethical Approval for the Study  
 
Ethical approval for the PMTCT survey was obtained from the Medical Research 
Council, National Department of Health, the provincial research ethics committees 
(as applicable) and from the United States Centres for Disease Control and 
Prevention Associate Director for Science (Appendix II). Ethical approval for the 
situational assessment was sought from the Medical Research Council (Appendix II), 
and the provincial research ethics committees (as applicable). Approval and buy-in 
was obtained from National and Provincial Departments of Health before 
commencing the fieldwork.  
3.6.Quality control/quality assurance measures 
 
During data collection, field supervisors were assigned for each province to manage 
the field work activity and act between fieldworkers and project coordinators for 
logistics and other queries from field sites.  
 
3.7.Validity/Reliability 
 
The six weeks immunisation visit has a very high attendance nationally (over 95%) 
suggesting limited selection bias using this approach.
123
 Actual 6 week immunisation 
coverage at each sampled facility was reviewed to estimate possible bias due to lower 
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than expected coverage. A few facilities (<5) were found with lower than expected 
immunisation coverage, and these facilities were re-categorised/moved into their 
appropriate strata (small, medium or large strata) and a replacement facility was 
sampled for their substitution.  
 
To validate our data, the demographic characteristics (i.e. maternal age distribution) 
and the HIV exposure prevalence of our survey was compared with the antenatal 
survey maternal age distribution and HIV prevalence data.  Both our survey and the 
antenatal survey data have comparable age distribution and infant HIV exposure 
prevalence (table 2 and fig 2). 
 
Table 2: Comparison of age distribution between the antenatal survey and the six week PMTCT 
survey 
 
Maternal age in years  PMTCT survey 2010  (%) ANC survey 2009 (%) 
<15  0.1% 0.3% 
15 - 19  15.9% 18.7% 
20 – 24  30.1% 31.1% 
25 – 29  25.4% 23.9% 
30 – 34  16.1% 14.5% 
35 – 39  8.1% 8.1% 
40 – 44  2.3% 2.2% 
45 – 49  0.3% 0.2% 
>49  1.7% 0% 
Not specified  0% 0.8% 
Total  10735 (100%) 32861 (100%) 
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Figure 2: Comparison of the PMTCT survey infant HIV exposure prevalence and the antenatal survey 
HIV sero-prevalence  data 
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Bias in data collection, measurement & analysis  
Potential Selection Bias  
Potential bias in this study includes the following:  
a) The uptake rate we report in this study is not an expression of service uptake at a 
population level. We calculated uptake for mothers that attended the 6 weeks 
immunisation visit.  However, 6 weeks immunisation visit has a very high attendance 
in South Africa (>95%), suggesting limited selection bias using this approach    
b) Neonatal deaths were not included in this study; hence the PMTCT cascade results 
from this study cannot represent utilisation of PMTCT service by mothers whose 
infants died before 6 weeks immunisation visit.  
d) Only clinics and community health centres were included in this study, while these 
are the primary care facilities providing well child services in South Africa they may 
not be representative of all types of health facilities.  
e) This study provides facility, not community-based estimates of uptake of PMTCT 
cascade. However as DTP1 immunisation rates are high (>95%) in South Africa, the 
results can closely represent infants in the age of 4-8 weeks old in the population. 
122
  
f) The study does not also provide estimate on uptake of PMTCT service given at late 
postnatal period (>4-8 weeks of infant age). 
g) Missed opportunities (for enrolment in  PMTCT programme) among mothers 
infected late in pregnancy  may not be identified if maternal antibodies are not yet 
present in the baby’s blood or as some studies show if extended ARV use may delay 
infant HIV diagnosis 
132
   
 
Potential Information Bias  
a) There is always potential for recall bias, however the relatively short recall period 
(recall period of <1 year) should reduce this potential bias. Non response rates were 
high for CD4 count and duration of treatments due to the long recall period. We 
therefore did not use these two variables for multivariate analysis. 
b) Social desirability bias and fear of disclosure and stigma may cause mothers to 
either over or under-report participation in the PMTCT programme. Confidentiality 
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was assured and discussed as part of the informed consent process and a private place 
was secured for the conduct of interviews. HIV prevalence calculated from infant 
DBS test shows most mothers reported their true HIV status. 
c) National Health Laboratory Service (NHLS) and National Institute for 
Communicable Diseases (NICD) conducted the validation EIA testing on dried blood 
spot (DBS) samples. The result of this validation test showed that the sensitivity and 
specificity of the EIA test ranges from 89.1-95.2 (sensitivity) and 99.6-99.9 
(specificity).  Established sensitivity and specificity of the HIV testing was 
operational, but this was minimized through proper handling of specimens and 
assurance of laboratory quality control.  
3.8. Work plan 
Table 3: Time frame for the 6 week SA PMTCT survey project 
Description of activities  2009  Jan-
May 
2010 
June –
Dec 
2010  
2011  Jan-
Mar
ch 
2012  
April 
2012 -   
April 
2013 
May 
2013 
 
Timeline for the main PMTCT survey 
Planning and finalisation of 
questionnaire,  SOPs  
X  
 
Selection of field workers                    X  
Training  of field workers                   X  
Data collection                                   X 
Data entry, data cleaning,  
and preliminary analysis  
                                               X 
Timeline for PhD 
Proposal writing                                                  X  
Data analysis                                                             X 
Write-up of 3 manuscripts                                                                                 X  
Submission for external 
examiners  
                                                                                                                            
X 
 
3.9. Contribution of the student to the study 
 
Ms Woldesenbet is a Senior Scientist at the MRC. She was responsible for the overall 
planning, coordination and implementation of the situational assessment study, and 
the planning and coordination of the 2010 PMTCT survey until July 2010. During 
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survey implementation Ms Woldesenbet’s responsibilities included overseeing field 
work in three provinces and overseeing the work of two scientific coordinators who 
managed the field work in the other six provinces. From July 2010 she was also 
mainly in charge of reviewing and cleaning the data from the survey (in her role as 
Scientific Manager). The PMTCT survey main objective was to estimate the MTCT 
among infants aged 4-8weeks old. The second and third objective of the PMTCT 
survey was to report on uptake of PMTCT cascade and factors associated with 
transmission rate. The findings of the main objective of the study were written by the 
principal investigators (Dr. Ameena Goga, Prof. Debra Jackson, and Dr. Thu-Ha 
Dinh). The principal investigators oversaw the overall coordination and 
implementation of the study and had the final decision on the scope of the study 
(including decision on main objectives and depth of data/information gathered), study 
procedures and budget allocation.  They employed staff, including Ms Woldesenbet 
to implement the study. In accordance with previous discussions with the Principal 
Investigators Ms Woldesenbet was responsible for data management, analysis and 
write-up of reports and manuscripts from the situational assessment study and the 2nd 
and 3
rd
 objectives of the PMTCT study which make up her PhD analysis and thesis. 
Data weighting was done by an MRC statistician. The rest of the analysis in this 
thesis was done by the student (Ms Woldesenbet), with guidance from the principal 
survey statistician, PhD supervisor and PIs and inputs from co-authors.   
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Chapter 4:  RESULT AND DISCUSSION  
 
4.1. Paper 1: Uptake of PMTCT services  
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Abstract 
 
Objectives 
This study aimed to assess uptake of antenatal and perinatal PMTCT services and 
missed opportunities for PMTCT service in a national survey conducted in nine 
South African provinces. 
 
Methods 
A cross-sectional survey was conducted among 4-8 weeks old infants receiving first 
immunisations in 580 facilities selected from the nine provinces of South Africa 
using a multistage stratified sampling method. Interviews were conducted with 
mothers to assess uptake of antenatal and peripartum PMTCT services. HIV status of 
mothers was determined from maternal report or enzyme immunoassay (EIA) testing 
of infants’ dried blood spots. A weighted analysis was performed to assess uptake of 
antenatal and perinatal PMTCT services. 
 
Results 
 
From 10299 mothers with unknown or HIV-negative status prior to pregnancy, 
97.7%   reported receiving antenatal HIV testing and test results. 3209 (32.2%) 
infants were HIV-exposed (HEI) per maternal report (known HEI 89.6%) or infant 
blood EIA test (unknown HEI 10.4%). 75% of HIV-positive (per maternal report or 
EIA result) mothers received a CD4 count test and 67% received their CD4 count test 
results. Of those mothers who reported CD4 count ≤350cells/µl, only 64% received 
highly active antiretroviral treatment (HAART). In total 82% of all mothers of HEI 
(known and unknown) received HAART or azidothymidine (AZT) prophylaxis 
during pregnancy and 78% received both maternal HAART/AZT and infant 
nevirapine/AZT.  
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Conclusion 
Substantial loss to follow-up occurred at CD4 count and antiretroviral treatment 
(HAART) initiation points. Given the observed high dropout at CD4 count point and 
related delays in initiation of HAART, this study supports the recent adoption of the 
WHO Option B treatment guideline in South Africa which recommends initiation of 
HAART to all HIV-positive mothers regardless of CD4 count. The adoption of the 
new guideline should be accompanied by decentralisation of HAART services 
(NIMART) to prevent loss to follow-up at antiretroviral referral points.  
 
Key words: prevention of mother-to-child transmission, uptake of PMTCT, 
PMTCT cascade 
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Background  
 
Evidence now shows elimination of mother-to-child transmission can be a realistic 
goal for resource limited countries.
1
 Providing the most effective antiretroviral 
regimen for HIV-positive pregnant women using Option A or Option B WHO 
treatment guidelines can reduce the risk of mother-to-child transmission (MTCT) to 
less than 5% in a breastfeeding population and to <2% in non-breastfeeding 
populations.
2,3
 In a clinical trial setup, both Option A and Option B WHO treatment 
guidelines are proven to be efficacious in reducing the risk of mother-to-child 
transmission.
2,4
 At programmatic level however, delivering a comprehensive 
prevention of mother-to-child transmission of HIV/AIDS (PMTCT) programme to 
HIV-positive mothers and their infants requires longitudinal follow-up of both 
mothers and infants and delivery of high quality PMTCT preventive, treatment and 
care services called the PMTCT cascade services.  
 
Globally only 48% of the estimated 17 million HIV-positive women receive ARVs 
for prevention of mother-to-child transmission.
5
 The literature indicate achievement 
of the paediatric HIV elimination goal requires at least >95% uptake of antiretroviral 
treatments among HIV-positive women.
6
 In countries that implement the WHO 
treatment Option A guideline, CD4 count testing is a crucial component for initiating 
effective ARV regimens.
5
  
 
A number of studies have been carried out to measure uptake of the PMTCT cascade 
and missed opportunities in sub-Saharan African countries.
7-14
 Most of these studies 
are small in scale,
7,9-11,14
 or measure uptake of simple regimens (single dose 
nevirapine) rather than combination antiretrovirals.
8,12,13
 A recent systematic review 
of PMTCT studies indicates uptake of simple regimens (single dose nevirapine) in 
four low income sub-Saharan African countries was on average 55%.
15
 The study 
highlights the lack of operational research studies that measure uptake of combination 
ARV regimens.  
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This paper presents data on uptake of antenatal and perinatal PMTCT services and 
missed opportunities at a national level in the context of the WHO 2010 Option A 
treatment guideline in South Africa. The study was conducted between June and 
December 2010 during a time when most provinces of South Africa were at an early 
stage of adopting the WHO Option A treatment guideline. We identify key dropout 
points in the PMTCT cascade services, including their policy implications, and 
provide national and provincial level baseline data on uptake of WHO Option A 
guideline in South Africa.  
 
Methods 
 
Study design 
 
A cross-sectional survey was conducted from June to December 2010 among 
mother/caregiver-infant pairs visiting immunisation service points within public 
primary health care facilities (PHCs) and community health centres (CHCs) in all 
nine provinces of South Africa. The primary and secondary objectives of the survey 
were to provide national and provincial level estimates of mother-to-child 
transmission (MTCT) rates and uptake of PMTCT services, respectively. This study 
analyses the national uptake of PMTCT services and identifies drop out points at each 
step of the PMTCT service pathway.  
 
Sample size and Sampling  
 
The desired sample size for the study was the collection of interview data and infant 
blood samples from 12200 mother-infant pairs. Sample size was calculated with a 
projected transmission rate of 7% with dual therapy, 15% with sdNVP, and 29% for 
untreated MTCT. A precision level of 1%-2%, an estimated 29% of HIV-exposure 
among infants and a design effect of 2 was considered in calculating sample size. 
Further details on parameters used for sample size calculation and provincial details 
are presented elsewhere.
16
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The sampling frame comprised all PHCs and CHCs throughout the country. Satellite 
or mobile clinics, small facilities (immunisation number below 130 per annum), 
private facilities and public hospitals were not included in the sampling frame. A 
stratified multistage sampling method was used to select sample facilities. Facilities 
in the sampling frame were stratified into three groups based on the 2007 district 
health information system (DHIS) immunisation data and the 2009 antenatal HIV 
prevalence estimates: medium size facilities with 130 -300 annual immunisation 
(DTP1) coverage, large (≥ 300 annual DTP 1 coverage) facilities with HIV 
prevalence below the national HIV prevalence estimate (<29%), and large facilities 
(≥300 annual DTP1coverage) with HIV prevalence above or equal to the national 
HIV prevalence estimate (≥29%). Probability proportional to size sampling method 
was used to select five hundred eighty (580) medium and large size facilities for 
inclusion in the survey and 3-4 weeks were spent in each facility to collect interview 
data and infant dried blood spots (DBS) from mother-infant pairs attending six weeks 
immunisation visit.  
 
Data collection 
 
10820 mother/caregiver-infant pairs visiting six weeks immunisation services were 
approached and screened for eligibility. Mothers/caregivers were requested for 
consent to participate in the study if infants were between 4-8weeks of age and had 
no emergency illness. Those who gave consent were interviewed on reasons for the 
visit, antenatal and peripartum PMTCT services received, and knowledge about 
MTCT and PMTCT services attended.  
 
After the interview was conducted, pre-test counselling was given to each mother 
individually and mothers were requested for their written informed consent to receive 
infant HIV testing.  Mothers who agreed to infant testing were given confidential 
linked testing and results were returned to mothers through the health facility using 
the routine system. Anonymous testing was offered if mothers /caregivers did not 
want the result.  
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Data were collected on electronic (cell phone) questionnaires and then transferred to 
STATA SE (version 12, Texas, 77845 USA) for analysis.  
 
Statistical analysis 
 
Infants were included in this analysis if they were brought by their mother and the 
PMTCT section of the questionnaire was answered. A weighted analysis was 
performed to describe the socio-demographic characteristics of participants.  HIV 
status of mothers was determined from self-report of mothers or from enzyme 
immunoassay (EIA) (Genscreen HIV antibody assay) test done on infants DBS. EIA 
test result was considered a biomedical marker for maternal HIV status. Mothers who 
either self-reported an HIV-positive status or had an EIA positive infant were 
classified as HIV-positive mothers. These mothers were considered as the target 
population for the PMTCT programme. Mothers who reported HIV-negative status 
with negative or no infant EIA test result were considered as HIV-negative mothers 
and classified as non-target for the PMTCT programme. A Socioeconomic score 
(SES score) was created from availability of the following working items in the 
house: stove, refrigerator, radio, TV and car. Results are weighted for sample size 
realisation and the 2010 live birth distribution across provinces. 
 
We calculated a weighted proportion of mothers who had antenatal testing and who 
received an antenatal test result, proportion of reported HIV-positive mothers, 
proportion of HIV-exposed infants (per EIA test or maternal report) whose HIV-
exposure status was known and reported by the mother; and proportion of all HIV-
exposed infants (known and unknown) whose mother received a CD4 count test, CD4 
count test result, maternal ARV prophylaxis/HAART and both maternal and infant 
ARVs. Maternal AZT or HAART received for any duration during pregnancy plus 
infant nevirapine (NVP)/AZT received at birth was considered as a marker for uptake 
of both maternal and infant ARV regimen. Percentage of known HIV-exposed infants 
who dropped out at each step along the cascade and missed opportunities for PMTCT 
services due to unknown infant HIV-exposure status are reported.  
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The survey protocol was approved by the institutional review board of the Medical 
Research Council of South Africa and the Office of Associate Director of Science at 
the Centers for Disease Control and Prevention, United States of America. All study 
participants provided written informed consent. 
 
Results 
Description of the study population 
 
Ten thousand eight hundred twenty (10820) mothers/caregivers who brought infants 
to sample clinics for six weeks immunisation service were approached and screened 
for eligibility (fig 3). Mother-infant pairs who were eligible were requested for 
consent to participate in the survey. Ninety-nine percent (10735) of total screened 
mother/caregiver infant pairs were eligible and agreed to an interview, of which 
10357(97%) mothers who responded to maternal sections of the survey were included 
in this analysis. Of mothers interviewed, 9896 (96%) had both interview data and 
laboratory results. This yielded 81% (9896) national sample size achievement of the 
desired/planned 12200 sample size.  
 
The socio-demographic characteristics of the study population are presented in table 
4.The majority of participants were single mothers (74.4%), whose infants are from 
African/black race (98.6%), and had finished 1-5 years of high school education 
(77.6%). The average maternal age was 25.9 years. Most (60.2%) pregnancies were 
unplanned and the majority of mothers attended the first antenatal care visit in their 
second (48%) or third (12.5%) trimester. 
 
Uptake of services along the PMTCT cascade  
 
From the total 10357 mothers interviewed on the maternal section of the study, 58 
(<1%) mothers reported knowing their HIV-positive status prior to pregnancy. From 
the remaining 10299 mothers with unknown or HIV-negative status prior to 
pregnancy, 98.7% reported receiving HIV testing during antenatal visits (fig 4). 
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Almost all (97.7%) mothers who received HIV testing received their test results.  Of 
those who tested and received their test result, 29.5% reported being HIV-positive as 
opposed to 32.2% (3209) total HIV-exposed infants identified from both infant EIA 
test and maternal report. 
 
Figure 4 presents weighted estimates of maternal knowledge of infant HIV-exposure 
status and attendance of the PMTCT programme among both known and unknown 
HIV-exposed infants. According to our estimate, of the 3209 HIV-exposed infants in 
the study, 89.6% were known HIV-exposed infants as reported by mothers and 10.4% 
were unknown HIV-exposed infants - eight percent (8.2%) reported HIV-negative 
status and the remaining 2.2% reported unknown HIV status (fig 5 step A and B).  
 
Of all HIV-positive mothers, 75% (2339) received a CD4 count test and 67% (2110) 
received their CD4 count test results (fig 5 step C and D). In total 22.6% of HIV-
positive mothers  missed CD4 count test or result – 14.6% did not have CD4 count 
test, and 8.0% did not receive their CD4 test result (fig 5 step B–D, step B-C, and 
step C-D respectively).  
 
Of all HIV-positive mothers (known and unknown), 29.5% of mothers received 
HAART and 52.5% of mothers received maternal ARV prophylaxis (AZT) during 
pregnancy. In total 82% (2584) of all HIV-positive mothers (known and unknown) 
received maternal HAART or ARV prophylaxis (AZT). Among those who received 
HAART, 37%, 57% and 6% of mothers were initiated on HAART before pregnancy, 
during pregnancy and after delivery respectively. AZT prophylaxis was started at 14 
weeks or earlier in 5% of mothers, 47% started AZT prophylaxis between 14 weeks 
and 28 weeks, and 24% received AZT prophylaxis at or after 28 weeks. Close to a 
quarter (24%) of mothers who received AZT prophylaxis did not recall the duration.  
 
Infant NVP was received by 83.2% of all HIV-exposed infants. Among those who 
received infant NVP, 41% of HIV-exposed infants were on NVP prophylaxis for 4 
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weeks or more, 45% received NVP for less than 4 weeks, and the rest 14% of 
mothers did not recall duration of infant NVP.  
 
Figure 6 presents the regimen mother-infant pairs received. Seventy eight percent 
(78%) of all HEI received both maternal (AZT and HAART) and infant ARVs. The 
remaining 2.6% received single dose maternal and infant NVP, 4.3% received 
maternal ARV only, 2.7% received infant NVP/AZT only, and 1.4% of known HEI 
and 10.4% unknown HIV-exposed infants missed both maternal and infant ARVs.  
 
Lifelong antiretroviral treatment (HAART) 
 
Among 1797 mothers who reported their CD4 count number, 49% (881) had CD4 
count ≤350 cell/µl.  Of the 881 mothers with CD4 count ≤350 cell/µl, 74% (652) 
were referred to ART clinics for initiation of HAART and 64% (564) reported they 
received HAART (fig 7).Ten percent (10%) of mothers eligible for HAART were 
referred to ART clinics but did not receive HAART (4% reported they did not go to 
ART clinic and 6% reported visiting the ART clinic but were not initiated on 
HAART). In total 36% of eligible mothers with CD4 count ≤350 cell/µl missed 
lifelong ART (fig 7 A-C).  However, almost all (97%) eligible women who did not 
receive HAART received maternal ARV prophylaxis.  
 
Uptake of HAART was relatively higher (77.3% 95% CI: 71%-82%) among mothers 
with CD4 count ≤200 cell/µl compared to mothers with CD4 count  200-350 cell/µl 
(56.0% 95% CI:51%-61%). All provinces initiated HAART for both women with 
CD4 count ≤200 cell/µl and CD4 count 200-350 cell/µl as recommended in the new 
WHO and South African guidelines. Across provinces between 30% and 60% of 
mothers who were initiated on HAART had CD4 count 200-350 cells/µl. 
 
Discussion  
The study shows high uptake of antenatal HIV testing (97.7%) and more than 75% 
uptake of both maternal and infant ARVs among all HIV-exposed infants. Significant 
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improvement has been made in increasing uptake of PMTCT service in South Africa. 
Since the national scale-up of the PMTCT programme in 2003/2004 the uptake of 
antenatal testing has doubled.
17
 A number of interventions, including the introduction 
of universal offer of testing at antenatal clinics, and increased access to ARV 
treatments, have made a notable contribution to the success of the South African 
PMTCT programme. Despite this success, the country is still one of the highest 
burden countries globally with 30% HIV prevalence among antenatal women and an 
estimated 40000 new infections occurring annually among infants.
18,19
 Hence 
achieving the new infection elimination goals in South Africa requires intensive 
effort to substantially increase the uptake of effective ARV regimens among all 
HEIs.
6
 Certain gaps that may challenge the achievement of this target are identified in 
this study.  
 
The study identifies high attrition rate of mother-infant pairs between HIV diagnosis, 
CD4 count test and initiation of highly active antiretroviral therapy with 10.4% of 
mothers who do not know their HIV-positive status, 14.6% of known HIV-positive 
mothers who do not receive a CD4 count test, additional 8% of mothers who do not 
receive their CD4 count results and 10% of mothers who do not initiate ART despite 
eligibility and referral to ART sites.   
 
Most mothers had at least one antenatal HIV test (97.7%) during pregnancy. Despite 
this, 10.4% of mothers did not know their HIV-positive status. Our study did not 
assess timing of testing and uptake of late pregnancy repeat tests. However, in light 
of increasing research that shows higher rate of new infections during pregnancy,
20
  
both early and repeat antenatal tests should be considered essential for all mothers 
attending antenatal services unless HIV-positive status is confirmed prior to 
pregnancy or at the first antenatal visit. 
 
Several studies have reviewed challenges surrounding the current centralised CD4 
count testing system.
21-23
 Challenges that have been found to be the main contributors 
to the drop out at CD4 count service points in the current centralised system are 
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supply chain failures, unreliable specimen transport systems, long turnaround times, 
and distance. As demands for CD4 count testing increase, these challenges will 
continue to prevail unless laboratory systems necessary to support an effective testing 
service are strengthened.  
 
Point-of-care CD4 diagnostic tests can improve access to CD4 count and turnaround 
time for results.
24
  However, the feasibility of implementing this strategy in resource 
limited countries including the cost of placing CD4 count machines in each clinic, 
human resource, logistic and infrastructural needs of such laboratory tests at 
peripheral levels is not well established.  Best practices from studies in sub-Saharan 
African countries recommend simple strategies such as on-site same day blood draw 
for CD4 count test which could increase uptake of CD4 count testing.
11
 
 
While innovative studies are urgently needed to advance cost-effective and feasible 
solutions that simplify the provision of CD4 count service, governments should also 
consider the alternative WHO Option B treatment as a strategy to curb the operational 
challenges of increasing uptake of effective ARV regimens. The South African 
government recently adopted the WHO Option B treatment guideline. The adoption 
of this guideline will improve care to the close to one quarter (22.6%) of mothers 
(and their infants) who drop out at CD4 count service and those that receive less 
effective ARV regimens without assessment of their eligibility for HAART.  
 
A recent analysis of cost-effectiveness of the WHO treatment Options A and Option 
B guidelines shows that treatment Option B is more cost-effective than treatment 
Option A due to the paediatric HIV costs averted by initiating ARVs early for all 
HIV-positive mothers regardless of CD4 count.
25
 However, the study notes poor 
adherence to treatment and loss to follow-up after delivery could lead to virologic 
failure and shorter maternal life expectancy.  In the South African programme, the 
WHO Option B is launched with a fixed dose combination therapy (a single dose 
therapy given once a day). This is expected to significantly lower the pill burden (and 
side effects) on patients, and improve adherence to treatment.   
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However, the other concern in this study was the significant proportion (10%) of 
mothers who dropped out after referral to antiretroviral treatment sites. Research in 
sub-Saharan African countries indicates that gaps in the referral and tracking systems 
of PMTCT programmes are major barriers for early initiation of HAART.
26,27
 With 
the adoption of treatment Option B in South Africa, the readiness of antenatal 
facilities to introduce nurse initiated ARV treatment (NIMART) should be assessed. 
In areas where ARVs are not initiated at antenatal sites, drop out at antiretroviral 
referral points could pose a significant challenge for early initiation of ARV 
treatments.
28
   
 
Our findings on the two key drop out points (CD4 count, and referral to ARV sites) 
are similar to other studies in South Africa and sub-Saharan African countries.
29
 In a 
study in KwaZulu-Natal, CD4 count testing points and initiation of HAART are 
reported as the key drop out points in the antenatal PMTCT programme.
30
  Other 
studies in Sub-Saharan African countries also report similar findings.
15,29,31
  
 
According to our study findings, although the 2010 guideline was adopted in South 
Africa in the same year as our study was conducted, all provinces initiated HAART 
for mothers whose CD4 count was between 200 and 350 cells/µl per the new 
guideline. More than half (52.3%) of mothers also received ARV prophylaxis before 
28 weeks as opposed to 24.1% of mothers who received ARVs at or after 28 weeks as 
per the old guideline.  
 
Reports indicate most sub-Saharan African countries have lower coverage of ARV 
regimens compared to the PMTCT coverage we report for South Africa.  The PEARL 
study in Zambia,  and Cote d’Ivoire reported 30%, and 17.9% umbilical cord 
maternal and infant NVP coverage and 89% and 70.1% maternal NVP coverage from 
record review respectively.
8,13
 Our ARV uptake rates are lower than uptake rates 
reported from routine data in the UNAIDS country report. The UNAIDS country 
progress report gathered from countries routine data for 2010 reports >95% of 
antenatal testing and maternal antiretroviral treatment coverage for South Africa.
5
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Reports from routine data may overestimate the coverage of PMTCT programme as 
these reports are limited to women that are in the PMTCT programme (known HEI) 
only, and the data collation system of routine data may introduce double-counting 
when data from different sources are aggregated. 
 
Our study has several limitations. Although the study measured uptake of PMTCT 
services at national and provincial level, children who had already died by the age of 
4–8 weeks, children who did not receive first immunisation at public facilities and 
children who received first immunisation after 8 weeks of age were not included in 
this study. However most immunisations occur in primary health care facilities and 
attendance of six weeks immunisation clinic in South Africa is high (>95%), hence 
our results represent most infants.  Repeat antenatal testing, timing of antenatal 
testing, uptake of early infant diagnosis, cotrimoxazole coverage and uptake of 
postnatal PMTCT services are not captured in this study.  Due to the structure of our 
questionnaire, only those mothers who had not had an antenatal test responded to the 
question asking about ‘prior knowledge of HIV status’. Hence the number of mothers 
who reported to know their HIV-positive status prior to pregnancy (<1%) may be an 
under representation. Lastly the data on all PMTCT cascade indicators was collected 
from interviews with mothers. Recall bias could be expected on certain PMTCT 
cascade indicators, although the duration of recall is not very long (<52 weeks).   
 
Conclusion 
 
This is the first national survey in South Africa presenting data on coverage and 
missed opportunities for PMTCT services at national and provincial level. Studies 
conducted prior to this study in South Africa or elsewhere are smaller in scale or 
measure coverage of simple regimens (single dose nevirapine) implemented at initial 
rollout phase of the PMTCT programme. The study findings highlight CD4 count and 
initiation of ART as key drop out points that require urgent attention and innovative 
solutions. Given the observed high dropout at CD4 count point and related delays in 
initiation of HAART, this study supports the recent adoption of the WHO Option B 
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treatment guideline in South Africa which recommends initiation of HAART for all 
HIV-positive mothers regardless of CD4 count. The adoption of the new guideline 
should be accompanied by decentralisation of HAART services (NIMART) to 
prevent loss to follow-up at antiretroviral referral points.  
 
Acknowledgment: CDC, NRF, NICD/NHLS, UNICEF, Mickey Chopra, Tanya 
Doherty, Nathan Schaffer, Thabang Mosala, Wondwossen Lerebo, Katherine 
Robinson, Nobuntu Noveve, provincial supervisors, data collectors, mothers and 
infants,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86 
References 
1. Marazzi M, Liotta G, Haswell J et al. Extended use of highly active 
antiretroviral therapy (HAART) during pregnancy in Southern Africa is 
highly protective in HIV-1 prevention of mother-to-child-transmission 
(PMTCT) also in women with higher CD4 cell counts. Paper presented at: 
5th International AIDS Society Conference on HIV Pathogenesis, Treatment 
and Prevention; 19-22 July, 2009  Cape Town, South Africa. 
2. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine 
and single-dose nevirapine prophylaxis during pregnancy and breastfeeding 
for prevention of mother-to-child transmission of HIV-1 (Kesho Bora 
study): a randomised controlled trial. Lancet InfectDis. 2011;11(3):171-180. 
3. Thomas TK, Masaba R, Borkowf CB et al. Triple-antiretroviral prophylaxis 
to prevent mother-to-child HIV transmission through breastfeeding--the 
Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. Mar 
2011;8(3):e1001015. 
4. Chasela CS, Hudgens MG, Jamieson DJ et al. Maternal or infant 
antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. Jun 17 
2010;362(24):2271-2281. 
5. UNAIDS. Global HIV/AIDS response epidemic update and health sector 
progress towards universal access 2011 progress report. 
http://www.who.int/hiv/pub/progress_report2011/en/index.html. Published 
30 November 2011. Accessed 20 September 2012. 
6. Ciaranello AL, Perez F, Keatinge J et al. What will it take to eliminate 
pediatric HIV? Reaching WHO target rates of mother-to-child HIV 
transmission in Zimbabwe: a model-based analysis. PLoS Med. Jan 
2012;9(1):e1001156. 
7. Coetzee D, Hilderbrand K, Boulle A, Draper B, Abdullah F, Goemaere E. 
Effectiveness of the first district-wide programme for the prevention of 
mother-to-child transmission of HIV in South Africa. Bull World Health 
Organ. Jul 2005;83(7):489-494. 
 
 
 
 
 87 
8. Coffie PA, Kanhon SK, Toure H et al. Nevirapine for the prevention of 
mother-to-child transmission of HIV: a nation-wide coverage survey in Cote 
d'Ivoire. J Acquir Immune Defic Syndr. Jul 1 2011;57 Suppl 1:S3-8. 
9. Horwood C, Vermaak K, Butler L, Haskins L, Phakathi S, Rollins N. 
Elimination of paediatric HIV in KwaZulu-Natal, South Africa: large-scale 
assessment of interventions for the prevention of mother-to-child 
transmission. Bull World Health Organ. Mar 1 2012;90(3):168-175. 
10. Jackson DJ, Chopra M, Doherty TM et al. Operational effectiveness and 36 
week HIV-free survival in the South African programme to prevent mother-
to-child transmission of HIV-1. AIDS. Feb 19 2007;21(4):509-516. 
11. Mandala J, Torpey K, Kasonde P et al. Prevention of mother-to-child 
transmission of HIV in Zambia: implementing efficacious ARV regimens in 
primary health centers. BMC Public Health. 2009;9:314. 
12. Stringer EM, Ekouevi DK, Coetzee D et al. Coverage of nevirapine-based 
services to prevent mother-to-child HIV transmission in 4 African countries. 
JAMA. Jul 21 2010;304(3):293-302. 
13. Stringer JS, Sinkala M, Maclean CC et al. Effectiveness of a city-wide 
program to prevent mother-to-child HIV transmission in Lusaka, Zambia. 
AIDS. Aug 12 2005;19(12):1309-1315. 
14. Tsague L, Tsiouris FO, Carter RJ et al. Comparing two service delivery 
models for the prevention of mother-to-child transmission (PMTCT) of HIV 
during transition from single-dose nevirapine to multi-drug antiretroviral 
regimens. BMC Public Health. 2010;10:753. 
15. Tudor Car L, Brusamento S, Elmoniry H et al. The Uptake of Integrated 
Perinatal Prevention of Mother-to-ChildHIV Transmission Programs in 
Low- and Middle-Income Countries: A Systematic Review. PLoS ONE. 
2013;8(3):e56550. 
16. Goga A, Dinh T, Jackson D, for the SAPMTCTE study group. Evaluation of 
the Effectiveness of the National Prevention of Mother-to-Child 
Transmission (PMTCT) Programme Measured at Six Weeks Postpartum in 
South Africa, 2010. 
 
 
 
 
 88 
http://www.info.gov.za/view/DownloadFileAction?id=165280. Accessed 17 
August 2012. 
17. Reagon G, Irlam J, Levin J. The national primary health care facilities 
survey 2003. Durban: Department of Health. 
http://www.hst.org.za/uploads/files/phc_survey04.pdf. Published June 2004. 
Accessed 12 January 2011. 
18. Statistics South Africa. Mid-year population estimates 2010. Statistical 
release P0302. Published 
http://www.statssa.gov.za/publications/P0302/P03022010.pdf. Accessed 
Accessed  15 June 2011. 
19. National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South 
Africa. Pretoria: Department of Health;  2009. http://www.health-
e.org.za/documents/85d3dad6136e8ca9d02cceb7f4a36145.pdf. Accessed 14 
October 2012. 
20. Humphrey JH, Marinda E, Mutasa K et al. Mother to child transmission of 
HIV among Zimbabwean women who seroconverted postnatally: 
prospective cohort study. BMJ. 2010;341:c6580. 
21. Peter T, Badrichani A, Wu E et al. Challenges in implementing CD4 testing 
in resource-limited settings. Cytometry B Clin Cytom. 2008;74 Suppl 
1:S123-130. 
22. Peter T, Shimada Y, Freeman R, al. e. The need for standardization in 
laboratory networks. Am J Clin Pathol. 2009;131:867–874. 
23. Birx D, DeSouza M, Nkengasong J. Laboratory challenges in the scaling up 
of HIV, TB, and malaria programs: the interaction of health and laboratory 
systems, clinical research, and service delivery. Am J Clin Pathol. 
2009;131:849-851. 
24. Cheng X, Irimia D, Dixon M et al. A microchip approach for practical label-
free CD4+ T-cell counting of HIV-infected subjects in resource-poor 
settings. J Acquir Immune Defic Syndr. Jul 1 2007;45(3):257-261. 
 
 
 
 
 89 
25. Ciaranello AL, Perez F, Engelsmann B et al. Cost-effectiveness of World 
Health Organization 2010 guidelines for prevention of mother-to-child HIV 
transmission in Zimbabwe. Clin Infect Dis. Feb 2013;56(3):430-446. 
26. Baek C, Mathambo V, Mkhize S, Friedman I, Apicella L, Rutenberg N. Key 
Findings from an Evaluation of the mother2mothers Program in KwaZulu-
Natal,South Africa. Washington DC: Horizons/Population Council, Health 
Systems Trust. URL:http://www.hst.org.za/uploads/files/m2m.pdf. 
Published 2007. Accessed 14 August 2009. 
27. mothers2mothers Program. Improving Client Retention in the PMTCT 
Cascade through Active Client Follow-Up (ACFU), finding from a 4- 
country pilot 
project.URL:http://maternalhealthtaskforce.org/component/docman/doc_vie
w/1331-m2m-acfu-report-december-2011?Itemid=220. Published 2011. 
Accessed 22 April 2012. 
28. Georgeu D, Colvin CJ, Lewin S et al. Implementing nurse-initiated and 
managed antiretroviral treatment (NIMART) in South Africa: a qualitative 
process evaluation of the STRETCH trial. Implement Sci. 2012;7:66. 
29. Ahoua L, Ayikoru H, Gnauck K et al. Evaluation of a 5-year programme to 
prevent mother-to-child transmission of HIV infection in Northern Uganda. 
J Trop Pediatr. Feb 2010;56(1):43-52. 
30. Horwood C, Haskins L, Vermaak K, Phakathi S, Subbaye R, Doherty T. 
Prevention of mother to child transmission of HIV (PMTCT) programme in 
KwaZulu-Natal, South Africa: an evaluation of PMTCT implementation and 
integration into routine maternal, child and women's health services. Trop 
Med Int Health. Sep 2010;15(9):992-999. 
31. van Lettow M, Bedell R, Landes M et al. Uptake and outcomes of a 
prevention-of mother-to-child transmission (PMTCT) program in Zomba 
district, Malawi. BMC Public Health. 2011;11:426. 
 
 
 
 
 
 
 
 90 
Table 4: Socio-demographic characteristics of the study population by eligibility for 
PMTCT programme  
 
 HIV-positive mothers 
(mother HIV infected or 
infant HIV-exposed) [# (%)]  
N1 = 401,947  (n1=3209)  
Maternal and infant Characteristics  Number   (%) 
Maternal Age  
Mean (Range) 
 
27.6(15-46) 
Maternal Education   
None 
Grade 1-7 
Grade 8-12 
Above Grade12 
No information 
 
95 (2.7) 
624 (18.3) 
2410 (76.3) 
78 (2.6) 
2 (0.05) 
Marital status  
Single 
Married/cohabiting 
Widowed/Divorced 
No information  
 
2445 (78.8) 
740 (20.5) 
24 (0.8) 
0 
SES score created from working items (CI) -0.11 [-0.21, -0.03] 
No of live  children 
1 
2 
 ≥ 3 
 
922 (28.1) 
1215 (38.2) 
1072 (33.7) 
Planned Pregnancy 
Yes 
No  
Missing 
 
1209 (36.9) 
1989 (62.8) 
11(0.4) 
Gestational age at first ANC 
1
st
 trimester 
2
nd
 trimester 
3
rd
 trimester 
Missing  
 
 
723 (20.1) 
1545 (49.7) 
378 (12.5) 
563(17.7) 
Infant gender 
Male 
Female 
 
1594 (49.8) 
1615 (50.2) 
Infant  Race  
Black  
Coloured 
White, Indian and other 
 
3134 (98.6) 
69(1.3) 
6 (0.1) 
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Total mothers and caregivers 
interviewed  
10735 (99%) 
Figure 3: 2010 SAPMTCTE interview data study profile 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Uptake of antenatal HIV testing, national result, South Africa 2010 survey 
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Figure 5: Uptake of services along the PMTCT cascade, national result, South Africa 
2010 survey  
 
 
 
 
 
Figure 6:Antiretroviral Regimens received by mother-infant pairs 
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Figure 7: Cascade for lifelong ART 
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Abstract 
 
Objectives  
Global targets aim to virtually eliminate mother-to-child transmission of HIV 
(MTCT). The 2010 overall national perinatal HIV transmission rate in South Africa is 
reported at 3.5%, however wide geographical differences (ranging 1.4%-5.9%) in 
MTCT were documented. We sought to determine reasons for these geographical 
differences. 
 
 Methods 
A situational assessment was conducted among public facilities randomly selected 
from all nine provinces of South Africa using health worker interviews and record 
reviews. This was followed by a national survey which involved caregiver interviews 
and collection of blood samples (for HIV testing) from infants attending six weeks 
immunisations in sampled facilities. Maternal report of receiving antenatal 
antiretroviral treatment/ prophylaxis for any duration during pregnancy plus infant 
nevirapine (NVP)/ azidothymidine (AZT) received at birth was considered as a 
marker for total perinatal antiretroviral coverage. Provinces were categorised into two 
groups according to achievement of the UNGASS universal (defined as at least 80% 
coverage) antiretroviral coverage target. Individual, health facility and provincial 
level factors were considered in multivariate analysis. 
 
Results  
By 2010 three provinces achieved the target for universal access (≥80%) to 
antiretroviral treatments (range 80%-88%). The remaining six provinces had an 
average antiretroviral coverage of 69% (range 64%-76%). The average transmission 
rate in the three provinces that achieved ≥80% antiretroviral coverage was 2.8% 
compared to 4.9% in the six provinces that achieved <80% antiretroviral coverage. In 
a multivariate analysis provinces that did not achieve universal coverage had 
significantly higher transmission risk [OR 1.7, 95%CI 1.2 -2.6] compared to 
provinces that achieved universal coverage.  
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Conclusion 
Our study shows PMTCT services coverage is a significant determinant of 
geographical variations in MTCT rates. The achievement of 2.8% transmission rate 
with 80-88% antiretroviral coverage contrasts with results from modelling studies 
that report the requirement of 95%-100% antiretroviral coverage for achieving 
perinatal MTCT elimination targets. 
 
Key words: geographical variations, mother-to-child transmission of HIV, 
PMTCT cascade, universal access  
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Background  
 
Global targets aim to reduce the risk of mother-to-child-transmission of HIV (MTCT) 
to below 2% perinatally and 5% by 18-months postnatally.
1
 By mid-2010, an 
estimated 390 000 children globally were infected with HIV through mother-to-child 
transmission.
2
 Reaching the global target for reducing new infant HIV infections 
from current levels to below 2% perinatally and 5% (43000) postnatally by 2015 
requires substantial decline in  the number of new infant HIV infections.
2
 
  
Mother-to-child-transmission rates have been shown to have wide variations across 
populations and geographical areas. In South Africa substantial subpopulation level 
transmission rate differences have been reported. The Good Start study reported 
MTCT rates ranging from 8.6% in a well-functioning peri-urban site (Paarl) to 13.7% 
in a poorly functioning rural site (Rietvlei).
3
 In the prevention of mother-to-child 
transmission (PMTCT) survey completed recently (2010), overall national perinatal 
HIV transmission rate in South Africa was reported at 3.5% (95%CI, 2.9-4.1), 
however there was wide variation between provinces in the perinatal transmission 
rate ranging between 1.4%-5.9%.
4
 What explains this variation in transmission rates 
across provinces is not well understood.   
 
To date no study attempts to assess the impact of PMTCT services coverage on 
transmission rate. A few mathematical modelling studies estimate the level of 
PMTCT services coverage required in order to significantly reduce population level 
MTCT rates.
5,6
 Results from these modelling studies indicate a minimum of 95%-
100% PMTCT coverage is required in order to approach the 2% perinatal and 5% 
postnatal (18-months) MTCT targets.
1,5
 
 
 In 2001, the United Nations General Assembly (UNGASS) set a target to ensure 
universal access (80% coverage) to effective antiretroviral treatment by 2010.
7
 
Recently new and ambitious targets have been set to achieve 90% coverage of 
PMTCT services.
1
 Whilst there are progress reports and data from modelling 
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exercises tracking the achievement of these targets, no study has used real data to 
measure population level MTCT reductions achieved as a result of the attainment of 
the above targets.     
This study aims to explore health facility and individual level factors that explain 
geographical variations in mother-to-child transmission rate across the nine provinces 
of South Africa, using national survey data collected from randomly selected public 
primary health care facilities within the nine provinces of South Africa. By doing 
this, the study assessed the level of MTCT rates achieved as a result of the attainment 
of the UNGASS ≥ 80%  provincial PMTCT cascade  coverage target. 
 
Methods 
 
Study design, sample size, sampling   
Two quantitative studies: (i) a cross-sectional situational assessment of health 
facilities and (ii) a facility-based six weeks cross-sectional survey among 
mother/caregiver-infant pairs were conducted at public primary health care facilities 
randomly selected from the total 3390 public primary health care facilities (PHCs) 
and community health centres (CHCs) in South Africa. 
 
A stratified multistage sampling design was used to select the study facilities. 
Facilities in each province were stratified into four groups based on their six weeks 
annual immunisations number (extracted from the 2007 district health information 
System)  and antenatal HIV prevalence of the district (from 2009 antenatal survey) as 
follows: small facilities with <130 annual immunisation, medium size facilities with 
130 -300 annual immunisation, large (annual immunisation >= 300) facilities with 
antenatal HIV prevalence below the national HIV prevalence estimate (29%), and 
large facilities (>=300 annual immunisation) with antenatal HIV prevalence above or 
equal to  29%.
8
  
 
The sample size of medium and large facilities was determined based on antenatal 
HIV prevalence and transmission rate estimates (detailed description of sample size is 
 
 
 
 
 99 
presented elsewhere
4
). Five hundred and eighty (580) facilities were selected from 
medium and large size facilities using probability proportional to size sampling 
method. Additional 100 facilities (10-20 per provinces) were purposively selected 
from small facilities. This gave a total of 680 facilities selected from small, medium 
and large facilities. 
 
Situational Assessment 
The situational assessment was conducted from January to May 2010 in the total 680 
facilities selected from small medium and large facilities. This component of the 
survey targeted collection of data on human resources, referral systems, record 
keeping, linkage and organization of the PMTCT programme using structured 
interviews with clinic managers, health information officers, immunisation nurses, 
PMTCT nurses and  sick-child (IMCI) nurses. 
 
SAPMTCTE survey  
Following the situational assessment from June to November 2010, a cross-sectional 
survey was conducted among mother/caregiver-infant pairs visiting immunisation 
service points in the 580 facilities selected from medium and large size facilities. The 
100 facilities selected from small facilities were not included in this component of the 
survey due to logistic feasibility. A fixed number of mother/caregiver-infant pairs 
were enrolled from each facility over a planned three to four weeks recruitment 
period. The desired sample size for the study was the collection of interview data and 
infant blood samples from 12200 mother-infant pairs. Sample size was calculated 
with a projected transmission rate of 7% for dual therapy, 15% for sdNVP, and 29% 
for untreated MTCT.   A precision level of 1%-2%, an estimated 29% of HIV-
exposure among infants and a design effect of 2 was considered in calculating sample 
size. Further details on parameters used for sample size calculation and provincial 
details are presented elsewhere.
4
 
 
10 820 mother/caregiver-infant pairs visiting six weeks immunisation service were 
approached and screened for eligibility by trained nurses. Mothers/caregivers were 
 
 
 
 
 100 
requested for consent to participate in the study if their infants were 4-8 weeks old 
and had no emergency illness. Those who gave consent were interviewed on 
antenatal and peripartum services received socioeconomic status, and knowledge 
about PMTCT and PMTCT services attended. The infant Road-to-health-card was 
checked for documentation of maternal and infant status, gestational age at birth and 
birth weight.  
 
After interview, pre-test counselling was given to each mother individually and if 
mothers consented, infant blood samples (dried blood spots) were collected from heel 
prick. Dried blood spot (DBS) specimens were tested for HIV by means of an 
enzyme immunoassay (EIA) (Genscreen HIV antibody assay). A positive EIA result 
showed HIV-exposure of infant. A qualitative DNA PCR (Amplicor HIV-1 DNA 
PCR version 2.0 assay, Roche Diagnostics, Branchburg, NJ) test was performed on 
all EIA positive DBS to determine whether the infant was currently HIV-positive. 
Infant test results were returned to mothers through the health facility using the 
routine transportation system. De-identified infant test results were linked with the 
interview data using patient identifier (barcode).  
 
Statistical analysis 
Hard copy questionnaires were used for data collection of the situational assessment. 
The SAPMTCTE survey data was collected on electronic (cell phone) questionnaires. 
The PMTCT survey and the situational assessment data were combined on STATA 
SE (version 12, Texas, 77845 USA) for analysis. Survey design data analysis method 
was applied in all univariate and multivariate analysis. Data was weighted for sample 
size realisation and number of live births in each province.   
 
Provincial (province level) perinatal ARV regimen coverage was calculated from the 
total number of known and unknown HIV-positive mothers in the province who 
received maternal azidothymidine (AZT) or HAART for any duration during 
pregnancy plus infant nevirapine (NVP)/AZT received at birth (maternal and infant 
ARV prophylaxis/ HAART) – this was considered as a marker for perinatal PMTCT 
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cascade coverage. Provinces were categorised into two groups based on their 
achievement of the UNGASS universal access (defined as achievement of at least 
80% antiretroviral coverage) target for ARV regimens. Provinces that achieved≥80% 
maternal and infant ARV prophylaxis/HAART coverage were classified as provinces 
that achieved the universal PMTCT coverage target; and provinces that achieved 
below 80% total ARV regimen (maternal and infant ARV prophylaxis / HAART) 
coverage were categorised as provinces that did not achieve the universal PMTCT 
coverage targets for 2010.  
 
Whilst our marker for ARV regimen coverage (maternal and infant ARV 
prophylaxis/ HAART) permits monitoring of the total coverage of maternal and 
infant ARV regimens, this indicator does not distinguish whether appropriate type of 
regimen was received or for how long the treatment was received. For this reason, 
CD4 count number was used to calculate the number of mothers eligible (CD4 count 
≤350 cells/µl) for initiation on HAART, and consecutively HAART coverage was 
calculated for each province. However, six out of the nine provinces had poor 
response rate for CD4 count number, therefore we could not use the HAART 
coverage data to assess coverage of appropriate ARV regimen. In three of the 
provinces we had a relatively higher CD4 count number response rate, thus HAART 
coverage data was used to explain differences in the three provinces transmission 
rates. We also had incomplete data for calculating duration of treatment.  
 
Multivariate analysis of factors affecting mother-to-child transmission rate using 
multiple logistic regression model included analysis of individual biological, clinical 
and behavioural factors, facility level factors (health systems characteristics) and 
provincial coverage of the PMTCT cascade. A logistic regression model was fitted to 
compare transmission differences between provinces that achieved universal 
coverage (80%) of ARV regimens and provinces that did not achieve universal 
coverage. The dependent variable for this analysis was –infant HIV infection. 
Independent variables were taken from both the situational assessment and the six 
weeks survey data. The following variables were considered in adjusting this model: 
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from individual level factors, marital status, maternal age, education, socioeconomic 
status (SES), planned pregnancy, number of life time pregnancies, gestational age at 
birth, infant birth weight, and  history of child sickness since birth. At facility level, 
human resources, referral system, availability of on-site ARV clinic, task shifting and 
community involvement were included. List of variables included in the final model 
are presented in table 7.   
 
SES score was created from five socioeconomic indicators namely: stove, 
refrigerator, radio, TV and car. All variables except gestational age at first antenatal 
visit and CD4 count had 85% and above response rate. Data was imputed using 
chained equations multiple imputation method for all variables included in the 
analysis. Data imputation was considered for CD4 count data, but with six of the nine 
provinces having more than 50% of data missing, imputed CD4 count data could not 
be used for multivariate analysis. For the three provinces that had a relatively higher 
(>60%) response rate for CD4 count number (two of the province had >75% response 
rate and one province had 63% response rate), we used imputed data to explain 
provincial transmission differences.  
 
The survey protocol was approved by the institutional review board at Medical 
Research Council of South Africa and the Office of Associate Director of Science at 
the Centers for Disease Control and Prevention, United States of America. All study 
participants provided written informed consent. 
 
Results 
 
Six out of nine provinces achieved above 80% of the desired sample size in the 
PMTCT survey. One province (Limpopo- LP) had 73% sample size realisation and 
two provinces (Eastern Cape -EC and Northern Cape-NC) had sample size realisation 
below 70%. 10820 mothers/caregivers who brought infants to sample clinics for six 
weeks immunisation services were approached and screened for eligibility. Ninety 
nine percent (10735) of total screened mother/caregiver infant pairs were eligible and 
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agreed for interview, of which 94% provided blood sample for infant HIV testing. In 
total 10182 interview and blood sample data was available for both HIV-exposed and 
-unexposed infants. For this study 3085 HIV-exposed infants who had both EIA and 
PCR test result were included in the analysis (fig 8).  
 
Mothers of HIV-positive and HIV-exposed uninfected infants had similar maternal 
age, and education in both provinces that achieved universal coverage and provinces 
that did not achieve universal coverage (table 5). SES in provinces that achieved 
universal coverage was slightly higher than the provinces that did not achieve 
universal coverage; and within provinces that achieved universal coverage, SES of 
HIV-infected infants was slightly lower. In both provincial categories, more than a 
quarter of mothers of HIV-exposed infants reported their pregnancy was a first 
pregnancy compared to below a quarter of mothers of HIV-exposed uninfected 
infants who reported their pregnancy as first pregnancy. Planned pregnancies were 
higher in provinces that did not achieve the universal coverage target compared to 
provinces that achieved the universal PMTCT coverage target. Low birth weight 
(<2.5kg) among HIV-infected infants was higher (25%) among provinces that did not 
achieve universal coverage compared to provinces that achieved universal coverage 
(19%).  
 
Provincial coverage of PMTCT services and transmission rates 
 
PMTCT service coverage 
 
Three provinces achieved the target for universal access (≥80%) to antiretroviral 
regimens (maternal and infant ARV prophylaxis/HAART) by 2010. The other six 
provinces achieved below 80% total ARV regimens coverage (table 6).  
 
A prominent difference between the provinces that achieved the universal access 
target and the provinces that did not achieve the universal access target was that 
whilst the three provinces that achieved the universal access target had >90% 
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coverage for HIV status knowledge and ≥80% coverage for CD4 count and total 
ARV regimens, the other six provinces that did not achieve the universal access 
target had below 90% coverage for HIV status knowledge and below 80% coverage 
for CD4 count and total ARV regimens coverage. The average total ARV regimens 
(maternal and infant ARV prophylaxis/HAART) coverage in the three provinces that 
achieved the universal access target was 84% (range: 80%-88% ; 95% CI: 81% – 
86%) as compared to 69% (range: 65%-77%; 66% -71%) total ARV regimens 
coverage in the remaining six provinces. Similarly average CD4 count coverage in 
the three provinces was substantially higher (83%; ranging 80%-89%; 95% CI: 80% - 
86%) compared to the remaining six provinces (62%; ranging 54%-69%; 95% CI: 
59% - 65%) (table 6).  
 
Transmission rates 
The average perinatal transmission rate in the three provinces that achieved the 
universal access target for antiretroviral regimen coverage was 2.8% (95% CI: 2.0%-
3.6%) compared to 4.9% (95% CI: 3.8%-6.0%) in the remaining six provinces that 
did not achieve the universal access target (table 6).  
 
Transmission rates in the three provinces that achieved universal (80%) coverage 
Among the three provinces that achieved universal coverage, two provinces had 
below 3% (2.5% and 2.9%) transmission rate and one province had above 3% (3.9%) 
transmission rate. Among these three provinces, HAART coverage was relatively 
higher (65%) in the province (Gauteng -GP) with the lowest (2.5%) transmission rate, 
whilst the province (Western Cape -WC) with the highest transmission rate (3.9%) 
had the lowest HAART coverage (59%) of the three provinces (table 6).  
 
Transmission rates in the six provinces that did not achieve universal (80%) 
coverage 
Among the six provinces that achieved below 80% total ARV regimen coverage, 
three provinces had transmission rate above 5%, one province had transmission rate 
above 4% (4.4%) and two provinces had below 4% transmission rate.  
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The province (North West - NW) which had 4.4% transmission rate had the highest 
HIV status knowledge (87%), and total ARV regimens coverage (77%) of the six 
provinces.  
Of the provinces with below 4% transmission rate, one province (NC) had poor 
sample size realisation, hence we could not confirm whether the estimated 
transmission rate (1.4%) for this province was a true estimate.  
 
The other province (LP) which had below 4% transmission rate had the lowest ARV 
regimen coverage (65%) and the lowest CD4 count coverage (54%) of the nine 
provinces, but the province also had low (3.6%) transmission rate. We did not see any 
association between the PMTCT cascade coverage and transmission rate in this 
province. The province had below 80% (73%) sample size realisation. 
 
Free State (FS) also had the second highest ARV regimen coverage compared to the 
six provinces that did not achieve the universal access target but this province has the 
highest transmission rate (5.9%). Most socio-demographic, maternal and infant 
history indicators were similar between LP, FS and the rest of the 4 provinces in this 
group.    
 
Multivariate analysis  
In a multivariate analysis (table 7), after adjusting for other covariates, provinces that 
had below 80% ARV coverage had significantly higher transmission risk [OR1.7, 
95%CI 1.2 -2.6] compared to provinces that  achieved ≥80% ARV coverage.  
 
Among other factors found influential in multivariate analysis, transmission rate 
among mother-infant pairs who received both maternal and infant ARVs was lower 
by 56% compared to infants who received no or incomplete (mother only or infant 
only ARVs) ARVs. Any breastfeeding (from eight days recall data) was associated 
with 1.8 times higher risk of HIV transmission compared to not breastfeeding. At 
health facility level, facilities that have two or less than two health care personnel 
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who provide VCT service had 2.2 times higher transmission occurrences compared to 
facilities that have more than two health care personnel providing VCT service. 
Uptake of maternal and infant ARV regimen in facilities that have two or less than 
two health care personnel for VCT was lower by 20% from the national uptake of 
maternal and infant ARV. Low birth weight was significantly associated with 
transmission in both the univariate and multivariate analysis (AOR 1.8, 95% CI 1.1 -
2.9). 
 
Other socio-demographic indictors and antenatal and postnatal histories did not have 
statistically significant influence on transmission. 
 
Discussion  
 
In recent years South Africa has shown significant progress in implementing effective 
interventions that are designed to reduce mother-to-child-transmission rates to below 
elimination thresholds. This survey shows while the efforts to implement effective 
interventions has resulted in declining national transmission rate trends, these gains 
are not necessarily uniform across provinces. According to our survey, there are 
substantial transmission differences across provinces (ranging 1.4%-5.9%). Reports 
from other studies also show similar variations in transmission rates within 
subpopulations in South Africa.
9
 National level estimates often mask geographical 
and subpopulation differences in HIV transmission rates. Thus in assessing PMTCT 
programmes progress, subpopulation level inequalities should be recognised.
9
  
 
Our study findings show that provincial level transmission rate differences are 
explained by differences in uptake of ARV regimens and PMTCT cascade services. 
Three provinces achieved universal (80%) ARV regimen coverage. PMTCT services 
coverage (i.e. HIV status knowledge, coverage of CD4 count and ARV regimen 
coverage) varied widely between the three provinces that achieved universal 
coverage and provinces that did not achieve universal coverage. Provinces that 
achieved universal coverage had lower transmission rates compared to provinces that 
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did not achieve universal coverage. The average transmission rate in the three 
provinces that achieved universal coverage was close to the global target at 2.8% 
compared to 4.9% in the six provinces that did not achieve universal coverage. After 
adjusting for multilevel covariates, the transmission rate in low (<80%) ARV 
regimen coverage provinces was higher by 70% [AOR 1.7, 95%CI 1.2 -2.6] 
compared to the transmission rate in the provinces that achieved ≥80% ARV regimen 
coverage.   
 
This study shows that significantly lower transmission rates (2.8%) can be achieved 
by increasing PMTCT uptake rates to 80% and above across subpopulations. Two of 
the three provinces (GP and KZN) that achieved the 80% universal coverage target 
had below 3% transmission rate. Whilst the third province (WC) in this group had 
above 3% transmission rate, this may be explained by the somewhat lower (59%) 
HAART coverage in the province.   
 
In the other six provinces ARV regimen coverage was below 80%. Consequently, 
three of the provinces with below 80% ARV regimen coverage had above 5% 
transmission rate. Of the six provinces, one province (NW) that achieved below 80% 
ARV regimen coverage had 4.4% transmission rate - this relatively lower 
transmission rate compared to the other provinces in the group may be explained by 
the province’s higher ARV regimen (77%) and HIV status knowledge coverage 
(87%). 
 
In the remaining two provinces of the six provinces with ARV regimen coverage 
below 80%: (i) one province (NC) had low transmission rate (1.4%), but the 
transmission rate of this province could not be confirmed as a true estimate due to 
poor sample size realisation in the province (<70%), (ii) LP had low transmission rate 
(3.6%) and low ARV regimen coverage (65%) compared to the other five provinces 
in this group, whilst FS had the second highest ARV regimen (76%) coverage of the 
six provinces but had the highest transmission rate (5.9%). We did not see any 
association, in a univariate analysis, between PMTCT cascade coverage and MTCT 
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in the three provinces mentioned above. This lack of association could be due to 
factors that are not considered in the study (e.g. adherence to treatment, duration and 
type of treatment were not considered in measuring ARV regimen coverage) or due 
to sample size inadequacy (two of the province had a relatively lower -<75% - 
sample size realisation).  For this reason, in the three provinces where clear 
association was not established, we recommend results from repeat surveys to be 
monitored to establish the trend in both the coverage of PMTCT cascade services and 
transmission rate. 
 
None of the provinces achieved the UNAIDS 90% effective ARV regimen target. 
The maximum total ARV coverage achieved was 88% in KZN. In the three provinces 
HAART coverage for women with CD4 <350 was assessed, the coverage of HAART 
was below 70% in all three provinces. Despite this relatively lower antiretroviral 
regimens coverage, two provinces achieved transmission rate below 3% close to the 
eMTCT targets. These results are somewhat in contrast with the findings of a recent 
modelling study by Ciaranello et al. that emphasises the need to achieve near to 100% 
effective ARV regimen coverage in order to approach the MTCT elimination targets.
5
  
According to Ciaranello and colleagues, with 95% uptake of WHO Option A 
treatment guideline, 4-8 weeks transmission rates could only be lowered to 4.1%. In 
contrast to Ciaranello and colleagues’ findings, our study shows, in all provinces that 
achieved 80% ARV regimen coverage, transmission rate was below 4%.   
 
PMTCT services coverage (i.e. HIV status knowledge, coverage of CD4 count and 
ARV regimen coverage) varied widely between the three provinces that achieved 
universal coverage and the remaining six provinces that did not achieve universal 
coverage. Given the observed strong association between PMTCT cascade coverage 
and transmission rates, this study recommends attention to be given to provinces that 
have reported high transmission rates and low PMTCT cascade coverage. One of the 
predictors of transmission rate in this study was shortage of human resources. In the 
study facilities with two or less than two health care personnel providing voluntary 
counselling and testing (VCT) had higher (AOR 2.2, 95% CI  1.1-4.3) transmission 
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risk compared to facilities that had more than two health care personnel that provide 
VCT service. Sufficient and equitable distribution of human resources is an important 
influential factor in the provision of PMTCT services.  
 
Our findings on human resources are substantiated by a report from Day and Gray 
(2008) and reports from provincial departments.
10-12
 According to Day and Gray 
(2008), three of the six provinces identified in this study as low performing provinces 
(>5% transmission rate provinces) have the lowest number of professional nurses for 
their population level compared to the rest of the six provinces; whilst availability of 
human resource and non-governmental supporting organizations (NGOs) in the three 
well performing provinces is reported to be higher compared to the remaining six-
provinces. The 2009 provincial report from one of the low performing provinces also 
reported chronic human resource shortages as the key challenge of the health service. 
The report stated most clinics in the province are overcrowded and patients are often 
returned home due to long queues.
12
 
 
In addition, strategies tailored to specific problems of the provinces are required in 
order to meet the unique challenges that each specific province is confronted with. 
Some of these challenges may include, distance to health facilities, inadequate ARV 
sites, inequity in allocation of PHC expenditure, and lack of a strong monitoring 
system.
10,12
 Further in-depth research is required to better understand this and other 
operational, structural and social challenges of PMTCT programmes in provinces 
identified as low performing provinces.  
 
Comparison of provincial ARV coverage with provincial  maternal mortality ratio 
(MMR) showed no trend/association between ARV coverage and MMR (table 8).
13
  
Transmission rate was not also associated with  antenatal HIV prevalence  (table 9).
14
 
 
The following limitations of this study are recognized. Our sample size is calculated 
to give a stable transmission rate estimate at provincial level. However, since our 
sample size achievement in two of the nine provinces was lower (<70%), the 
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transmission estimates for the two provinces have lower precision. We attempted to 
validate our data by comparing with district health information system (DHIS) data. 
However the reports from DHIS data are exaggerated due to double counting and 
data quality problems. Thus comparison could not be made between DHIS and the 
PMTCT survey data. We had incomplete CD4 count and treatment duration data, and 
viral load data was not collected. Lastly, neither our studies nor other modelling 
studies have factored the influence of adherence to treatment, maternal previous 
experience of treatment and maternal health condition in assessing the influence of 
ARV regimens coverage on transmission rate.  
 
In conclusion our study shows that PMTCT services coverage is a significant 
determinant of geographical variations in MTCT rates. The 2.8% transmission rate 
reported in provinces that achieved universal coverage suggests achievability of 
MTCT elimination targets with PMTCT service coverage levels lower than 95%. 
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Figure 8: Study profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligible for inclusion in survey 
10820 (%) 
Refused participation in survey 
85 (0.8%) 
Interviewed 
10735 (99.2%) 
Refused DBS 
553 (5.2%) 
Interview + DBS available 
10154 (94%) 
Insufficient DBS 
24 (0.2%)  
Interview + DBS analysed 
10178 
HIV-exposed infants  
3107  
HIV-unexposed infants 
7071  
HIV-exposed infants with PCR 
result 
N=3085 
HIV-exposed uninfected infants 
N2=2957 (96.42%) 
HIV-positive infants 
N1=128 (3.58%) 
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Table 5: Socio-demographic characteristics of the study population by infant HIV 
infection status and provincial categories  
 
 Provinces achieved 
universal access [# %)] 
 n1=1349 
Provinces did not achieve 
universal access [# %)] 
n1 =1736 
ZA [# (%)] 
 (n1=3085) 
HEI infected 
[# (%)]  
n1=41 
HEI 
uninfected [# 
%)] 
n1=1308 
HEI infected 
[# (%)]  
n1=87 
 
HEI 
uninfected  
[# %)] 
n1=1649 
HEI (both 
infected 
and 
uninfected)  
Maternal Age  
Mean (Range) 
 
27.7(16-46) 
 
26.3 (17-40) 
 
27.8 (15-46) 
 
27.8 (16-46) 
 
27.7 (15-46) 
Maternal  
Education   
None 
Grade 1-7 
Grade 8-12 
Above Grade12 
No information 
 
 
0 (0) 
9 (24) 
30 (71) 
1 (1) 
1(4) 
 
 
100 (2) 
202 (15) 
1029 (79) 
43 (3) 
9(1) 
 
 
2 (2) 
14 (15) 
68 (79) 
3 (4) 
0 (0) 
 
 
62 (4) 
366 (22) 
1165 (71) 
33 (2) 
23 (1) 
 
 
89 (2.6) 
591(18.2) 
2292 (75.8) 
80 (2.7) 
33 (0.81) 
Marital status  
Single 
Married/cohabiting 
Widowed/Divorced 
No information  
 
33 (80) 
7 (16) 
0 (0) 
1 (4) 
 
1029 (82) 
260 (17) 
13 (1) 
6 (0) 
 
65 (76) 
22 (24) 
0 (0) 
0 (0) 
 
1204 (73) 
418 (25) 
12 (1) 
15 (1) 
 
2331 (78.5) 
707 (20.1) 
25 (0.8) 
22 (0.6) 
Infant  Race  
Black  
Coloured 
White, Indian, other 
 
38 (97) 
3 (3) 
0 (0) 
 
1280 (98) 
25 (1) 
3 (1) 
 
85 (98) 
2 (2) 
0 (0 
 
1607 (98) 
39 (2) 
3 (0) 
 
3010 (98.6) 
69(1.3) 
6 (0.1) 
SES quintile  
Lowest 
Lower  
Average  
Above average  
 
7 (21) 
10 (22) 
21 (52) 
3 (5) 
 
200 (15) 
246 (19) 
747 (57) 
115 (9) 
 
23 (27) 
18 (23) 
41 (44) 
5 (6) 
 
401 (27) 
358 (23) 
782 (44) 
108 (6) 
 
631 (19.9) 
632 (20.6) 
1591 (51.6) 
231 (7.8) 
Number of  lifetime 
pregnancy  
1 
2 
3 
 ≥ 4 
missing 
 
 
12 (30) 
15 (34) 
9 (21) 
3 (9) 
2 (6) 
 
 
269 (20) 
513 (39) 
302 (23) 
198 (16) 
26 (2) 
 
  
24 (27) 
24 (27) 
20 (22) 
16 (20) 
3 (4) 
 
 
370 (24) 
556 (33) 
370 (22) 
300 (18) 
53 (3) 
 
 
675 (21.5) 
1108(36.6) 
701 (22.7) 
517 (16.8) 
84 (2.4) 
Planned Pregnancy 
Yes 
No  
Missing 
 
 
7 (20) 
31 (72) 
3 (7) 
 
 
414 (32) 
858 (65) 
3 (7) 
 
 
33 (40) 
50 (56) 
4 (4) 
 
 
672 (41) 
912 (55) 
65 (4) 
 
 
1126 (35.5) 
1851 (61.4) 
108 (3.1) 
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Table 6: Provincial coverage of PMTCT services and transmission rates 
Provinces achieved the UNGASS  target  of ≥80% ARV regimen coverage 
 HIV status 
knowledge 
CD4 count 
[95% CI] 
ARV regimen** HAART 
coverage 
Transmission 
rate [95% CI] 
GP 92% 
[89%-94%] 
80%   
[74%-83%] 
80% 
[75%-84%] 
65% 
[62%-69%] 
2.5%  
[1.5-3.6] 
KZN 96% 
[94%-98%] 
86% 
[82%-89%] 
88% 
[84%-90%] 
62% 
[60%-66% 
2.9% 
[1.7-4.0] 
WC 95% 
[88%-98%] 
89% 
[84%-93%] 
86% 
[81%-90%] 
59% 
[52%-63%] 
3.9% 
[1.9-5.8] 
Aver
age  
94% 
[93%-96%] 
83% 
[80%-86%] 
84% 
[81%-86% 
 2.8%  
[2.0-3.6] 
Provinces achieved below the UNGASS (<80%) ARV regimen target  
EC 82% 
[77%-87%] 
57% 
 [49%-4%] 
66% 
[60%-72%] 
*** 5.5% 
[2.9-8.1]* 
FS 87% 
[84%-90%] 
74% 
[68%-79%] 
76% 
[71%-81%] 
*** 5.9% 
[3.8-8.0] 
LP  79% 
[94%-98%] 
54% 
[46%-61%] 
65% 
[59%-70%] 
*** 3.6% 
[1.4-5.8] 
MP 84% 
[76%-87%] 
63% 
[57%-68%] 
65% 
[60%-69%] 
*** 5.7% 
[4.1-7.3] 
NC 87% 
[76%-93%] 
66% 
[53%-77%] 
73% 
[64%-80%] 
*** 1.4% 
[0.1-3.4]* 
NW 88% 
[84%-91%] 
69% 
[64%-74%] 
77% 
[71%-81%] 
*** 4.4% 
[2.9-5.9] 
Aver
age 
85% 
[82%-86%] 
62% 
[59%-65%] 
69% 
[66%-71% 
*** 4.9% 
[3.8-6.0] 
* Sample size achievement was low in the two provinces  
** Receiving maternal HAART or ARV prophylaxis and infant NVP/AZT 
***Response rate for CD4 count number  <50% hence HAART coverage is not reported.   
 
 
 
Gestational age 
at 1st ANC 
1
st
 trimester 
2
nd
 trimester 
3
rd
 trimester 
Missing  
 
 
6 (15) 
17 (43) 
5 (15) 
13 (27) 
 
 
254 (18) 
648 (53) 
157 (13) 
249 (16) 
 
 
14 (14) 
42 (42) 
8 (9) 
23 (35) 
 
 
397 (23) 
732 (42) 
183 (11) 
337 (24) 
 
 
671 (19.3) 
1439 (48.3) 
353(12.4) 
622 (20.0) 
Infant gender 
Male 
Female 
 
21 (53) 
20 (47) 
 
651 (49) 
657 (51) 
 
45 (56) 
42 (45) 
 
813 (49) 
836 (51) 
 
5222 (50.5) 
5135 (49.5) 
Infant birth weight 
<2.5kg 
>=2.5kg  
 
 
7 (19) 
34 (81) 
 
 
219 (17) 
1089 (83) 
 
 
26 (25) 
61 (75) 
 
 
284 (17) 
1365 (83) 
 
 
536 (16.8) 
     2549 (83) 
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Table 7: Factors explaining transmission differences 
 
Significant Predictors of transmission  Unadjusted ratio 
[95% CI], p.value 
Adjusted Odds ratio  
[95%CI], p.value 
Provinces with ARV regimen coverage 
below the universal coverage  (80%)  target 
1.8 [1.2-2.6] 
0.003 
1.7 [1.2 – 2.6 
0.011 
Facilities that have two or less than two 
health care personnel doing VCT   
2.1 [1.1 -3.8]  
0.019 
2.2 [1.1 -4.3] 
0.024 
Low  (2.5 kg) birth weight  1.7 [1.1 – 2.9] 
0.030 
1.8 [1.1-2.9]  
0.028 
Receiving maternal and infant ARV 
prophylaxis/HAART 
0.3[0.2-0.5] 
0.000 
0.44[0.27-0.71] 
0.001 
Any breastfeeding  received in the last 8 
days 
2.2 [1.4-3.4] 
0.000 
1.8 [1.2 – 2.9] 
0.007 
Child sick (needing clinic attendance/ 
hospitalization) since birth  
1.1 [0.5-2.2] 
0.847 
1.3 [0.6 -2.7] 
0.510 
Gestational age at first antenatal visit (in 
weeks) 
1.0 [1.0-1.1] 
0.257 
2.0 [1.0 – 1.1] 
        0.320 
Not planned pregnancy  1.2 [0.8-2.0] 
0.339 
1.3 [0.8 – 2.1] 
0.266 
Socioeconomic scores  0.9 [0.8-1.0] 
0.161 
1.0 [0.9-1.3] 
0.820 
Maternal age (5 years interval)  0.9 [0.8-1.1] 
0.431 
1.0 [0.8 -1.2] 
0.904 
Attending facilities with on-site ARV clinic 0.9 [0.6 -1.4] 
0.804 
0.7 [0.5 – 1.1] 
0.139 
Attending facilities that have linkage with 
community  
1.0 [0.6 -1.7] 
0.840 
1.1 [0.6-1.7] 
0.829 
Mothers who ever heard of PMTCT 
programme 
1.2 [0.6-1.9] 
0.813 
1.3 [0.6-2.1] 
0.629 
Education  level (4 grades interval) 1.1 [0.7-1.5] 
0.777 
1.4 [0.8-1.8] 
0.335 
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Table 8: Comparison of ARV regimen coverage with maternal mortality ratio 
2008- 
Province  ARV regimen 
coverage 
MMR*   
KZN 88% 192.3 
WC 86% 84.9 
GP 80% 147.5 
NW 77% 229.5 
FS 76% 289.1 
NC 73% 249.98 
EC 66% 193.3 
MP 65% 183.5 
LP 65% 164.7 
* National Committee on Confidential Enquiries into MaternalDeaths. Saving Mothers: Fourth Report on the Confidentia 
Enquiries into Maternal Deaths in South Africa 2005-2007. Pretoria: National Department of Health; 2008. 
 
Table 9: Comparison of provincial transmission rate level with antenatal HIV 
prevalence 
Province  Transmission rate Antenatal HIV prevalence 
FS 5.9% 29% 
MP 5.7% 34% 
EC 5.5% 24% 
NW 4.4% 30% 
WC 3.9% 15% 
LP 3.6% 20% 
KZN 2.9% 37% 
GP 2.5% 31% 
NC 1.4% 14% 
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Abstract 
Objectives: 
Early infant diagnosis (EID) services are recommended to be offered at six week 
immunisation visits.  Despite the high six week immunisation attendance rate, many 
sub-Saharan countries have low EID coverage. We explored reasons for missed 
opportunities of EID services at six week immunisation visits. 
 
Methods: 
A national situational assessment was undertaken among randomly selected facilities 
(n=680) to ascertain procedures for EID. Following this, a cross-sectional survey was 
conducted in a sub-sample of selected facilities (n=580) to assess the HIV-status of 
4-8 weeks old infants receiving six weeks immunisation.  Frequency tables were 
used to describe potential missed opportunities for EID. Logistic regression assessed 
key factors influencing maternal reporting for EID.    
  
Results:  
EID services were available in >95% facilities, and 72% immunisation service points 
(ISPs). The majority (68%) of ISPs provide EID for infants with reported (by 
mothers) or documented (on infant’s Road to Health Chart - RtHC) HIV-exposure; 
only 9% ISPs offered provider-initiated counselling and testing (PICT) for 
undocumented/unknown HIV-exposed infants (HEI). In the cross-sectional survey 
32% of infants were HIV-exposed, similar with the infant HIV-exposure rate 
reported in the 2009 antenatal survey. However, only 35% of known HIV-positive 
mothers intended to report their HIV-exposure, and   only 55% had RtHC that reflect 
their HIV-status. Poor maternal reporting for EID was associated with feeling 
discriminated, missing maternal/infant antiretrovirals, and inadequate knowledge 
about transmission. 
Conclusion:  
Attendance of six weeks immunisation is high among HEI. Missed opportunities for 
EID were attributed to poor documentation of HIV-status on RtHC, inadequate 
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maternal knowledge and fear of discrimination to disclose HIV-status, and the lack 
of PICT service to undocumented/unknown HEI.  
 
 Key Words: EID service, PICT, Targeted testing, universal testing, missed 
opportunities   
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Background  
 
HIV is a significant contributor to child morbidity and mortality in sub-Saharan 
countries.
1,2
 
HI
V progresses more rapidly in children, especially in infants who 
acquired the infection in utero.
3,4
 Early initiation of systematic antiretroviral 
treatment (ART) substantially reduces the risk of death and disease progression and 
is standard of care in South Africa.
3,5 
Without treatment 48% of perinatally infected 
and 22% of infants infected through breastfeeding die before their first birthday.
6 
HIV-exposed uninfected infants also have higher risk of morbidity and mortality than 
HIV-unexposed infants.
7  
 
Identifying HIV-exposed infants is the first critical step in the provision of EID 
services and linkage to care. In many developing countries, including South Africa, 
despite substantial improvement in antenatal testing, and maternal enrolment into 
prevention of mother-to-child transmission (PMTCT) programmes, identifying HIV-
exposed infants after birth for early testing and follow-up services has proven to be 
challenging.
8-10
  
 
Following the introduction of HIV DNA PCR (deoxyribose nucleic acid polymerase 
chain reaction) testing on dried blood spots (DBS), which simplified the collection 
and transportation of infant blood samples, many sub-Saharan countries have made 
significant progress in scaling-up EID services to lower level health care facilities.
11
  
EID services are recommended to be offered at six week immunisation visits.  Many 
sub-Saharan countries have high coverage rates for six week immunisations. This 
however has not yet translated into high early infant diagnosis rates for HEI.
11,12
 In 
2010 globally less than one-third (28%) of HEI received testing   by the age of 2 
months.
13
 In South Africa a review of 2008 and 2010 laboratory data for eight of the 
provinces (excluding KwaZulu-Natal) indicated 69% and 45% of HEI, respectively, 
missed opportunities for testing by the age of 2 months.
12
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The 2010 World Health Organization (WHO) guidance on EID recommends that the 
exposure status of all infants should be determined at the six weeks postnatal visit or 
earlier, and that all HIV-exposed infants should receive a virological  test at six 
weeks.
14 
Currently
 
countries are at various stages of adopting this guideline. At the 
time of this study, South Africa (SA) was transitioning from the 2008 to the 2010 
national EID guideline. The 2008 and 2010 guidelines recommended that infant 
HIV-exposure status be determined by checking documentation on RtHC or through 
maternal reporting of HIV-status (referred as targeted testing).
15
 The 2010 guideline 
further stipulated that if infant HIV-exposure status is undocumented/unknown, 
provider-initiated-counselling and maternal HIV testing should be offered, with 
same-day infant PCR testing for HIV-exposed infants.
16
 If mother refuses or is 
unavailable for HIV testing an infant rapid test to assess exposure is recommended 
with same-day PCR testing for HEI.  At the time of this study most facilities 
implemented the previous (2008) EID guideline.  
 
Few studies have gathered national data to assess programs for identifying HIV-
exposed and infected infants.
11,17
 Several challenges to implementing EID services 
(including structural challenges, geographical accessibility, maternal knowledge, and 
psycho-social barriers) have been reported in these studies.
11,17-21
 However no study 
has explored the   impact of approaches used at facility level for identifying HIV-
exposed and infected infants. This study combined facility and individual-level data 
collected from across the nine provinces of South Africa to explore how HIV-
exposed infants are identified and diagnosed at immunisation service points and  
report  missed opportunities (for EID) occurring  due to gaps in approaches used for 
identifying HEI from six week immunisation visit.   
 
Methods 
Study design  
A cross-sectional facility-level situational assessment of EID services was conducted 
from January-May 2010. Between two and nine months later, a cross-sectional 
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PMTCT survey was conducted among caregiver-infant pairs attending a sub-sample 
of facilities for their six weeks immunisation.  
  
Facility Sampling 
Three thousand three hundred ninety (3390) community health centres and clinics 
were eligible for inclusion in the sampling frame.
22
 These facilities were stratified 
into four groups:  small (<130 annual Diphtheria-Tetanus-Pertussis-1 (DTP1) 
coverage), medium (130-300 annual DTP1 coverage), large (≥300 annual DTP1 
coverage) with below the 2009 national average antenatal HIV prevalence (<29%)  
and large with above the 2009 national average antenatal HIV prevalence (≥29%). 
Immunisation coverage was based on the 2007 district health information system 
(DHIS) data.   
 
The following parameters were taken into account to determine the sample size of 
medium and large facilities: the 2009 antenatal HIV prevalence data, transmission 
rate estimates from two KwaZulu-Natal (KZN) surveys, and the coverage of ARV 
prophylaxis in each province from DHIS report. Sample size was calculated using 
nQuery Advisor Version 7 software  for specified precision levels (+2% ) and a 
design effect of 2. Five hundred eighty (580) facilities were selected from medium 
and large size facilities using probability proportional to size (PPS) sampling 
method. The sample size of small facilities was decided based on consideration of 
the resource allocated for the study. Based on this, 100 facilities (10-20 facilities per 
province) were selected from small (<130 annual immunisation number) facilities 
using the PPS sampling method. We took into consideration the logistic and financial 
resource allocated for the study to decide on.  In total 680 facilities were planned for 
the situational assessment. The cross-sectional PMTCT survey was conducted in a 
sub-sample of facilities (n=580) selected from medium and large facilities. Small 
facilities were not included in the cross-sectional PMTCT survey due to logistic 
feasibility. Detailed description of sampling frame, sampling and sample size is 
presented elsewhere.
23
 
 
 
 
 
 
 124 
 
Data Collection Procedures: Situational assessment  
 
Trained field workers (not nurses) used structured questionnaires to conduct face to 
face interviews with clinic managers and nurses providing immunisation, PMTCT 
and sick-child services in each selected facility and with district health information 
officers. Open-ended and close-ended questions were used to collect data on 
implementation of EID-related policies and procedures, staff attitudes towards EID, 
and the use of the RtHC at ISPs to identify HEI.  
 
The questionnaire was piloted in two clinics that were not sampled for the main 
study. Field workers underwent standardised training (four days). The Medical 
Research Council Ethics Committee approved the final protocol (Ref: EC09-002). 
Approval was obtained from National and Provincial Departments of Health before 
commencing the fieldwork. Informed verbal consent was obtained from all 
respondents.  
 
 
The PMTCT cross-sectional survey  
From June to November 2010, a cross-sectional survey was conducted among 
mother/caregiver-infant pairs visiting primary healthcare (PHC) facilities for six 
weeks immunisation. The main objective of the survey was to provide national and 
provincial level estimates of infant HIV prevalence and vertical HIV transmission. 
The calculated desired sample size was the collection of interview data and infant 
blood sample from 12200 mother-infant pairs visiting for six weeks immunisation 
service.  
 
10820 mother/caregiver-infant pairs visiting six weeks immunisation services were 
approached by trained nurse data collectors and screened for eligibility. Consenting 
mothers, with infants aged 4-8 weeks and no emergency illness were enrolled and 
interviewed face-to-face. Data on reasons for the visit, antenatal and peripartum 
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PMTCT services received and knowledge about PMTCT were gathered. The road-to-
health-card was checked for documentation of maternal and infant status. The 
questionnaire was translated into all 11 South African official languages and piloted 
in three languages prior to the survey.  
 
After the interview, pre-test counselling was given to each mother individually, 
following which  mothers were requested for consent to collect a heel prick blood 
sample from the infant with an option to know the HIV test result of the infant.  
Mothers who agreed to infant testing were given confidential linked (names were 
written on lab forms) testing and infant results were returned to mothers through the 
health facility. Mothers of HIV-exposed infants were referred for HIV testing. 
 
Data Management and Data Analysis 
Hard copy questionnaires were used for data collection in the situational assessment. 
The data was captured in Excel and transferred to STATA SE (version 12, Texas, 
77845 USA) for analysis. Descriptive methods (simple frequency tables) were used 
to analyse the situational assessment data on EID services availability (i.e. EID 
availability within the health facility and at ISPs), and approaches for identifying 
HEI for EID services. The cross-sectional survey data were collected on electronic 
(cell phone) questionnaires and the data was transferred to STATA for analysis. A 
weighted analysis (weighted for sample size realisation and population live birth) 
was performed to calculate the proportion of known HIV-positive mothers who 
brought their child for HIV testing at six weeks immunisation visit, documentation of 
infant or mother HIV-status (or documentation of maternal/infant prophylaxis) on 
RtHC among both known HIV-exposed and unexposed infants and acceptance of 
provider-initiated HIV testing offered as part of the survey.   
 
In the cross-sectional survey, we could not directly measure missed opportunities for 
EID (in the routine service) as we offered provider-initiated HIV testing to all 4-
8weeks old infants visiting six week immunisation services.  However, we used the 
following method to assess potential missed opportunities for EID   that could have 
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occurred in the absence of testing offered in our survey:   we assumed that in the 
absence of the cross-sectional survey, facility policy within the past year would have 
dictated EID practice.   Therefore, HIV-exposed infants who attended health 
facilities that reportedly use the targeted testing approach (testing 
documented/reported HEI)  for EID would miss opportunities of early (six week) 
testing unless their HIV-status is documented  on the road-to-health-card or their 
mothers were intending to request for infant testing at 4-8 weeks of infant age.  With 
this assumption, potential missed opportunities for EID were assessed among HEI 
attending facilities that provided targeted testing.  
 
A logistic model was fitted to examine factors influencing maternal intention to 
receive EID at six week visit among known HIV-positive mothers. The following 
variables were considered in a bivariate analysis: maternal age >35 years, maternal 
age <20 years, education, marital status (being married), socioeconomic score 
(constructed from availability of the following working items in the house: stove, 
refrigerator, radio, TV and car), planned pregnancy, number of life time pregnancies, 
facility delivery, no of postnatal visits, history of child sickness since birth,  
knowledge about availability of PMTCT service, knowing all three modes of mother-
to-child transmission (MTCT), feeling discriminated by the community (for their 
HIV status), MTCT risk behaviour (missing   one or both of  maternal and infant   
ARV regimens), and exclusive formula feeding. In the multivariate analysis: 
variables that were significant at 10% cut-off point in the bivariate analysis and the 
following variables reported in the literature as influential factors were considered: 
formula feeding, maternal education, unplanned pregnancy, and health facility 
delivery. Variables kept in the final model were either a significant influential 
predictors (at significance level of 0.05) or had a ≥10% effect on the overall model.  
 
Results 
Facility Situational Assessment Profile 
Out of the 680 sampled facilities, 625 (92%) were visited for the situational 
assessment. Fifty-five (8%) of the sampled facilities could not be visited due to time 
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constraints, temporary closure or reported absence of main staff members needed for 
the interviews (table10). 
 
The cross-sectional  survey study profile 
In the national cross-sectional survey, 10820 mothers/caregivers who brought infants 
to sampled clinics for six weeks immunisation service were approached and screened 
for eligibility. Ninety nine percent (10735) of screened mother/caregiver infant pairs 
were eligible and agreed to be interviewed. Ninety-six percent (96%) of participants 
were mothers;  4% (378) were caregivers. Of the 10735 participants offered PICT, 
95% (10178) agreed to confidential linked infant testing, and 32% of infants tested 
were HIV-exposed.   
 
EID service availability 
More than 95% of facilities in the situational assessment reported availability of EID 
(PCR testing) service within the facility. The majority (72%) of the facilities 
reportedly provided EID services at ISPs. Five percent (5%) reported that EID 
services are provided at six week immunisation visits in conjunction with 
PMTCT/voluntary counselling and testing (VCT) services and 15% reported that 
ISPs are not involved in the provision of EID services. The rest (8%) did not respond 
to this question.  
 
Of the facilities that offered EID services at ISPs, 76% reported that offering EID 
services during routine immunisation visits is feasible. 
 
Testing approach  
Our study indicates that more than half (68%) of ISPs provide EID services to infants 
with reported or documented HIV-exposure (fig 9). Only 9% ISPs reportedly 
provided PICT for undocumented and unknown HIV-status infants. Nationally 15% 
of facilities reported that ISPs are not involved in the provision of EID services. The 
rest 8% did not respond to this question.  
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Maternal intention and acceptability of provider-initiated counselling and 
testing  
 
During interviews, mothers were asked to list their reasons for visiting the health 
facility at the six week immunisation visit: only 35% of self-reported HIV-positive 
mothers reported that they had intended to request infant HIV testing during the six 
week immunisation visit (fig10). In a multivariate analysis, mothers who felt 
discriminated against for their HIV-positive status were less likely to report their 
HIV-exposure during six week immunisation (AOR:1.8; CI:1.1-2.8). Knowledge of 
all MTCT modes (AOR:0.5; CI:0.2-0.9), and MTCT risk behaviour (i.e. missing 
maternal, infant  or both ARV regimens - AOR:1.7; CI:1.2-2.5) were also significant 
predictors of  maternal intention    for  receiving EID service (table 11).  
 
When PICT was offered to all infants during six weeks immunisation visits, 95% of 
mothers consented to named testing with receipt of results. Almost all (97%) of 
reported HIV-positive mothers who had no intention to request infant testing agreed 
to infant antibody testing after provider-initiated  testing was offered in our study.  
 
Patient held records  
Of 10612 (99%) mother-infant pairs who brought the infant’s road-to-health-card, 
only 34% had a road-to-health-card that indicated maternal/infant HIV-status (fig 
11). Among infants born to self-reported HIV-positive mothers, 49% had road-to-
health-card with  documentation of either a PMTCT code (confidential code 
indicating maternal HIV-status) or maternal or infant ARV prophylaxis, 6% had 
maternal HIV test result documented on RtHC, and 45% had no documentation of  
HIV-status on the RtHC.  
  
Potential missed opportunities in the targeted testing approach  
In facilities that reported providing targeted testing, the data (table 12) indicate a 
substantial number (38%) of HIV-exposed infants would have potentially missed 
opportunities of early testing as they had neither a documentation of HIV-status on 
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RtHC nor were their mothers intending to request EID services at the six weeks 
immunisation visit.  Since our study offered PICT   to identify all exposed infants 
and offer EID for all exposed infant at ISPs, none of the infants actually missed HIV 
testing.  
 
Discussion  
 
We found that, EID services are available in>95% of PHC facilities in South Africa, 
with 72% of facilities offering EID services at ISPs. Despite this progress in 
delivering decentralised EID services, our study indicates substantial missed 
opportunities for EID occur at six week visits, posing significant challenges for early 
initiation of treatment. 
 
The HIV-exposure prevalence (32%) at six week immunisation visits reported in our 
study was similar with the HIV prevalence (29%) reported for pregnant women in 
the 2009 antenatal survey, which shows the high attendance of six week 
immunisations by HEI in the age 4-8 weeks old.  However, our assessment of infant 
HIV testing services at ISPs identified several gaps related to the approaches used for 
identifying HIV-exposed infants from six weeks immunisation visits. The majority 
(68%) of facilities offered targeted testing which relies on maternal reporting or 
documentation (on RtHC) of HIV-exposure. Despite this, both the RtHC and 
maternal reporting were poorly utilised for conveying the HIV-exposure status of 
infants to health workers responsible for EID.  Thus, facilities that use targeted 
approaches potentially missed opportunities of early testing on significant numbers 
(38%) of HEI. 
 
Close to half (45%) of self-reported HIV-positive mothers, had an RtHC that has no 
documentation of   HIV-status. Poor communication between antenatal, delivery and 
postnatal facilities and lack of good information systems have been reported as main 
barriers for continuity of postnatal PMTCT services in developing countries.
9,24
 
Several efforts in sub-Saharan countries to improve the utilisation of patient-held-
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cards for documenting HIV-status had varying outcome.
25-27
 In South Africa, the 
RtHC coding system, MTCT stickers, stamps and the new RTHbooklet were 
introduced at various stages of the implementation of the PMTCT programme. 
Health care providers seldom used the coding system, as it required complex and 
time consuming decoding.
27,28
 At the time of the PMTCT survey the new 
RtHbooklet, revised to include maternal and infant HIV information was being 
implemented (April 2010). Whilst meticulous documentation of HIV-status using 
this new RtHbooklet might improve identification of HEI, the reliance on RtHC to 
identify HEIs has several limitations, including the dependence on mothers to bring 
the RtHC at all postnatal visits, and the inability to track infants who drop out at six 
week visit.
29
  This sole dependence on patient held cards and the lack of an internal 
mechanism for exchange of client records between antenatal and postnatal facilities 
could also result in lack of clear accountability for tracing loss to follow-up infants 
during early postnatal period and contribute to high early postnatal attrition rate.
30
  
 
A number of pilot studies in less developed countries indicate the introduction of 
technology such as web-based medical recording system (EMR) could be more 
effective for identifying and tracking HIV-exposed infants.
31,32
  The use of EMR 
could enable tracking of the six week check-up due date of PMTCT mothers at 
postnatal units, thus facilitating early identification of dropouts at postnatal visits. 
However, web-based medical recording systems are rarely available in developing 
countries due to the cost and infrastructural requirement of setting-up this 
technology.   
 
Maternal reporting for six weeks infant HIV testing service was also low in this 
study. Only 35% of known HIV-positive mothers reported they intended to disclose 
their HIV-status to the immunisation nurse. Knowledge of the mode of mother-to-
child transmission, missing one or both of maternal and infant ARV regimens, and 
feeling discriminated were significant influential predictors of maternal intention for 
disclosure of HIV-status. Our study findings are supported by several studies that 
indicate PMTCT knowledge,   adherence to treatment, and discrimination as main 
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determinants of uptake of EID.
20,21,33
 A study in rural Kenya that assessed reasons for 
dropout from EID services indicates most mothers are unsure of the number, exact 
time points or type of tests to be done for EID services,
33
 which suggests that lack of 
awareness about EID service could be one of the reasons why mothers do not report 
for testing. Reports from other similar studies conducted in rural areas of sub-
Saharan countries indicate lack of privacy at  immunisation rooms, and fear of 
stigma and discrimination  as main barriers for maternal disclosure of HIV-status at 
immunisation visits.
34,35
    
 
The 2010 WHO EID guideline recommends to improve early identification of 
undocumented and unknown HIV-exposed infants through the use of PICT. South 
Africa adopted this new EID guideline in 2010, in the same year as this study was 
conducted. This EID guideline recommends that all infants at six week visit with 
undocumented/unknown HIV-status be offered maternal or infant rapid screening. 
The latest revision (2013) to this guideline in South Africa further recommends to 
offer PICT for HIV-negative mothers.
36
 These guidelines are introduced in absence 
of studies that adequately assess the capacity of immunisation facilities to absorb 
new services introduced as part of the   new EID guidelines.  We estimate at least 
three out of five children (66%) that present to immunisation facilities present 
without a documentation of HIV-status on the RtHC, therefore the number of infants 
that require screening test is expected to substantially increase with the introduction 
of the new guidelines.  In order to ensure full transition to the new guidelines, the 
resource need (staffing, budget and supplies) of the introduction of the new 
guidelines should be monitored closely. Clear policy guidelines are also needed in 
the use of lay counsellors and community health workers for performing infant HIV 
testing.   
 
Similarly, the suitability of the setup of immunisation units for implementing the new 
guidelines should be assessed. Assessing (asking) maternal antenatal HIV testing 
histories in immunisation rooms with inadequate privacy may result in false 
reporting, high refusal rate, and tendency to avoid immunisation services due to fear 
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of stigma.
26,37
  South Africa is a better resourced country compared to other African 
countries but insufficient space and inadequate privacy at immunisation visits are 
reported as one of the challenges for providing infant HIV testing services in some 
areas of the country.
38
 
 
In conclusion, these findings show that improving the EID service uptake requires 
efforts to improve the identification of HIV-exposed infants at six week visits. The 
current targeted testing approach is leading to a significant number of missed 
opportunities for early infant diagnosis. The high attendance of six week 
immunisations by HEI aged 4-8weeks indicate the presence of a potential for 
attaining high coverage of EID services at immunisation visits. Missed opportunities 
for EID were attributed to poor documentation of HIV-status on RtHC, inadequate 
maternal knowledge and fear of discrimination to disclose HIV-status, and the lack 
of PICT service to undocumented/unknown HEI. Hence improvement is needed in 
the following areas: documentation of HIV-status on RtHC, educating mothers about 
infant testing, reduction of stigma and discrimination through community level 
educational campaigns, improving privacy at immunisation facilities, and 
implementing the new EID guideline recommending PICT for 
undocumented/unknown HEI. 
 
The results from this study are based on reports from service providers and 
caregivers. However we have triangulated service providers’ data with caregiver 
reports to crosscheck consistency and validity of responses. In this study we were not 
able to directly measure the link between approaches for identifying HIV-exposed 
infants for EID service and uptake of EID service as the study offered PICT to all 
infants, hence preventing us from measuring uptake of EID service in the routine 
system. Thus far the only data source for routine EID uptake rate is the national 
health laboratory data. We recommend future studies to consider monitoring the 
uptake of routine EID services and continuity of care, particularly to assess the 
impact of the new guidelines recommending increased maternal screening and the 
new RtHC. 
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 Table 10: Sampled Facilities for the situational assessment in Total and By 
Province 
 
Province Total PHCs + 
CHCs   
(DHIS 2007) 
No sampled 
(% provincial 
PHC+CHC) 
No. visited 
(% sampled 
in province) 
Facility stratum 
Small  
No (column %) 
Medium   
No (column %) 
Large  
No (column %) 
EC  714 87 (12%) 87 
(100%) 
10 (10%) 38 (17%) 39 (13%) 
FS 266 83 (31%) 73 (88%) 13 (14%) 28 (12%) 32 (11%) 
GP 340 76 (22%) 76 
(100%) 
16 (17%) 14 (6%) 46 (15%) 
KZN 562 74 (13%) 71 (96%) 10 (10%) 23 (10%) 38 (13%) 
LP 438 84 (19%) 56 (67%) 10 (10%) 23 (10%) 23 (8%) 
MP 267 87 (33%) 87 
(100%) 
12 (13%) 25 (11%) 50 (17%) 
NC 138 43(31%) 42 (98%) 10 (10%) 24 (11%) 8 (3%) 
NW 338 79 (23%) 74 (94%) 7 (7%) 34 (15%) 33 (11%) 
WC  327 67 (20%) 59 (88%) 8 (8%) 18 (8%) 33 (11%) 
Total 3390 680 (20%) 625 
(92%) 
96 
(100%) 
227 
(100%) 
302 
(100%) 
 
 
 
 
Table 11: Predictors of intention to receive EID service among HIV positive 
mothers who know their HIV status 
 
Significant predictor factors 
explaining poor maternal 
reporting for infant HIV testing  at 
six week immunisation visit among 
self-reported HIV positive mothers 
Unadjusted odds 
ratio  
Adjusted Odds 
ratio  [95%CI], 
p.value 
Maternal age below 20 years 1.5 [1.1-2.1] 
0.012 
1.3 [0.9-1.9] 
0.130 
Mothers who felt discrimination 
by the community  
1.9 [1.2 – 3.0] 
0.009 
1.8 [1.1-2.9] 
0.025 
Socioeconomic status 
score*(continuous) 
0.9 [0.9-0.99] 
0.035   
0.9    [0.9  -1.0] 
0.139 
Maternal education (four 
categories)* 
0.9 [0.7-1.1] 
0.321 
0.9    [0.7-  1.2] 
0.475 
Unplanned pregnancy  1.1 [0.9-1.4] 
0.351 
1.0   [0.8 -    1.3] 
0.722 
Missing   one or both of  maternal 
and infant   ARV regimens  
1.8 [1.3 -2.6] 
0.001 
1.7   [1.2-    2.5]   
0.004 
Exclusive formula feeding   vs any 
breast feeding   
0.9 [0.7-1.2] 
0.442 
1.0   [0.8-    1.2] 
0.742 
Knowledge of all MTCT mode 0.5 [0.3 -0.97] 0.5    [0.2-0.9] 
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0.041 0.032 
Knowledge about availability of 
PMTCT programme 
1.5 [1.0 – 2.4]  
0.060 
1.4 [0.8-2.2] 
0.205 
a. Additionally  Sick child, facility delivery, postnatal visit and number of pregnancy(classification of 4: 1 pregnancy, 2 
pregnancies, 3 pregnancies, 4 and above pregnancies) were considered in the logistic regression but were not influential ( 
had <0.10 effect). 
*Education categories:  None, Grade 1-7,Grade 8-12, Above Grade12 
  
 
 
 
Table 12: Potential missed opportunities for EID among infants who attended 
facilities that use the targeted approach* 
Documentation of HIV status on RTHC  and mothers intention - among 
infants attended facilities that use the Targeted approach)*  
No (%)of 
HEI   
Infant who attended facilities  that use  the targeted approach  who would have 
potentially accessed HIV testing: 
- HIV-exposure status documented on RtHC and/or mothers 
intentionally brought child for EID 
1815 
(62%) 
Potential missed opportunities  among infants who attended facilities  that 
use  the targeted approach:  
-  Infants   HIV-exposure status not documented on RtHC and mothers 
had no intention to request EID  
1041 
(38%) 
Total  HIV exposed infants  who attended facilities that use the targeted 
approach  
2856 
(100%) 
*Targeted approach refers to the offer of testing to infants who have 
documentation of   HIV exposure on RtHC or whose mothers request HIV testing 
 
 
Figure 9: Coverage of testing per the WHO 2010 EID guideline and targeted infant HIV 
testing at six week immunisation service points (per immunisation nurses report 
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Figure 10: the increase in identification of HIV-exposed infants born to 
women aware of their HIV positive status, achieved by offering provider 
initiated testing versus relying on a maternal request for EID  
 
 
 
 
 
 
Figure 11: Recording on RtHC for maternal/infant HIV status identification   
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Chapter 5: CONCLUSION AND RECOMMENDATIONS  
 
5.1. Conclusion  
 
This study provides the first systematically collected national baseline data on 
coverage of the South African antenatal and early postnatal PMTCT services. Our 
findings show that 78% of all (known and unknown) HIV-exposed infants in South 
Africa received both maternal and infant ARVs in 2010. Contrary to our study 
findings, the coverage figures reported in the routine programme (DHIS) data 
indicates achievement of >95% ARV regimen coverage in 2010, reporting South 
Africa as one of the few African countries (Botswana, Swaziland and South Africa) 
that achieved both the UNGASS (80%) and UNAIDS (90%) ARV regimen coverage 
targets.
3
 However, according to our findings, South Africa is on track to meet the 
UNGASS (80%) antiretroviral coverage target, but has not yet achieved the UNAIDS 
90% ARV regimen coverage target. Several studies have shown the limitations of 
routine programme data. Incompleteness and inaccuracy of reports and use of 
denominators limited to known HIV-positive mothers are some of the limitations of 
the DHIS data that could lead to the overestimation of the coverage of PMTCT 
services. These quality gaps in DHIS data are well-known, but due to lack of 
alternative data, DHIS data have been used as a primary source of data to monitor 
PMTCT programmes performance. This study provides global partners with more 
reliable data to track progress towards the achievement of international targets.  
 
Although close to 80% (78%) of mother-infant pairs received both maternal and 
infant ARV regimens, our coverage indicator did not assess duration and 
appropriateness of maternal and infant treatments. The optimal indicator for assessing 
PMTCT programmes performance is the coverage of effective ARV regimen which 
documents the percentage of mothers who receive appropriate type of regimen (for 
e.g. HAART if eligible) for the full duration of the treatment period per 
recommendations in the guidelines. In order to calculate effective ARV regimen 
coverage, information on maternal CD4 count numbers (to establish eligibility of 
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women for HAART) and duration of treatment is required. The assessment of 
effective ARV regimen coverage was not possible in this study due to significant 
number of missing data on both CD4 count and duration of treatment. This was the 
first national survey globally to apply a cross-sectional survey design and 
retrospective caregiver interview methods to collect PMTCT services coverage data. 
Response rates for CD4 count number and duration of treatment were low due to the 
relatively long recall period. In consecutive surveys, adding a record review 
component in the survey could improve the collection of detail information needed 
for quantifying coverage of effective ARV regimen.   
 
We estimated the coverage of ARV regimen from the total known and unknown 
HIV-positive mothers that are target populations for the PMTCT programme. This 
assessment was possible due to the study design that enabled the collection of data 
from both known and unknown HIV-positive mothers at six weeks immunisation 
service points. The high (>95%) attendance rates of DTP1 immunisation services 
enabled us to give results that closely represent the population under study
122
 Unlike 
cross-sectional six weeks surveys, routine programme data and other cohort study 
designs do not allow the assessment of missed opportunities among unknown and 
newly seroconverted HIV-positive mothers, as these methods mainly target mothers 
enrolled in  the PMTCT programmes. Our estimates do not represent infants who 
died before six weeks of age, infants who attend  six weeks immunisations after eight 
weeks of age and infants who attend private facilities, hospitals and small (<130 
annual immunisation) and mobile PHCs. 
 
Overall, according to this data South Africa is well on track to achieve the 80% 
universal access target. However, substantial effort would be required in order to 
increase the coverage of effective ARV regimens to above 90%.   
 
Geographical differences in uptake of PMTCT cascade services 
Uptake of the PMTCT cascade services was widely different across provinces. Whilst 
three provinces, which are relatively better off in resource allocation, achieved the 
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UNGASS universal access target (≥ 80%), the remaining six provinces had an 
average ARV regimen coverage of 69% (ranging 65-76%). Variations in uptake of 
the PMTCT cascade services were directly related to variations in mother-to-child 
transmission rates. The difference in PMTCT programme performance resulted in 
significant geographical differences in transmission rates. 
 
This study identified shortage of human resources as a significant contributor of low 
uptake of the PMTCT cascade services and higher transmission rates. Provinces with 
higher transmission rates were characterized by a shortage of human resources for 
PMTCT services and a considerably lower PMTCT service uptake. External 
provincial reports from three of the six low (PMTCT coverage <80%) performing 
provinces indicated shortage of human resource as the major barrier for provision of 
good quality HIV/AIDS and other basic services in these provinces.
152-154
 Innovative 
strategies to attract professional health workers to rural and resource poorer settings 
and task shifting should be used to improve equity in distribution of human resources 
between better off and resource poorer settings. Budget allocation for provinces 
should consider these challenges in attracting human resources to resource poorer 
settings and rural sites.  Other challenges such as distance to health facilities, 
inadequate ARV sites, inequity in allocation of PHC expenditure and NGOs support, 
and lack of strong monitoring system should also be addressed in order to improve 
PMTCT services coverage.   
 
The impact of universal access on transmission rate 
 
Universal access (≥80% coverage) to antiretroviral regimens had significant impact 
on transmission rate. Provinces that achieved below 80% ARV regimen coverage had 
significantly higher (AOR: 1.7) transmission rates than provinces that achieved 80% 
and above ARV regimen coverage. In six of the nine provinces a general trend of an 
increase in transmission rate was observed with a decrease in PMTCT cascade 
coverage.  Three of the nine provinces (of which two had <75% sample size 
achievement) did not exhibit this trend, however this could be due to the lack of 
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detail information on other determinant factors (e.g. on adherence to treatment, 
duration of treatment and type of regimen) or in the two provinces that achieved 
below 75% sample size, inadequacy of sample size may have decreased precision of 
estimates. Therefore we recommend the transmission rate and PMTCT cascade 
coverage in the three provinces be monitored at continuous basis to further strengthen 
the evidence.    
 
Mathematical modelling estimates predict that 95%-100% effective coverage of 
PMTCT cascade services is required in order to approach the 2% perinatal and 5% 
postnatal (18-months) MTCT elimination targets.
41
  In contrast, results from our 
study showed with 80-88% maternal and infant ARV regimen coverage, perinatal 
transmission rates could be reduced to below 3%. The accurateness of results from 
modelling studies is dependent on the quality of parameters and assumptions they are 
based on.  PMTCT modelling is often done using parameters from clinical trials and 
routine programme data.  Since routine programme report could overestimate the 
coverage of ARV regimens, and transmission rates achieved in clinical trials are 
sometimes lower than transmission rates that can be achieved in real life settings, 
results from modelling studies may underestimate the impact of PMTCT services 
coverage. From the findings of this study we argue that lower (<3%) transmission 
rates can be achieved with ARV regimen coverage levels between 80% and 90%.  
 
However, this argument should be strengthened through repeat surveys. Neither the 
models nor our study considered type of maternal ARV regimen, duration of ARV 
regimen and adherence to treatment in measuring the impact of PMTCT cascade 
coverage on transmission rates. In our study even if we assume highest adherence and 
effective and long course ARV regimens were received, achieving transmission rate 
of < 3% with 80-88% effective ARV regimen coverage is still a significant reduction 
in transmission rate compared to the reports from models that show achievement of  
4.1% transmission rates with >95% effective ARV regimen coverage.  
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Dropout points along the PMTCT cascade  
 
According to our findings South Africa has substantially improved the uptake of the 
PMTCT programme at antenatal visits, with almost all (97.7%) pregnant mothers 
having received antenatal HIV testing and significant number (89.6%) of HIV-
positive mothers being aware of their HIV-positive status. However, gradual loss to 
follow-up that occur between CD4 count testing, and referral to ART clinics 
substantially reduce uptake of effective ARV regimen.  
 
Dropout at CD4 count and ART initiation 
 
Even though 78% of HIV-exposed mother-infant pairs received both maternal and 
infant ARV regimen, the HAART eligibility of 22.6% of HIV-positive mothers’ was 
not assessed using CD4 count. In addition, of those mothers with CD4 count data, 
significant number (10%) of mothers identified as HAART eligible (CD4 count <350 
cells/µl) did not receive HAART due to dropout at ART referral points. The 
estimated 10% dropout rate at ART referral point could be an under estimation of 
dropout at ART referral point as CD4 count data was missing in >50% of the data. 
Failure to initiate HAART for eligible women results in high risk of mother-to-child 
HIV transmission and maternal mortality. The main reasons for the identified gaps in 
assessing eligibility and initiating HAART could be associated with quality of care, 
unreliable CD4 count testing service, and poor linkage and tracking system at 
antenatal service points and ART referral points. 
 
The World Health Organization (WHO) recommends treatment Option B be adopted 
in countries that experience challenges with centralised CD4 count testing service. 
An analysis of the cost-effectiveness of the WHO treatment Option A and Option B 
guidelines show that treatment Option B is more cost-effective than treatment Option 
A if treatment adherence is ensured.
114,144
 Treatment Option B benefits both the 
mother and the infant: women who are on a HAART regimen have the least risk of 
perinatal transmission and a greater likelihood of an expanded lifespan and better 
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quality of life. South Africa recently adopted Option B treatment guideline. With the 
adoption of treatment Option B, significant gains in reduction of MTCT rates are 
expected as mothers who need lifelong HAART can receive treatment without any 
delay. The South African Option B is also launched with a fixed dose combination 
therapy (a single dose therapy given once a day) which significantly reduces pill 
burden and increase adherence to treatment.  
 
With the introduction of Option B, the demand for ART will increase. Dropout rates 
at ART referral points could also pose major challenge unless nurse initiated 
antiretroviral treatments are (NIMART) introduced at antenatal clinics. Other 
methods such as verifying with ART clinic staff that referred clients (mothers) 
honoured their appointments, conducting home visits by community health workers 
(CHWs), and health staff accompanying mother to the ART clinics are best practices 
that have been shown to reduce dropout at referral points.    
 
Dropout at EID service and linkage  
 
The study also identified that a substantial number of mother-infant pairs potentially 
(if universal infant testing was not given in our study) missed opportunities for early 
infant diagnosis due to gaps in the approaches used for identifying HIV-exposed 
infants at six weeks visits. The study reports although the majority of facilities 
reported  relying on targeted testing (i.e. testing reported/documented HEI), both the 
RtHC and maternal reporting are poorly utilised  for notifying nurses at six weeks 
immunisation service points  on the HIV-exposure status of infants. The six weeks 
infant HIV diagnosis service is key for ensuring access to needed health services for 
both HIV-exposed/infected infants and their mothers.  
 
Limited communication between antenatal, perinatal and postnatal services has been 
found as the major bottleneck for continuity of postnatal PMTCT services.
149,170
 This 
study indicates whilst the PMTCT programme is linked with immunisation facilities 
and antenatal services, the lack of linkage (communication) between antenatal, 
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perinatal and postnatal PMTCT and non-PMTCT maternal and child health services 
creates substantial missed opportunity to identify and  follow-up HIV-exposed and 
infected infants during the early postnatal period. Efforts need to focus on improving 
linkage and communication between the three (antenatal, delivery and postnatal) 
MCWH service points. Rapid scale-up of the new RtHC and monitoring its utilisation 
for identifying HIV status of infants could improve early identification of infants. 
Regular meetings between antenatal, perinatal and postnatal facilities should be held 
to discuss on expected number of deliveries and six weeks immunisation 
appointments. In addition, postnatal service points should fully integrate postnatal 
PMTCT follow-up services into immunisation services, including the responsibility 
of identifying and tracking loss to follow-up mothers with the support of community 
health workers.  
 
Electronic medical recording system (EMR) 
 
This study highlights that communication gaps and lack of linkage between antenatal, 
perinatal and postnatal services are major barriers contributing to high missed 
opportunities at early infant diagnosis service points. Good information management 
systems are fundamental to improve the linkage between antenatal, perinatal and 
postnatal service points. In the current service, paper-based recording system is 
widely used for capturing PMTCT follow-up data. In most facilities the PMTCT 
record/register is either kept at antenatal facilities or shared between antenatal and 
postnatal maternal and child health services. In sites where antenatal and postnatal 
services are not provided in one facility, the postnatal services do not have access to 
information regarding the expected number of PMTCT mothers that should receive 
postnatal PMTCT services.  Hence, given the fragmented nature of the health care, 
and the large volume of patients (one in three pregnant mothers) that require PMTCT 
follow-up and referral services, it will be natural to conclude that linkage and 
communication cannot be improved by sole reliance on paper-based information 
system. The health system needs the important support of electronic medical 
recording technology to simplify tracking of HIV-positive mothers and their infants.  
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The EMR would enable antenatal, perinatal and postnatal services, as well as ART 
sites to have electronic information of each HIV-exposed mother-infant pairs enrolled 
in the PMTCT programme.  
 
In developed countries, information technologies are widely used to simplify the 
delivery of health service, whilst in developing countries the success stories of EMR 
are limited to research based sites.
181,182
 Most information technology applications 
have also centred on administrative and financial transactions rather than on 
delivering clinical care.  In some areas of developing countries, the infrastructure 
(network coverage, capacity including space, furniture, and trained staff) required for 
setting up the EMR system is non-existent. Given the communication problems that 
can be rectified  by introducing EMR, focusing the government health spending on 
infrastructural development and introduction of technology at health facilities could 
be worthwhile and could help achieve the MDG goals for reducing both HIV-related 
and non HIV-related maternal and infant mortalities.  
 
Secondly, the findings of this study indicate that current early infant diagnosis 
programmes rely on targeted approach to identify HIV-exposed infants. The targeted 
approach relies on notification of the HIV-exposure status of infants through maternal 
report or RtHC documentation.  Recent national EID guidelines recommend to use 
provider-initiated counselling and testing approach at immunisation service points to 
identify unknown/uncertain HIV status infants and infants of recently sero-converted 
mothers who missed opportunities of PMTCT services at antenatal visits.  
 
Our study shows that majority (61%) of infants were brought to the health facility 
with a RtHC that have no HIV identifying information. We also identified maternal 
reporting for six weeks infant HIV testing was low. Hence, the PICT approach 
recommended in the EID guidelines should be used as a primary approach in order to 
identify the majority of unknown/undocumented HIV-exposed infants. Our study 
findings show that universal maternal or infant HIV testing at six weeks 
immunisation visit could be a more acceptable and feasible approach to increase the 
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uptake of early infant diagnosis service. However, there is a lack of research that 
examines the cost-benefit of the universal testing approach in comparison to the 
approach recommended in current guidelines. Our result shows that the majority of 
HIV-positive mothers are not identified at postnatal visits due to gaps in the 
communication between antenatal, perinatal and postnatal facilities. Hence, the 
postnatal PMTCT service has to find another way of re-identifying and linking HIV-
exposed infants to postnatal services. Regular screenings at six weeks visits using  
either the PICT or universal testing approach could help identify HIV-exposed and 
infected infants early, allowing for timely treatment that can significantly reduce 
infant mortality risks. 
 
5.2. Recommendations  
 
1. Immunisation facilities should be able to have access to information on 
antenatal PMTCT mothers that should receive EID services after child birth. 
Given the large volume of PMTCT clients, electronic medical recording 
system may provide an option to simplify communication of this information 
between antenatal, delivery and postnatal facilities.  
2. Government should spend on infrastructural development (expanding internet 
access to grassroots level facilities, providing adequate space, furniture, and 
computers to enable the use of EMR at PHC level) and introduction of 
technology in order to improve communication and linkage between antenatal 
and postnatal services using electronic medical recording system.  
3. The use of the new RtHC for communicating the HIV status of infants should 
be monitored 
4. Routine offer of provider initiated testing at six weeks could improve EID 
service coverage. 
5. The implementation of new EID guidelines  should be monitored at local 
levels 
6. Substantial improvement in effective ARV regimen coverage is expected with 
the introduction Option B in South Africa.  However in order to reduce loss to 
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follow-up at referral points, nurse initiated ARV treatments should rapidly be 
expanded to all primary health care facilities.  
7. Modelling estimations should be reviewed  given the population level reports 
from our study that indicate ARV regimens lower than 90% can reduce 
perinatal transmission  to below 3% 
8. Provincial variations in coverage of the PMTCT cascade services should be 
narrowed through strengthening the health-system infrastructure. Equitable 
distribution of human resources could narrow differences in provincial 
coverage. 
9. More in-depth need assessment is needed in each province to address health 
service challenges specific to each province.  
10. In future PMTCT surveys, duration and appropriateness of ARV treatment,  
and viral load level could be measured in order to assess adherence and 
coverage of effective ARV treatment.   
11. The implementation of this survey required a significant resource (budget, 
human resource etc) allocation as the study was independently carried out by 
the MRC research team.  This type of survey is a useful tool for on-going 
surveillance and evaluation of the effectiveness of the PMTCT programme. 
However, to continue the on-going monitoring in a feasible way, the survey 
could be integrated into the routine programme, as similar with  the antenatal 
survey, (data on few important biomedical markers could be collected  - e.g.  
HIV exposure, transmission, viral load and biomedical markers for adherence 
to treatment).  
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Appendices  
 
Appendix I: Sample size calculation by province 
 
Antenatal 
HIV 
Prevalence 
2007  
% 
Antenatal 
HIV test  
% 
admin 
of 
PMTCT 
to 
babies  
Estimated 
Coverage 
(prevalence 
X %tested 
X %admin 
to baby)  
Estimated 
Not 
Covered  
Transmission 
Rate in 
exposed 
assuming SD 
NVP 
MTCT=15% & 
untreated 
MTCT=29% 
(Rollins)*  
Overall 
Population 
Prevalence 
per 100 
kids  
Same 
precision 
across 
provinces  
Same 
relative 
precision 
across 
provinces 
(%)  
sample 
size for 
30% 
relativ
e 
precisi
on  
Sample size for 
design effect** of 
2 & relative 
precision 30%  
Overall 
Population 
Prevalence 
per 100 
kids  
Varyin
g 
precisi
on by 
provin
ce  
Varying 
relative 
precision 
by 
province 
(%)  
Sample size 
using 
varying 
precision 
level 
without 
design 
effect  
Sample 
size using 
varying 
precision 
level with 
design 
effect** 
of 2  
National  29  67  47 31.5%  68.5% 24.6% 7.1% 2.1 30 575  1150       
WC*  15  97  75  72.8%  27.3%  13.0%  1.9%  0.6  30  1989  3978  1.9%  1.0  51  716  1400  
NC  14  81  70  56.7%  43.3%  21.1%  2.9%  0.9  30  1336  2672  2.9%  1.8  60  350  700  
EC  24  73  35  25.6%  74.5%  25.4%  6.1%  1.8  30  680  1360  6.1%  1.8  30  700  1400  
FS  29  70  52  36.4%  63.6%  23.9%  6.9%  2.1  30  560  1120  6.9%  2.0  29  617  1300  
KZN  37  66  52  34.3%  65.7%  21.4%  7.9%  2.4  30  485  970  7.9%  2.0  25  699  1400  
MP  34  56  36  20.2%  79.8%  26.2%  8.9%  2.7  30  428  856  8.9%  2.0  22  779  1600  
LP  20  74  54  40.0%  60.0%  23.4%  4.7%  1.4  30  878  1756  4.7%  1.5  32  703  1400  
NW  29.9  86  50  43.0%  57.0%  23.0%  6.9%  2.1  30  560  1119  6.9%  2.0  29  601  1200  
GP  31  65  27  17.6%  82.5%  26.5%  8.2%  2.5  30  463  926  8.2%  2.0  24  723  1800  
Total  7379  14758   12200  
ANC Prevalence & Coverage Data from DHIS  *WC & KZN assume full coverage dual therapy - Rollins KZN Study is 7%  
** Design Effect = 1+(100-1)*(ICC=.01)=2  
 
 
 
 
 
 
 
 
 
SAMPLING – SEE TEXT THAT FOLLOWS  
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EASTERN CAPE 
Strata  Total 
Annual 
DTP 
for the 
provin
ce  
Percentage  Adjusted  
Percentage  
Sample 
size 
proporti
onal  
Sample size 
adjusted 
proportion
al  
Median 
yearly 
clinic 
DTP1 
number  
Median 3 
week 
clinic 
DTP1 
number  
number 
of 
facilities 
need to 
be 
visited  
number of 
facilities need 
to be visited 
based on 
adjusted 
distribution  
Medium size clinics 
(130-300 annual 
DTP1#)  
41620  36.38%  30%  509  420  186.5  11  47  39  
large size (Annual 
DTP1 #>300) but 
low prev clinics  
41646  36.40%  43%  510  602  459  26  19  23  
The table below shows the number of facilities needed to be sampled from each province to collect data within 3wks (4 weeks for 
Northern Cape) duration from each facility.  
Note DTP1 = 1st DTP  
 
 
WESTERN CAPE  
Strata  Total Annual 
DTPDTP#  
Percen
tage  
Sample size 
proportional  
Median yearly 
clinic DTP1 
number  
Median 3 week 
clinic DTP1 
number  
number of 
facilities need to 
be visited  
Medium size clinics (130-300 
annual DTPDTP1#)  
15953  17.85%  250  192  11  23  
large size (Annual DTPDTP1 
#>300) but low prev clinics  
62884  70.38%  985  535  31  32  
large size (Annual DTPDTP1 
#>300) but high prev clinics  
10517  11.77%  165  857  49  3  
Overall Total 89354           100%  1400   58  
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FREE STATE  
large size (Annual 
DTP1 #>300) but 
high prev clinics  
31141  27%  27%  381  378  402  23  16  16  
Over all Total  114407  100%  100% 1400 1400   83  78  
Strata  Total 
Annual DTP 
for the 
province  
Percentage  Sample size 
proportional  
Median 
yearly clinic 
DTP1 number  
Median 3 
week clinic 
DTP1 number  
number of 
facilities need 
to be visited  
Medium size 
clinics (130-300 
annual DTP1#)  
14418  27.34%  355  201  12  31  
large size (Annual 
DTP1 #>300) but 
high prev clinics  
38326  72.66%  945  404  23  41  
Over all Total  52744  100%  1300    71  
 
GAUTENG 
Strata  Total Annual 
DTP for the 
province  
Perce
ntage  
Sample size 
proportional  
Median 
yearly clinic 
DTP1 
number  
Median 3 
week clinic 
DTP1 
number  
number of 
facilities 
need to be 
visited  
Medium size clinics (130-300 
annual DTP1#)  
15359  8.95%  161  237.5  14  12  
large size (Annual DTP1 
#>300) but low prev clinics  
33023  19.25
%  
347  549  32  11  
large size (Annual DTP1 
#>300) but high prev clinics  
123199  71.80
%  
1292  629  36  36  
Over all Total  171581  100%  1800   58  
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KZN  
 
Strata  Total 
Annual 
DTP for 
the 
province  
Percentage  Sample 
size 
proportio
nal  
Median 
yearly 
clinic 
DTP1 
number  
Median 3 
week 
clinic 
DTP1 
number  
number of 
facilities need 
to be visited  
Medium size clinics (130-300 annual 
DTP1#)  
40070  20.84%  292  209  12  24  
large size (Annual DTP1 #>300) but low 
prev clinics  
6505  3.38%  47  536.5  31  2  
large size (Annual DTP1 #>300) but high 
prev clinics  
145661  75.77%  1061  483  28  38  
Over all Total  192236 100%                                                    1400   64  
 
 
LIMPOPO 
Strata  Total 
Annual 
DTP for 
the 
province  
Percentage  Sample size 
proportional  
Median 
yearly 
clinic 
DTP1 
number  
Median 3 
week clinic 
DTP1 number  
number of 
facilities need 
to be visited  
Medium size clinics (130-300 
annual DTP1#)  
41027  33.89%  474  206  12  40  
large size (Annual DTP1 
#>300) but low prev clinics  
80048  66.11%  926  470.5  27  34  
large size (Annual DTP1 
#>300) but high prev clinics  
0  0.00%  0  0  0   
Over all Total  121075  100%  1400  74  
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MPUMALANGA 
Strata  Total 
Annual 
DTP for 
the 
province  
Percentage  Adjusted 
percentage  
Sample 
size 
propor
tional  
Sample size 
adjusted 
proportional  
Median 
yearly 
clinic 
DTP1 
number  
Median 
3 week 
clinic 
DTP1 
number  
number 
of 
facilities 
need to 
be 
visited  
number of 
facilities 
need to be 
visited based 
on adjusted 
distribution  
Medium size clinics 
(130-300 annual 
DTP1#)  
20858  26.73%  20%  428  320  225  13  33  25  
large size (Annual 
DTP1 #>300) but 
low prev clinics  
0  0.00%  0  0  0   0  0  0  
large size (Annual 
DTP1 #>300) but 
high prev clinics  
57172  73.27%  80%  1172  1280  439  25  46  51  
Over all Total  78030  100%  100%  1600  1600  79  75  
 
 
NORTHERN CAPE  
Strata  Total Annual 
DTP for the 
province  
Percentage  Sample size 
proportional  
Median yearly 
clinic DTP1 
number  
Median 4 week 
clinic DTP1 
number  
number of 
facilities need to 
be visited  
Medium size clinics (130-
300 annual DTP1#)  
7766  51.82%  363  207.5  16  23  
large size (Annual DTP1 
#>300) but low prev clinics  
7221  48.18%  337  400  32  11  
large size (Annual DTP1 
#>300) but high prev clinics  
0  0.00%  0  0  0  0  
Over all Total  14987  100%  700    34  
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NORTH WEST  
Strata  Total 
Annual 
DTP for 
the 
province  
Percentage  Sample size 
proportion
al  
Median 
yearly clinic 
DTP1 
number  
Median 3 
week clinic 
DTP1 number  
number of 
facilities need 
to be visited  
Medium size clinics (130-
300 annual DTP1#)  
22925  34.26%  411  204.5  12  35  
large size (Annual DTP1 
#>300) but low prev 
clinics  
24100  36.02%  432  413  24  18  
large size (Annual DTP1 
#>300) but high prev 
clinics  
19887  29.72%  357  432.5  25  14  
Over all Total  66912  100%  1200    67  
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Each province was divided into 3 strata:  
 Stratum 1 is clinics & CHCs that have annual Dtp1st dose 130-300 based on the 2007 
DHIS data  
 Stratum 2 are clinics & CHCs with 300 & above Dtp1st dose & HIV prevalence 
below the national (<29%) rate based on the 2007 DHIS data & 2008 antenatal survey 
data respectively  
 Stratum 3 are clinics & CHCs with 300 & above Dtp1st dose (based on the 2007 
DHIS data) & HIV prevalence above the national rate based on the 2007 DHIS data & 
2008 antenatal survey data respectively  
 
Provinces that don’t have the third stratum WC, Limpopo & NC have no third stratum: 
that is because there is no district with >29% HIV prevalence & high delivery rate (>300 
Immunization) in the province. However, for Western Cape, we had a sub district level data 
from the ANC survey, which indicated that Khayelitsha sub-district has more than 29% HIV 
prevalence. So, the third stratum was created from large clinics in Khayelitsha. We were not 
able to do the same for Limpopo & NC, as we did not have sub-district level HIV prevalence 
data (from the ANC survey) for the two provinces.  
 
Reduced the sample size for Northern Cape province to 700  
Northern Cape had 76 facilities to be sampled, logistically 76 clinics may not be achievable 
target within the allocated time. So we decided to reduce the no of facilities that need to be 
visited to 34.  
 
Adjusting weighting for Mpumalanga & Eastern Cape  
The number of facilities needed to be sampled for Mpumalanga & Eastern cape was 79 & 83 
respectively. In addition, most of the facilities were from medium clinics. As this might be 
difficult to achieve with available logistics capacity, we have slightly shifted the weighting to 
the large clinics (see column D) & hence the number of facilities need to be sampled from 
medium facilities decrease from 47 to 39 for EC & from33 to 25 for Mpumalanga (see 
column J). This will be logistically feasible.  
In Free state, we have only two strata - we grouped the last two strata as one stratum.  
The second strata (large & low HIV prevalence clinics) in Free state had only 0.74% 
weighting which translates to sampling only 1 facility from the second stratum. Since 
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sampling cannot be done for one facility, the second stratum is combined with the third 
stratum & thus we have only two strata for Free state. 
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Appendix II - Information sheet and consent form and Questionnaires  
 
A. PMTCT survey consent form  
 
CONSENT TO PARTICIPATE IN RESEARCH  
 
Evaluation of the effectiveness of the national prevention of mother to child 
transmission programme on infant HIV at 6 weeks postpartum, South Africa  
 
 
INTRODUCTION  
 
Hello. I am Ms/Mr. ………………………… (field worker name) from the Medical Research 
Council. We ask if you can take part in a study entitled “Evaluation of the effectiveness of 
the national prevention of mother to child transmission programme on infant HIV at 6 weeks 
postpartum”. This study is being sponsored by the National Department of Health, the 
Medical Research Council, the University of Western Cape, UNICEF and the Centers for 
Disease Control and Prevention of the United States.  
 
WHY AND HOW ARE WE DOING THIS STUDY?  
 
We want to find out how clinics look after pregnant women and small babies. We would like 
to know about small babies who are 4 to 8 weeks old.  
We want to find out what care pregnant women got from the ANC clinic. Did pregnant 
women get an HIV test? Did pregnant women get care for HIV? Did pregnant women get 
care to prevent HIV in their baby? This is what we want to know.  
We also want to know about your baby or the baby that you look after: What type of birth did 
he or she have? Did he or she get any care for HIV? What milk or food does the baby get?  
We also want to know how many babies do not have HIV. So, we want to take some blood 
from the baby‟s heel. The heel is the bottom part of the foot. We call this a blood spot test. 
We will send this blood spot to the lab. A lab is a big place where they will test the blood for 
HIV. The lab will send the result back to the clinic within 4 weeks. When we test the baby‟s 
blood we know the baby‟s HIV result. If you come back for the result then the nurse in the 
clinic tell you the result.  
But the mother or you can also go for an HIV test today if you want to know your result now.  
We ask these questions and take the blood because we want the clinic to give you better 
service. We also want you and your baby to get all the care that you need. So if you or your 
baby tests HIV positive the nurses will make sure you get the right care and medicine.  
We do this because we do not want children to get sick or to get HIV or to die from HIV.  
The work is called a research study. This study is being done in all provinces of South Africa. 
We will ask 12 200 caregiver and their babies to take part in this study. If the mothers are not 
at the clinic then we will ask the person who looks after the baby to take part in the study, 
with the baby. 
 
BEING PART OF THE STUDY AND STOPPING THE STUDY  
If you agree to take part in this study, then we will ask you questions. You do not have to 
answer the questions. At any time during the questions or before the baby‟s heel is pricked 
you can stop the study. We will then stop.  
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The questions and the blood test will be done today in a separate part of the clinic.  
 
If you do not want to take part in this study you will still get the same care in the clinic that 
you would get if the study was not here.  
 
PRIVACY  
 
Your answers will be marked on a form or put into a cell phone. Your name will not be on 
the answers. Only a secret code will be linked to your answers. This secret code is called a 
study ID. This means that no one will know your answers. They will only know if they break 
the secret code and link it to your name.  
All information will be kept private. This means that we will not show anyone else your 
answers. No one will know what you said as a person.  
But we need to take your name on the blood test form so that you can get the test results if 
you want them.  
We will send all the results back to the clinic using the secret code. The clinic nurse who can 
give you the result will see the result and will be able to give it to you. So she will know your 
secret code. She will know the test result.  
We will not force you to come back to get the HIV result. But getting the result is a good idea 
because then the mother and baby can get the right care and medicine. If you get the right 
care you will not get very sick very often. The HIV test result will be at the clinic in 4 to 8 
weeks time. Please ask the nurse when you come back to the clinic, if you want the result. 
We strongly think you should know the result so you and your baby can get the right care. 
But as we said we will not force you to come back. The clinic staff will keep your results a 
secret from all other mothers in the clinic. When you come back and ask for the results they 
will answer your questions and give you the results.  
 
POTENTIAL BENEFITS 
  
There are some good things that you may see now if you take part in the study.  
If we see that you have not had an HIV test or do not know your HIV result then we will give 
you a card and ask you to go for the HIV test.  
Knowing if you have HIV is good as then you can get the right care. Taking the right 
medicine will keep you from getting sick. By being part in this study the mother of the baby 
can also get to know the baby‟s HIV result. If the mother knows the baby‟s result then the 
baby can also get the right care. This means that the baby will not get sick very often. If you 
are HIV positive then this test is the 6 week test that you were told about when you were 
pregnant. The clinic is not going to do a separate test for your baby.  
There are also some other good things for other people who use the clinic. The answers that 
we get from the 12 200 mothers/babies will help us make things better at the clinics in South 
Africa. 
 
 
POTENTIAL HARM  
 
The questions will take about 30 minutes of your time. If you are not the mother we will skip 
some questions. If we ask questions that are a problem for you, you do not have to answer 
them.  
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The blood spot test can cause a little pain to the baby. It may also leave a few blue marks on 
the baby’s foot. These will be gone in about one week.  
The good thing about the blood test is that the mother can get to know the baby‟s HIV result. 
This means that she can then get the right care for her baby when she comes back for the 
result.  
As we said your name and answers are kept private. This means that we do not share what 
you tell us with anyone in the clinic. We will only send the blood result back to the clinic so 
that you can come back and get it, so that you can help the baby.  
Please ask me if you have any problems with the questions, or with the study.  
 
WILL YOU GET ANY PAYMENT FOR BEING IN THE STUDY?  
 
You will not receive any money or food for being part of the study. You do not have to pay to 
be in the study.  
 
 
USE OF BLOOD SPOTS  
 
The blood spots will be used to test if the baby has HIV. After the HIV test any blood left 
over will not have a name or code with it. In future the blood may be used for other studies. 
These may include studies on HIV medicines. We will not put your name or address or any 
contact information on the blood sample and there will be no way to know it is from your 
child. Thus we will not be able to report back any test results to you from the future studies. 
A research ethics board, which watches over the human safety and rights, must approve any 
future research study using the blood samples from your child. Your child’s blood sample 
will not be sold.  
 
PEOPLE DOING THE STUDY  
 
If you have any questions or problems about the research study please phone the person in 
charge of the study. Her name and telephone numbers are:  
Dr Ameena Goga Specialist Scientist Health Systems Research Unit, MRC Van Zyl Drive, 
Parow Western Cape 7535 Tel: +27219380454 Mobile +2782 302 3168  
Or  
For Ethical or Rights questions contact:  
The MRC Ethics Committee with the following address: Prof Danie du Toit, tel. (021) 938 
0341; e-mail: adri.labuschagne@mrc.ac.za 
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CONSENT FORM  
 
Researcher: ……………………………(Research assistant's name)  
Research conducted by: Medical Research Council and University of the Western Cape and  
Mr/Ms ……………………………. has explained the research study and I agree to take part.  
My questions have been answered.  
 
___ I agree to answer questions  
___ I agree to the baby having a heel prick blood spot taken for an HIV test  
I understand that I can stop taking part in this study at any time without giving a reason. This 
will not change the care that I or my family get at this clinic/health centre.  
 
 
Name (print)…………………………………………  
Signature………………………………………… Date……………………………….  
Thanking you for helping us with our research 
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B.  PMTCT survey Questionnaire  
 
 
SCREENING QUESTIONNAIRE   
 
Evaluation of the effectiveness of the national prevention of mother to child transmission 
programme on infant HIV at 6 weeks postpartum, South Africa 
 
Patient identifier 
____________________ 
 
Name of the person collecting data (Interviewer code): [       ]        Date of interview:  
……../……./……. 
 
Province: __________   District: __________  Facility name: __________ 
 
Question  Questions and filters Coding categories 
S.1 Are you bringing this child for emergency 
medical care or urgent referral to hospital 
or other health facility?   
1=Yes Skip to S.13 
2 = No  Continue Questionnaire 
S.2 What is your relationship to the child? 1 = Mother  Skip to S.3 
2 = Father 
3 = Grandmother/father   
4=  Legal guardian (if orphan or 
abandoned) 
5 = Other caregiver 
S.3 Where is the mother of the child? 1 = At home/work/other place 
2 = No longer alive 
99 = Don’t know 
(specify)_______________________________ 
S.4 Age of MOTHER in YEARS       
                                          
_________________________ 
S.5 What is the highest school grade 
PASSED by the MOTHER? 
 
Only one response 
 
1= None 
2= Grades 1-7  
3= Grades 8-12 
4 = Completed tertiary/technical/university  
99 = Don’t Know 
S.6 Marital status of MOTHER 
 
Only one response 
 
1= Single  
2 = Married  
3 = Co-habiting  
4 = Widowed  
5 = Divorced/Separated 
99 = Don’t Know 
S.7 Child’s population group  
 
Only one response 
 
1= Black 
2=White 
3=Coloured 
4=Indian 
5=Other 
 
 
 
 
 179 
  
 
   
 
S.8 Is your child a boy or a girl? 1=Male 
2=Female 
S.9 How old is the child  in weeks? ____________ 
If less than 4 or more than 8 weeks 
entered     Skip to S.13 
S.10 Why did you bring this child to the clinic 
today 
 
Tick all that apply 
1 = Immunisation   
2=  HIV PCR 
 
3 = Other reasons,  please specify 
________________________________ 
 
S.11 Did your child receive the 1
st
 
DTPimmunization prior to this 
visit? 
Check RTH card to confirm 
1=Yes  Skip to S.13 
2= No 
 
S.12 Do you want the child to receive the 1
st
 
DTP immunization today/Did your 
child receive the 1
st
 DTP 
immunization during today’s visit?  
1=Yes  Skip to Instruction Field A 
2= No  Skip to Instruction Field A 
99=Don’t know  Check RTH Card or 
Query Clinic staff & click RETURN 
to select  yes /no. 
 
 
S.13a Is this child eligible for study participation 
 Is age 4 to 8 weeks old 
 Has received or will receive DPT1 
immunisation at this clinic visit 
1=Eligible Continue to 
Information sheet & consent 
procedure 
2=Not Eligible  Discontinue 
interview and thank the 
caregiver 
S.13b Are you sure you want to terminate the survey, 
please confirm 
Say thank you to caregiver 
 
1 = Yes confirmed not eligible  
2= No  want to go back 
 
 
If the child is eligible to participate in the survey, please discuss with the caregiver information 
provided in the information sheet and complete consent process 
 
 
S.14a Does the mother/caregiver give written consent to 
participate in study 
1=Yes Continue to 
questionnaire Skip to 1.1 
 
2=No  Discontinue interview 
and thank the caregiver 
S.14b Are you sure you want  to terminate the survey, 
please confirm  
Say thank you to caregiver 
 
1 = Yes confirmed caregiver 
did not give consent  
2= No  want to go back 
 
Say thank you to all caregiver of infants who do not meet eligibility criteria 
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QUESTIONNAIRE   
 
Evaluation of the effectiveness of the national prevention of mother to child transmission 
programme on infant HIV at 6 weeks postpartum, South Africa 
 
SECTION I: SOCIO-DEMOGRAPHICS 
Question  Questions and filters Coding categories 
1.1 What is the MAIN material that the house the 
child lives in built with? 
 
Only one response 
 
1=Brick/Cement Block 
2=Informal material/corrugated iron/wood 
3=Traditional material/mud 
4=Other, specify 
1.2 What is the MAIN source of water used for 
drinking in the child’s home? 
 
Only one response 
  
1 = Piped in house or in yard 
2 = Not piped in house or in yard 
1.3 What type of toilet do you use at the child’s home? 
Only one response 
 
1 = Flush toilet 
2 = Pit latrine (incl. Ventilated pit latrine) 
3 = None 
4 = Other (specify) 
1.4 What is the MAIN fuel used for cooking in the 
child’s house? 
 
Only one response 
 
1 = Electricity / gas / paraffin 
2= other (specify) 
 
1.5 Does the MOTHER receive money from any of the 
following sources? 
 
Tick all that apply 
 
1=Own Employment 
2=Child Support Grant 
3=Disability Grant 
4=Partner/husband/ex-husband 
5=Other family member 
6=Other 
7=doesn’t receive any money99=Don’t 
Know 
1.6 In the last year (2009) was there a time when you 
and your family ran out of food and had to ask for 
help      
Only one response 
1= Yes    
2 = No    
99 = Don’t Know 
 
1.7 Does the household where the child lives have any 
of the following items (working items only)? 
 
Tick all that apply 
1=Refrigerator 
2=Radio 
3=Television 
4=Stove (any type, incl primus) 
5=Telephone/Cell phone  
6=Car 
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SECTION II: INFANT & POSTNATAL VISITS  
(Ask Mother/Caregiver & Check Road to Health Card) 
2.1.  
Does the child have a RTHC – ask to see the card 
1=Yes 
2=No 
2.2.  
Does the child have a new RTHC (road to health 
booklet) 
1=Yes 
2=No 
2.3.  Birth weight 
(Write 99.99  if  Don’t Know/Not Documented) 
____ ____KG 
 
99= Don’t Know/Not Documented 
2.4.  
Gestational age at birth (from RTHC) 
_______ in wks 
99=Not Documented/No RTHC 
2.5.  
Has the child been weighed already ? 
(confirm from the RTHC) 
1= Yes 
2= Not yet  -> Skip to 2.7 
2.6.  
Current weight (weight during this visit from 
RTHC) 
____ ____KG 
 
2.7.  
Number of postnatal visit since after birth to check 
maternal & infant health  (Write 99 if Not 
Documented/Don’t know) 
______number of visits  
 
2.8.  
Did the child receive BCG Immunization at birth 
1=Yes 
2=Not Documented/No RTHC 
2.9.  
Is there a PMTCT code or an HIV test result to 
indicate maternal HIV result on the RTHC  
1=Yes PMTCT code 
2=Yes HIV test result 
3=No Skip to 2.11  
  99=Don’t Know/No RTHC Skip to 2.11 
2.10.  
Please write the HIV test results as it appears on 
the card (write code or test result) 
 
_________________ 
 
2.11.  
Is there any documentation of maternal PMTCT 
prophylaxis on the RTHC  
1 = Yes  
2 =  No   
99 = No RTHC 
2.12.  
Is there any documentation of infant PMTCT 
prophylaxis on the RTHC 
1 = Yes  
2 =  No   
99 = No RTHC 
2.13.  
Is the mother’s (syphilis) serology recorded on the 
RTHC (RPR on new RTHC)  
1 = Yes  
2 =  No   
99 = No RTHC 
2.14.  Type of delivery (from RTHC or mother) 1 = Vaginal delivery 
2 = Caesarean section 
99=Don’t Know/No RTHC 
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SECTION III: KNOWLEDGE ABOUT MTCT 
 
3.1.  Can a baby get HIV from the mother if the mother 
is infected with HIV? 
1 = Yes 
2 = No  Skip to 3.3 
99 =Don’t Know 
3.2.  How?  
 
Probe after each answer (e.g. any other way) 
Tick all that apply 
1= Breastfeeding  
2= During pregnancy 
3= During childbirth 
5= Other 
99= Don’t Know 
3.3.  Have you ever heard of the PMTCT programme? 1 = Yes 
2 = No 
 
 
SECTION IV: INFANT HEALTH and FEEDING PRACTICES 
 
4.1. Do YOU PERSONALLY normally feed and 
change the baby during the day? 
 
1 = Yes 
2 = No  Skip to 5.1 
 
 4.2. From the time you woke up yesterday morning, till 
you woke-up this morning, have you given the 
following to the baby 
 
Ask each item and tick yes or no 
1. [   ] Yes    [   ] No   Breast milk 
2. [   ] Yes    [   ] No   Infant formula 
3. [   ] Yes    [   ] No   Fresh Cow’s milk, tea with milk, weak porridge 
3. [   ] Yes    [   ] No   Water only, water with sugar/glucose, fruit juice, tea without milk, rice water    
4. [   ] Yes    [   ] No   Solid food (e.g. yoghurt, cheese, cereals, porridge, bread,  fermented porridge, 
fruits/vegetables, meat/fish/chicken, eggs)  
5. [   ] Yes    [   ] No   Traditional Herbs and/or Traditional Medicines, Non-prescribed over the 
counter medicines e.g. Gripe water, Panado   
6. [   ] Yes    [   ] No   Prescribed medicine   
7. [   ] Yes    [   ] No   Other, specify   _________________________ 
 
 
4.3. Now I am going to ask you if you gave the following 
items to the baby at all in the last week ending 
yesterday morning. 
 
Ask each item and tick yes or no 
2.15.  Has the child been sick requiring a sick child clinic 
visit or hospitalisation since birth for treatment?  
 
Ask the woman 
1=Yes 
2=No 
99=Don’t Know  
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1. [   ] Yes    [   ] No   Breast milk 
2. [   ] Yes    [   ] No   Infant formula 
3. [   ] Yes    [   ] No   Fresh Cow’s milk, tea with milk, weak porridge 
3. [   ] Yes    [   ] No   Water only, water with sugar/glucose, fruit juice, tea without milk, rice water    
4. [   ] Yes    [   ] No   Solid food (e.g. yoghurt, cheese, cereals, porridge, bread,  fermented porridge, 
fruits/vegetables, meat/fish/chicken, eggs)  
5. [   ] Yes    [   ] No   Traditional Herbs and/or Traditional Medicines, Non-prescribed over the 
counter medicines e.g. Gripe water, Panado   
6. [   ] Yes    [   ] No   Prescribed medicine   
7. [   ] Yes    [   ] No   Other, specify   _________________________ 
 
 
 
 
 
 
SECTION V: OBSTETRIC HISTORY, ANTENATAL & DELIVERY 
 
5.i 
FROM THE SCREENING QUESTIONAIRE 
What is the relationship of the person being 
interviewed with the baby? (do not ask question 
again – use as skip if not mother) 
1 = Child’s mother 
 2 = Not child’s mother  Skip to 8.1 
5.1. 
How many live-children do you have including this 
child 
___________number of live children 
5.2. 
How many times have you had been pregnant 
____________ number of times mother has 
been pregnant 
5.3. 
Was this pregnancy planned? 
1=Yes 
2=No 
99=Don’t know 
5.4. 
How many weeks pregnant were you in your first 
ANC visit during this last pregnancy   
_______in weeks 
99=Don’t know 
 
5.5. 
Number of ANC visits made during this last 
pregnancy 
_______ times 
99=Don’t know 
5.6. 
Did you have had Syphilis test done during the last 
pregnancy  
1 = Yes  
2 = No  
99 = Don’t know 
5.7. Were you screened for TB during this pregnancy? 1 = Yes 
2 = No 
99 = Don’t know 
5.8. During pregnancy did you ever discuss with anyone 
at the clinic what the best way for you to feed your 
baby is? 
Only one response 
1=Yes 
2=No 
99=Don’t Know 
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5.9. Where was the child born? 
Only one response 
 
1=Hospital 
2=Clinic 
3=Home or other 
5.10.  Who attended the birth of the child? 
Only one response 
 
1=Doctor 
2=Nurse/Midwife/Other Health Care 
Worker 
3=Traditional Birth Attendant or other 
5.11.  Did you receive services or support from any of the 
following during your pregnancy, delivery or 
postpartum? 
 
Tick all that apply 
1=Community Health Worker  
2=Traditional Birth Attendant 
3=Traditional Healer 
4=Mothers Support Group 
 
 
SECTION VI: HIV TESTING 
 
 
HIV TESTING 
6.1. During your last pregnancy, were you tested 
for HIV infection?  
1 = Yes  Skip to 6.3 
2 = No  
3 = Chooses not to answer - Skip to 6.3 
99 = Don’t Know  Skip to 6.3 
6.2. Why you were not tested for HIV during your 
last pregnancy? 
 
1 = Never offered  
2 = Did not want to test 
3 = No reason offered  
4 = Other (specify)      
                                                                     
6.3. Have you ever tested for HIV infection prior 
to the last pregnancy? 
1 = Yes 
2 = No  Skip to 8.1 
3 = Chooses not to answer  Skip to 7.1 
99 = Don’t know  Skip to 7.1 
 
6.4. Did you get the result of the test / most recent 
test?  
 
1 = Yes  Skip to 6.6 
2 = No 
3 = Chooses not to answer  Skip to 6.6 
6.5.  
Why did you not get the HIV test result?  
1 = Not available Skip to 8.1 
2 = Did not want the result  Skip to 8.1 
3 = Other (specify) and  Skip to 8.1                                                                 
6.6.  
What was the latest HIV result? 
1 = Infected / HIV positive 
2 = Not infected/HIV negative Skip to 8.1 
3 = Chooses not to answer  
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SECTION VII: PMTCT 
 
PMTCT  
(For this section refer to examples of medications to assist with ID of drugs taken) 
7.1. Did you receive AZT during your pregnancy with 
your last child?  [Explanation: AZT = a tablet you 
take every day on its own during pregnancy, starting 
from 14 weeks – show a picture of AZT] 
 
1 = Yes 
2 = No  Skip to 7.3 
3 = Chooses not to answer  Skip to 7.3 
99 = Don’t Know  Skip to 7.3 
7.2. For how long did you take the AZT before your last 
child was born?  
 
           _______    WEEKS 
7.3. Did you take any medicines to prevent transmission 
of HIV to your infant when you went into labour?  
 
1 = Yes 
2 = No  Skip to 7.5 
3 = Chooses not to answer 
99 = Don’t Know 
7.4. What medicines did you receive when you were in 
labour?  
 
[Explanation of Drugs:  See the relevant card with 
descriptions of each possible] 
 
1 = Nevirapine  
2 = AZT  
3 = TDF/FTC  
4 = Other, Specify 
5 = Chooses not to answer 
99 = Don’t Know  
7.5. Did you receive TDF/FTC after delivery 
 
[Explanation of drug:  sometimes refered to as 
Travada, one tablet after delivery – see card 
descriptions] 
1 = Yes 
2 = No 
3 = Chooses not to answer 
99 = Don’t know 
 
7.6. Was your last child given Nevirapine after delivery?  
[Explanation: Nevirapine for the child is a syrup 
given to the baby within 72 hours of delivery to 
prevent mother to child transmission.] 
 
1 = Yes 
2 = No  Skip to 7.8 
3 = Chooses not to answer Skip to 7.8 
99 = Don’t know  Skip to 7.8 
 
7.7. How many days was last child given NVP 
(write 99 if don’t know; if child is still on Nevirapine 
write 98) 
_______ days 
 
7.8. Did your last child get AZT?  
[Explanation: AZT for the child is a syrup given with 
a syringe twice a day to prevent mother to child 
transmission] 
1 = Yes 
2 = No Skip to 7.10 
3 = Chooses not to answer Skip to 7.10 
4 = Do not know  Skip to 7.10 
 
7.9. How many days was your last child given AZT?  
(write 99 if Don’t Know) 
________ days 
 
7.10.  
Have you told anyone about your HIV status? 
1=Yes   
2=No 
7.11.  
In general, have you felt discriminated against 
(treated badly) by your community due to your HIV 
status? 
1=Yes 
2=No 
99=Don’t Know 
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7.12.  
Is the baby getting any formula milk? 
1=Yes   
2=No   Skip to 7.16 
 
7.13.  
Where do you get the formula 
1=Purchase 
2=Receive from clinic 
3= Other(specify) 
99= Don’t Know 
7.14.  
Did you ever run out of formula   
1=Yes   
2=No  
99=Don’t Know 
7.15.  
If yes, what did you feed the baby when you did not 
have the formula  
1=breast milk 
2=glucose water 
3=water 
4=other (specify) 
CD4 
7.16.   
Have you had a blood test for a CD4 count? 
1 = Yes  
2 = No Skip to 7.18 
3 = Chooses not to answer Skip to 7.18 
99 = Do not know Skip to 7.18 
 
7.17.   
What was the last CD4 result? 
 
/_________/CD count 
7.18.   
Have you been referred to the ART clinic?  
1 = Yes  
2 = No  
3 = Chooses not to answer 
99 = Don’t Know  
7.19.   
Have you visited the ART clinic? 
1 = Yes  
2 = No  
3 = Chooses not to answer 
99 = Don’t Know  
7.20.   
Are you on HAART?  
[Explanation:  HAART is when the mother is on three 
ARV drugs] 
1 = Yes  
2 = No Skip to 8.1 
3 = Chooses not to answer Skip to 8.1 
99 = Don’t Know Skip to 8.1 
7.21.   
How long ago did you start taking HAART?  
1= Before Pregnancy with this infant 
2 = During Pregnancy with this infant 
3= After Delivery of this infant 
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SECTION VIII: BLOOD SPECIMENS 
 
8.1. Blood sample taken  
 
1=Yes Skip to 8.5 
2=Refused  Skip to 8.3 
8.2. If you are not willing to have your baby tested for 
PCR test can you tell me why not? 
1 = No Reason Go  to 8.32 = Lack of 
Time Skip to Stop1 
3 = Need permission from another 
person Skip to Stop1 
4 = Do not want to give name for the  test 
 Go  to 8.3 
5 = Other (specify) _______________ 
Skip to Stop1 
8.3 Would you accept testing using only a laboratory  ID 
number and not a name? 
1=Yes  Go to 8.4 
2=Refused Skip to Stop1 
8.4 Blood sample taken – study ID used 1=Yes  Go to 8.5 
2=Refused Skip to Stop1 
8.5 Cell Phone number belongs to 1=Mother   Go to 8.6 
2=Legal guardian/father (only if no mother 
is available)  Go to 8.6 
3=Do not have cell phone -  write down 
address on follow-up letter envelope, click 
NEXT to continue  
 Skip to 8.7 
8.6 Cell Phone Number 0##-###-#### 
 
8.7 Blood Sample Lab Form Bar Code 
 
_______________ Go to Stop2 
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C.  Situational analysis consent form and questionnaire  
 
Information sheet and Consent Form for 
HEALTH FACILITIES SERVICE REVIEW  
National Situational assessment  
 
 
Hello. I am Mr./Ms. _____________from Medical Research Council. The National 
Department of Health has asked the Medical Research Council & the University of the 
Western Cape to conduct a national PMTCT survey in all the nine provinces of South 
Africa. Your facility might be one of the facilities selected for this survey.  
Before this national survey is conducted, information about how your facility functions 
and how it offers PMTCT and child-health care is needed. During the national survey we 
plan to visit the immunization clinic of each facility for about 3-4 weeks. During this time 
interviews will be conducted with mothers/caregivers at 6 weeks immunization visits. 
Blood specimens will also be collected from infants at 6 weeks of age. The result of the 
test will be returned to the facility so that mothers can get their infants HIV status result.  
The National Department of Health has informed all Heads of Health that researchers 
from the Medical Research Council will be visiting primary health care clinics and 
community health centers to conduct a situational analysis and gather baseline 
information relevant for the planning of the PMTCT survey (show letter written by 
National Department of Health). Permission to conduct this situational analysis has been 
received from the Medical Research Council ethics committee (show letter).  Today we 
are here to conduct this situational analysis: we would like to find out about the most 
suitable means of transport needed to access your facility; the availability of local / 
suitable field workers for data collection;  your PMTCT and EPI services; your 
immunisation days; the equipment, supplies, communication and transport systems that 
exist for DBS PCR testing and the services that your clinic offers for HIV counseling and 
testing and for adult and paediatric antiretroviral treatment.   
 
The questions will take about 30-45 minutes of your time. The study will pose no risk to 
you or to your facility. You & your facility will not be identified by name or address in 
any of the reports we plan to write. Key findings will be reported in aggregate form only. 
You may refuse to answer some questions and you may withdraw from the interview at 
any point. Your withdrawal will not have any negative effects on your work. You will not 
personally benefit from this study, but the information collected will be used to 
strengthen the existing PCR testing & referral system of health facilities.  
 
If you have any questions or concerns about the research or about your welfare as a 
research subject, please feel free to contact the principal investigator: 
Dr Ameena E Goga 
Paediatrician and Specialist Scientist 
Health Systems Research Unit 
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Medical Research Council 
1 Soutpansberg Road, Pretoria, 0001 
Tel: +2712 3398531 / +2782 302 3168 
Or   
The MRC Ethics Committee with the following address: Prof Danie du Toit, tel. (021) 
938 0341; e-mail: adri.labuschagne@mrc.ac.za 
 
Would you be willing to assist us by answering some of our questions? (Please ask the 
respondent to read and sign the consent form if his/her answer is yes).  
We hope that this situational analysis will help us as we plan for this national survey that 
the Department of Health has asked for. 
 
 
 
CONSENT FORM 
 
 
Researcher: ……………………………(Field worker name)   
 Facility name: ………………………. 
 
 
Research conducted by: Medical Research Council and University of the Western Cape 
and  
Mr/Ms ……………………………. has explained the study and has shown me all 
permission letters. My questions have been answered and I agree to take part in this 
study.  
 
 
Name (print)…………………………………………   
Designation in facility………………………….. 
 
 
Signature…………………………………………  
Date…………………………………………….. 
 
Filed workers signature (as a witness)…………………………….. Date 
……………………… 
 
 
Thanking you for helping us with our research. 
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Situational Analysis questionnaire 
 
 
 
Interviewer read out: Thank you for agreeing to answer our questions. The questionnaire is 
divided into four sections. The first section assesses general postnatal PMTCT information. 
You can answer some or all of the questions in this section or you can refer us to a person 
who can best answer the relevant questions. The second section is particularly for you (the 
clinic manager). The third section has questions for the key nurse who coordinates or 
provides EPI / immunization services in the clinic & the fourth section is for the key nurse 
who provides IMCI or sick babies service.  
 
Section I – Basic postnatal PMTCT information   
Note to the field worker: start the interview with the clinic manager, however the clinic 
manager may answer all questions in section 1 or may refer you to one of the IMCI nurse, 
immunization nurse, PMTCT nurse or VCT nurse. Please note the name of the person who 
you are referred to (i.e. write ‘EPI nurse’ if you were referred to EPI nurse) next to the 
relevant question so that you remember the person you need to interview after the clinic 
managers interview.   
A. Assessment of the existing system for identifying HIV infected & exposed infants 
1. Does your clinic offer HIV testing for infants during 6 weeks immunization visit? 
1= Yes  
2 = No  if no skip to q2 
1.1. If yes,   which of the following algorithms/protocols  do you use  to  identify  HIV 
exposed or infected infants during 6 weeks immunization visit:  PROMPT  
RESPONDENTS &  CIRCLE ALL THAT APPLY 
 
1= All mothers bringing their infants for  6 weeks immunization visit  get offered a 
DNA PCR test  on their infant   
2= All mothers bringing their infants for a 6wks immunization visit get offered a 
rapid HIV test on their own blood   & if they are HIV positive (from the rapid test) 
their infants will be offered DNA PCR test    
3= Infants born to mothers who  report themselves as HIV positive get offered a 
DNA PCR test   during 6wks immunization visit   
4= Infants born to HIV positive mothers as recorded on the RTHC  get offered a 
DNA  PCR test   during 6wks immunization visit   
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5= Infants born to HIV positive mothers as recorded on the register  get offered a 
DNA  PCR test   during 6wks immunization visit   
6= Mothers who ask for HIV tests during 6 weeks immunization visit get offered 
an HIV test on themselves followed by a DNA PCR test on their infant if they are 
positive  
7= Mothers who ask specifically for an infant HIV test get offered an HIV  test on 
their infants during 6 weeks immunization  visit    
8= Other   
8.1= If yes to other, specify ______________ 
 
1.2.Do you provide PCR testing  for  infants that  comes  with a caregiver  (eg. 
grandmothers etc) without the mother present 
 
1=Yes     
2= No 
 
2. Do you offer HIV testing to infants  at visits  other than 6 weeks  immunization visit 
1= Yes 
2= No   if no skip to q 3 
      if no to both q1 & q2 skip to q13  
2.1. If yes,  other than 6 week visit, can you tell us on which other visits or   at what 
stages of  the infants life  HIV testing is provided  PROMPT   RESPONDENTS &  
CIRCLE ALL THAT APPLY  
1= All sick children suspected for HIV exposure from clinical symptoms will be 
offered HIV test at any age if they were not tested before  
2= All HIV exposed babies visiting the sick baby clinic will be given HIV test if 
were not tested before 
3= If a child is born from  a known HIV positive mother a PCR test will be given 
after cessation of breastfeeding   
4= If a child is born from  a known HIV positive mother a PCR test will be given  at 
9 months  
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5= If a child is born from a known HIV positive mother a rapid test will be given at 
18 months 
  6= Other  
6.1. =If yes to other, specify ______________ 
 
3. Do you have Standard Operating Procedures that you follow to do (i.e to collect, dry 
& pack blood specimens) PCR specimens? 
1=Yes 
2= No 
4. In which one of the following services/clinics do you offer HIV testing to identify 
HIV exposed/infected infants?  PROMPT  RESPONDENTS &  CIRCLE ALL 
THAT APPLY  
1= HIV testing is offered & performed at the PMTCT clinic 
2= HIV testing is offered & performed at the immunization clinic 
3= HIV testing is offered & performed at the IMCI/sick baby clinic 
4=Immunization clinic offers HIV testing to mother infant pairs & refers those who 
agree to test to the PMTCT clinic  
5= Immunization clinic offers HIV testing to mother infant pairs & refers those who 
agree to test to the VCT clinic 
6= IMCI/sick baby clinic offers HIV testing to mother infant pairs & refers those who 
agree to test to the PMTCT clinic  
7= IMCI/sick baby clinic offers HIV testing to mother infant pairs & refers those who 
agree to test to the VCT clinic 
8= Other  
8.1= Specify other  
 
B. Sending DBS for lab testing  
 
5. If your facility offers PCR testing, where (to which lab) do you send the DBS/whole 
blood specimens for testing? Specify the name & address of the laboratory where the 
blood specimens are sent. 
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Name 
 
Physical Address & telephone number 
 
 
6. Is there a transport system that takes these PCR specimens to the laboratory?  
1= Yes  
        2=  No   if No skip to q9 
 
6.1. If yes, please tell us what transportation system  is used: 
 
1= Routine provincial system 
2= Routine NHLS system        
3= Routine private courier        
4= if routine private courier, provide contact details 
Name  
 
 
Telephone number 
 
 
5= Other:   
5.1= If other, specify/provide contact details: 
 
Name  
 
 
Address 
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7. How frequently are these infant PCR specimens sent to laboratory for PCR testing? 
ONLY ONE RESPONSE  
1= Daily        
2= on certain standardised day/days of the week   
3= Once a week (no standardised day i.e. adhoc whenever there are enough 
specimens to send) 
4= Adhoc basis – sometimes once a week, sometimes fortnightly 
5= not sent to the lab  
6= other 
6.1= if other specify  
 
7.1. If lab specimens are sent on certain standardised day/days of the week, specify which 
day/days of  the week      ____________     and time of the day (i.e. 
mornings/afternoons) _________________ the DBS/whole blood specimens are sent 
to the lab  
 
8. Is this transportation system reliable 
1= Yes it is reliable  if  Yes  skip to q10 
2=Not reliable 
 
8.1. If the transportation is not reliable, describe the problems that you have been having 
with the transportation  system 
 
 
9. If there is no transportation system , ask how PCR specimens reach to the laboratory 
 
 
10. Where do you store infant PCR specimens in the facility until they are collected  
1= Consulting room in which they were taken 
2= Facility pharmacy 
3= Clinic Manager’s office 
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4= Facility’s staff tea room 
5= Facility fridge 
6= Other 
6.1= if other specify 
 
11. What is the average turnaround time for PCR test result – i.e. the number of weeks 
from the day the specimen has been taken from the infant to the day that the facility 
receives the result? 
 
12. When do mothers usually receive their infants PCR test result if the blood specimen was 
collected at the 6 week immunization visit. ONLY ONE RESPONSE 
1= usually at 10 weeks 
2= usually at 14 weeks 
3= other 
4= if other specify ______ 
 
To the field worker: if answered yes to q1 or q2 skip to q15 
13. If PCR testing service is not given in this facility, are there any other blood 
specimens (eg.  CD4 count) that you send to the lab?   
 
1= Yes   
2= No   if No skip to q15  
 
13.1. If yes, specify Name & address of the lab that you use for these other specimens 
Name 
 
Physical Address & telephone number 
 
 
13.2. If yes, please tell us what transportation system  is used: 
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1= Routine provincial system 
2= Routine NHLS system 
3= Routine private courier          
4= if routine private courier, provide contact details 
Name  
 
 
Contact number  
 
 
5= Other:   
5.1= If other, specify/provide contact details: 
 
Name  
 
 
Address 
 
 
14. If yes how frequently are these other blood specimens (eg. CD4 count) sent to the 
laboratory? ONLY ONE RESPONSE 
1= Daily        
2= on certain standardised day/days of the week   
3= Once a week (no standardised day i.e. adhoc whenever there are enough 
specimens to send) 
4= Adhoc basis – sometimes once a week, sometimes fortnightly 
5= not sent to the lab  
6= other 
6.1=  if other specify  
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14.1. If these other blood specimens (eg.  CD4 count etc)  are sent on certain 
standardised day/days of the week, specify which day/days of the week      
____________   &  time of the day (mornings/afternoons) _________________ they 
are sent to the NHLS lab  
 
C. Pretest counseling, providing test result & post-test counseling 
 
15. Who provides pretest counseling for infant  HIV testing CIRCLE ALL THAT 
APPLY 
1= VCT Counsellor (nurse) 
2= VCT lay counsellor 
3= EPI clinic Nurse  
4= Nurse – IMCI trained 
5= Nurse – not IMCI trained 
6= None (eg. PCR testing  not done and results not given)  if None skip to q19 
7= Other  
7.1= if other, specify 
 
16. Who provides PCR test result of the baby to the mother  CIRCLE ALL THAT 
APPLY 
1= VCT Counsellor (nurse) 
2= VCT lay counsellor 
3= EPI clinic Nurse  
4= Nurse – IMCI trained 
5= Nurse – not IMCI trained 
6= None (eg. PCR testing  not done and results not given)  
7= Other  
7.1= if other, specify 
17. Does the same person who gives PCR test result provide post-test counseling for 
infant HIV testing?  
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1= Yes -> if yes skip to q19 
2= No 
 
18. If no, who provides posttest counseling for  infant HIV testing   CIRCLE ALL 
THAT APPLY 
1= VCT Counsellor (nurse) 
2= VCT lay counsellor 
3= EPI clinic Nurse  
4= Nurse – IMCI trained 
5= Nurse – not IMCI trained 
6= None (eg. PCR testing not done and results not given)  
7= Other  
7.1= if other, specify 
 
19. Who provides posttest counseling for mothers that received testing on themselves 
CIRCLE ALL THAT APPLY 
1= VCT Counsellor (nurse) 
2= VCT lay counsellor 
3= EPI clinic Nurse  
4= Nurse – IMCI trained 
5= Nurse – not IMCI trained 
6= None (eg. rapid HIV testing  not done and results not given) ->  if none skip to 
q21 
7= Other  
7.1= if other, specify 
20. Who provides pretest counseling for  mothers that receive HIV testing  CIRCLE 
ALL THAT APPLY 
1= VCT Counsellor (nurse) 
2= VCT lay counsellor 
3= EPI clinic Nurse  
4= Nurse – IMCI trained 
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5= Nurse – not IMCI trained 
6= None (eg. rapid HIV testing  not done and results not given)  
7= Other  
7.1= if other, specify 
21. Where do mothers receive their infants PCR test results / post-test counselling: 
PROMPT 
1= in a separate room allocated for VCT 
2= in a separate routine consulting room 
3= in any available private space in the clinic 
4= in any available public space in the clinic 
5= Outside the clinic – under a tree or in a private space outdoors 
6= Others  
6.1= if other specify 
22. If there is a separate room available for post-test counseling, write down the 
directions to the room or the room name or number of the place where mothers 
receive PCR test results / post-test counseling. 
 
 
 
 
 
 
23. If  HIV testing is not done in this facility or if there is no separate room available for 
post-test counselling, write down  the full address of   the nearest facility where 
infants can be referred for receiving PCR test results & post-test counseling 
 
Name 
 
Address 
 
 
 
 
 
 
 200 
  
 
   
 
D. Supplies  (Skip this section if no PCR testing service is given from q1 & q 2) 
24. Do you have PCR test kits in stock today (field worker should ask to see the kits)?   
1 = Yes    2= No  -> if no skip to q26 
 
25. For the field worker to see: are all within the expiry date (ask to see the kits)? 
1 = Yes    2= No 
 
26. Does the clinic have stock-cards (or a similar system) to track supplies of PCR test 
kits  
1 = Yes    2= No 
27. How frequently  do you order PCR kits  ONLY ONE RESPONSE 
1= Daily 
2= Weekly - on a set day of the week 
3= Weekly – adhoc days  
4= Monthly 
5=  Other  
5.1= if other, specify 
28. Who is responsible for keeping track of PCR stock? 
1= EPI nurse 
2= IMCI nurse 
3= VCT nurse 
4= other  
4.1 if other, specify 
 
29. Has there been any day in the last month when the clinic ran out of PCR stock? 
1= Yes,               2= No  -> if no skip to q30 
29.1. If yes, for how long _________________ 
 
E. Mother baby follow-up system - registers & cards 
30. Is there any clinic-held recording system or register that tracks postnatal PMTCT 
follow-up of mother infant pairs?   
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1=Yes     
             2=No -> if no skip to q36 
30.1. If yes, in which unit(s) of the facility is this register(s) kept (ask to see & confirm).  
PROMPT RESPONDENT & CIRCLE ALL THAT APPLY 
1= At separate PMTCT clinic 
2= At immunization clinic 
3= At IMCI/sick baby clinic 
4= At VCT clinic  
5= Have one register for each of IMCI & immunization clinic 
6= Have one register for each of IMCI, immunization & PMTCT clinic 
7= kept in a room with multiple services (i.e PMTCT, IMCI, immunization given in 
same room)  
8= Other  
8.1= if other Specify 
 
 
30.2.If yes, which of the following is captured in this register(s) (ask to see & confirm): 
TICK ALL THAT APPLY 
Maternal testing                       
Maternal HIV status                           
 Infant PCR testing done at 6wks                
 Infant PCR testing done at any age                
 Infants HIV status                  
 Infant CD4 count     
 Mothers CD4 count              
Infant referral for ARV                
Mother referral for ARV                 
Infant & mother referral for support & care      
Infant postnatal prophylaxis     
Infant Cotrimoxazole  (bactrim)      
 Infant feeding      
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To the interviewer: write “no record” if there was no record for some of the 
questions 
31. According to this record(s), between September 1 & Nov 30, 2009, how many 
infants were tested for HIV at 6 weeks (DNA PCR) 
 
31.1.Of these infants tested for HIV at 6 weeks using DNA PCR how many were HIV 
positive  (If this is not recorded, please write not recorded) 
 
32. According to this record(s) , between September 1 & Nov 30, 2009, how many 
infants were tested for HIV using PCR in total (regardless of age) 
 
32.1.Of these infants (tested at any age) how many were HIV positive  
 
33. How many were routinely given Cotrimoxazole (bactrim)  at 6 weeks  as part of a 
PMTCT intervention_____ 
 
 
34. According to this records, between September 1 & Nov 30, 2009, how many of the 
HIV positive  infants were referred for ARV treatment _____ 
 
 
35. According to this record between September 1 & Nov 30, 2009 how many mothers 
were known HIV positive (both newly diagnosed & already 
known)___________________  
 
35.1. How many of these HIV positive mothers were  given  CD4 Count after giving 
birth  ______ 
35.2. Of those whose CD4 count was done, how many were documented  as having a 
CD4 cell count <200__ 
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35.3.How many of  the mothers with <200 CD4 count  were referred for ARV  service 
____ 
 
36. Is there any patient-held system that facilitates linkages between maternal antenatal 
and postnatal    care e.g. postnatal card/RHTC? 
1=Yes     
 2=No  -> if no skip to q37 
36.1. If yes, specify which card is used  CIRCLE ALL THAT APPLY 
1= postnatal card 
2= RHTC  
3= Antenatal card  
4= Other 
4.1= if other, specify  
36.2.If RTHC is used, which RTHC is currently used in the clinic?  
1= The new RHTC booklet   
2= The old RTHC with the coding system 
3= The RTHC with stamp 
4= The old RTHC with no coding system and no stamp 
5= Other 
5.1= if other specify  
37. Is there a PMTCT clinic in your facility? 
1= Yes  
2=No  ->  if no skip to q38 
37.1. If yes, which day(s) of the week does the PMTCT clinic run? CIRCLE ALL THAT 
APPLY 
1= Monday    4=Thursday 
2= Tuesday   5= Friday 
3= Wednesday                       6= Everyday  
38. Do infants born to PMTCT mothers receive immunizations at certain specific 
day/days of the week? 
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1= Yes  
2= No->  if no skip to q39 
 
38.1.If yes,  on which day/ days of the week do they  receive immunization service 
CIRCLE ALL THAT APPLY 
1= Monday    4=Thursday 
2= Tuesday    5= Friday 
3= Wednesday   6= Everyday  
 
39. Which of the following medical records do you use to capture patient level data   
CIRCLE ALL THAT APPLY 
1=  electronic  medical records (EMR)  
2= Paper based  -> if paper based skip to q40 
3= both electronic & paper based  
4= Other 
4.1= If other, specify  
 
39.1.Which electronic  medical records  do you use 
 
40. Do you capture your PMTCT data on an electronic database   
1= Yes  
2= No  ->  skip to q42 
 
41. If yes, please specify what system/database you use 
 
F. Referrals 
42. Do you normally routinely ask all mothers at 6 weeks visit whether they had HIV 
test (& received their result) during their last pregnancy    
1=Yes   
2=No 
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43. If yes, do you refer or provide VCT for  mothers who haven’t been  tested during 
pregnancy  
1=Yes   
2=No 
 
44. Do you normally ask  HIV positive mothers (as identified by the RTHC or mothers 
report)   when her last CD4 count was done  after delivery 
1=Yes   
2=No  -> if no skip to q46 
 
45. If yes, do you routinely  identify & provide CD4 count test for  mothers who haven’t  
had  a CD4 count  since giving birth 
1=Yes   
2=No 
 
46.  Can you please  tell us the name & address of the clinic/facility  where blood is 
taken /drawn for CD4 count test  
Name 
 
Address 
 
47. If you provide CD4 count test, what is the average turnaround time for a return of 
maternal CD4 cell count result i.e. the number of weeks from the day the specimen 
has been taken from the mother to the day that the facility  receives the results?  
 
48. Do you refer HIV positive infants (as identified by the RTHC or mothers report)  for 
CD4 count 1=Yes   
  2=No 
49. Do you refer HIV positive infants to ARV clinics?  
1=Yes 
2=No 
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50. Is there an ARV clinic (for children) in this facility?  
1 = Yes  
2=  No  -> if no skip to q52 
 
51. If yes, write down the room number or describe how to get to the room where the 
ARV clinic runs 
 
__________________________________________________________________
_____ 
 
 
            
________________________________________________________________________ 
52. If there is no ARV clinic  in this facility then write down the name  and address of 
the facility to which children are usually referred (more than one clinic can be 
stated) 
 
Name 
 
Address 
 
 
53. Is there a specific person that you refer them to?   1=Yes    2= No   
If yes, who ?  
Person’s name: 
 
 
53.1. Do you telephone and make an appointment for the infant or do you simply refer 
with a letter (no appointment) 
1= Referral letter written and appointment made 
2= No referral letter written but appointment made 
3= Referral letter written but no appointment made 
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4= Other 
 
53.2. Is there a follow-up mechanism in your clinic to  monitor how many referred 
children actually went to the ARV clinic?  
1= Yes  
2= No 
53.3. Do you know whether there is a follow-up mechanism in the ARV clinic to track 
attendance of children and follow-up of non-attendees?  
1= Yes  
2= No  
3= Don’t know 
54. Which day(s) of the week does the paediatric ARV clinic run? 
1= Monday                          4= Thursday              7= Don’t know  
2= Tuesday                          5= Friday   8= Other 
3= Wednesday                     6= Everyday   8.1. = if other specify 
55. Do you refer HIV positive mothers to ARV clinics?  
1=Yes  
2=No 
56. Is there adult ARV clinic in this facility?  
1=Yes  
2=No  -> if no skip to q58 
 
57. If yes, write down the room number or describe how to get to the room where the 
ARV clinic runs 
 
_____________________________________________________________________
__________ 
 
      
________________________________________________________________________
________ 
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58. If there is no ARV clinic in this facility then write down the name  and address of 
the facility to which mothers are usually referred (more than one clinic can be 
stated) 
 
Name 
 
Address (street name  & room no) 
 
 
 
59.  Is there a specific person that you refer them to?    1= Yes   2= No     
If yes, who? 
 
Person’s name: 
 
 
60. Which day(s) of the week does the adult ARV clinic run? CIRCLE ALL THAT 
APPLY  
 
1= Monday    4=Thursday                      7= Other 
2= Tuesday   5= Friday    7.1= If other specify  
3= Wednesday                       6= Everyday                 8= Don’t know 
 
61. Do you refer HIV positive mothers to community based support & care services?  
1=Yes   
2=No 
 
62. Do you have referral forms/letters to refer (ask to see & confirm): 
62.1. Infants to ARV clinics:                                                                1= Yes      2= No  
62.2. Mothers to ARV clinics:                                                             1= Yes       2= No 
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62.3. Infants to community based support & care services:                1= Yes       2= No 
62.4. Mothers to community based support & care services;              1= Yes      2= No 
 
63. For the interviewer: Which of the following clinic staff participated in the interview    
CIRCLE ALL THAT APPLY 
1= PMTCT nurse 
2= Immunization nurse 
3= IMCI/sick baby nurse 
4= VCT nurse 
5= clinic manager  
6= Other 
6.1= if other, specify  
Section II - Interview with clinic manager  
A. Training need assessment  
 
1. We would like to know more about the number of staff members in this facility, 
 Total 
number in 
facility 
PCR VCT How to 
immuniz
e 
children 
Routine child 
health services 
ARV 
services 
Do / 
provid
e 
service 
Traine
d in 
SOP 
for 
PCR 
Do 
Counselin
g 
Do 
VC
T 
Formally 
trained in 
VCT 
Do Trained 
in how 
to 
provide 
EPI 
services 
See sick             
children  
Trained in 
IMCI 
Do Trained in 
ARV 
initiation 
or 
monitoring 
Professional 
nurses 
            
Staff nurses             
Enrolled 
nurse 
assistant 
 
 
           
Lay 
counselors 
 
 
           
Doctors  
 
           
Other 
(specify) 
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what they have been trained in and what services they provide. Instruction to 
interviewer: if a service is not provided or no-one has been trained please write 
zero 
 
 
2. Of those staffs who provide EPI service,  how many  have been formally trained in 
how to do infant PCR testing?   
3. What have been the barriers to training on infant PCR? CIRCLE ALL THAT 
APPLY 
1= No time for training – clinic too busy 
2= No money for training 
3= Other  
3.1.If other specify  
 
4. If some staff members have been trained, have you experienced any barriers to 
offering PCR tests at EPI clinics?  
1=Yes 
2=No -> if no skip to q 6 
 
5. If yes, what are these barriers? CIRCLE ALL THAT APPLY 
1= Mothers resistant to HIV testing/ Mothers fear of disclosing status 
2= No time at EPI clinics 
3= No supplies for PCR testing 
4= Person other than mother brings infant to the clinic 
5= Staff shortages 
6= Too few staff trained 
7= No one trained on pre & post counseling  
7.1.Other 
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6. Of those staff who provide IMCI/sick babies, how many have been formally trained 
in how to do infant PCR testing? (give a definite number)  
 
7. If some staff members have been trained, have you experienced any barriers to 
offering PCR tests at sick child clinics?   1= Yes   2= No  -> if no skip to q9 
 
 
8. If yes, what are these barriers? CIRCLE ALL THAT APPLY 
1= Mothers resistant to HIV testing 
2= No time at sick child clinics 
3= No supplies for PCR testing 
4= Person other than mother brings infant to the clinic 
5= Staff shortages 
6= Too few staff trained 
7= No one trained on pre & post counseling  
8= Other 
7.1. If other specify 
 
9. Please tell us if you have used any of the following to improve your PMTCT 
services?  
9.1. Task shifting   1= Yes   2= No  
9.1.1. If yes, please explain what you have done 
 
 
 
 
 
9.2. Re-organising the clinic flow 1= Yes   2= No  
 
9.2.1. If yes please explain what you have done 
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9.3. Mothers to mothers groups 1= Yes   2= No  
 
9.4. Lay counselors 1= Yes   2= No  
9.4.1. If yes please explain how you use lay counselors in your clinic  (circle all that 
apply) 
1=  to do counseling  
2= do  testing for HIV 
2= to weigh babies 
3= to fill in the PCR form 
4= to do infant feeding counseling 
5= to clean the clinic 
6= to  talk to HIV positive mothers 
7= other 
7.1= if other, specify 
B. Attitude   
 
10. In your opinion, who / which service should offer routine infant DNA PCR testing? 
CIRCLE ALL THAT APPLY 
1= EPI/immunization clinic 
2= IMCI/sick baby clinic 
3= PMTCT clinics 
3= Hospitals only 
4= HIV clinics only 
5= Other   
5.1 = if other specify 
 
11. Can you give us reasons for  your answers   
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12. Would you be willing to send your EPI and IMCI / child health staff on DBS 
training sometime this year?      1= Yes   -> if yes skip to 13 
               2= No 
 
12.1.If no, please state why 
 
C. Arrangement of logistics for the 6 weeks survey  
Interviewer read out:  The following questions are aimed at assisting us with logistical 
arrangements for the 6 week survey. We would like to make arrangements for a suitable 
area to conduct the interviews, storage of blood samples and returning of lab results. 
Accommodation  
13. Is there accommodation within or nearby the facility (e.g. nursing residence)?   
1=Yes   
2=No      -> if no skip to 19 
14. If available, can we use your facility’s accommodation during the data collection 
period? 
1=Yes   
2=No  
3= Don’t know  
14.1.If don’t know, can you tell me who I can ask/talk to    
 
15. How many people can be housed in your facility’s accommodation  
16. Does the room(s) have a bed or beds? 
1=Yes                  if yes how many ______ 
2=No 
17. Does the room(s) has cooking utensils 
1=Yes   
2=No 
18. Do you serve food?   
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1= Yes                             if yes how much do you charge per dinner ___ 
2=No    
 
19. If accommodation is not available  within the facility, can you please give us your 
suggestions where field workers can stay during the survey (B&B or private homes)  
- get the name, address & contact number of this accommodations 
 
 
20. Do you perhaps know the costs of  these B&Bs/private homes  
 
 
Transport  
21. For the fieldworker: What is the road type that this clinic is on 
1=Tar 
2=Gravel 
3=Sand / dirt 
4=Other 
4.1= If other, specify: 
 
22. What is the suitable Car type for this road 
1=Normal motor vehicle 
2= by 4  SUV, Venture, bakkie, Condor 
3= 4 by 4 SUV, Venture, bakkie, Condor 
4= other 
4.1.= if other, specify 
23. Is there a regular Taxi/Bus/train that can be used to get to the facility -> if no to all 
skip to q25  
Tick all that apply 
Taxi   
Bus 
Train  
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24. If yes, ask how frequently does it run 
24.1. Taxi 
24.2. Bus 
24.3. Train  
24.4.1. Is there a 6am train in the morning? 
 
25. Cost of Taxi  from the nearest B&B /local private houses  to  the facility 
 
26. Cost of Bus from the nearest B&B /local private houses  to  the facility 
 
27. Cost of Train  from the nearest B&B /local private houses  to  the facility 
 
Other logistics (local field workers,  interview space & clinic address) 
28. Do you know anyone who has previous field work experience & that lives within the 
district/sub district?  
1= Yes 
2= No 
29. If yes,  can you give us the contact addresses of this person(s) & encourage them to 
send their CV to the following address: targetedevalhsur@gmail.com fax: 
0219380483 (instruction to the field worker: post the field workers advert on the 
clinics notice board after asking permission  of the clinic manager)  
 
30. We know that space is problem in most facilities but would you be able to allocate a 
space for us to interview mothers and collect DBS spots from babies when the 
national survey starts?   
1=Yes 
2=No 
 
31. If yes, ask to see this space & note what equipment this space has. Ask if you 
would be able to get a chair for the mother and a surface that you could use to lay 
the baby down when doing the DBS testing. (to the field worker: Note that some 
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small clinics may not be able to provide you with a room –  therefore any quite 
corner which is not far from the EPI clinic area & a place/or chair  to comfortably 
sit the mother will be enough.) 
 
 
32. Ask if we can use a corner of any secure room in the clinic for drying blood 
specimens (write down agreed room for drying specimens). Report if space is a 
major problem in the clinic. 
 
33. Ask for a secure place to keep the 6 weeks survey PCR specimens until collection 
time (write down  agreed  room for storing specimens)  Report if space is a major 
problem in the clinic 
 
34. What is the referral clinics postal address for return of PCR results    
 
Section III – Interview with key person/nurse that coordinates or provides 
immunization service 
 
Introduce the study to the interviewee using the information sheet & receive signed 
consent   before starting the interview 
 
1.  Are immunizations done every day?  
1= Yes  
2= No 
2. Is there any particular day / days of the week when more immunizations are done 
(compared with other days) – ask to see the register & confirm 
 
To the interviewer: Review the immunization register & capture the following data: 
3. How many DPT 1 Immunizations were done last week = __________ 
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4. How many DPT 1 Immunizations were done on the month of November 2009 = 
__________ 
5. How many DPT1 Immunizations were done from September 1 to November 30, 2009 
=_______ 
 
6. Do you provide PCR testing  when infants come for their 6 week immunization??   
PROMPT  
1= Yes we provide PCR testing at immunization clinic 
2= Yes we provide PCR testing in conjunction with VCT/PMTCT clinics     
3= No    if no Skip to q 8 
 
7. If yes how do you identify HIV exposed infants  at 6weeks? CIRCLE ALL THAT 
APPLY 
1= give rapid test to all mothers who presents at 6 weeks immunization visit 
2= from register 
3= if mother reported 
4= we ask mothers their status    
5= from the RTHC  
6=Antenatal card 
7= Others 
7.1= If other specify 
 
8. In your opinion, is it a good idea to offer infant DNA PCR testing routinely as part of 
EPI/immunization services?    
1=Yes  -> skip to q10 
2= No 
 
9.  If no, please state why: 
1= It is not part of Immunisation nurses responsibilities 
2= There is not time to do this 
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3= It is a good idea but it is not part of immunization nurses responsibilities or 
there is no time 
4= There is not enough staff to do this 
4= Other  
4.1=if other, specify 
 
10. If yes, in your opinion is it feasible to offer DNA PCR testing as part of routine EPI 
services?  
1=Yes  
2= No 
 
a. Please explain your answer 
 
 
11. Do you normally ask all mothers at 6 weeks visit whether they had HIV test (& 
received their result) during their last pregnancy    
1=Yes   
2=No 
12. If yes, do you refer or provide VCT for  mothers who haven’t been  tested during 
pregnancy  
1=Yes   
2=No 
13. Do you normally routinely ask  HIV positive mothers (as identified by the RTHC or 
mothers report)  at 6 weeks visit  when her last CD4 count was done 
1=Yes   
2=No 
 
14. If yes, do you routinely  identify & provide CD4 count test for  mothers who haven’t 
been checked  for their  CD4 count  since giving birth 
1=Yes   
2=No 
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15. Do you refer HIV positive infants (as identified by the RTHC or mothers report)  for 
CD4 count 1=Yes   
       2=No 
 
Section IV - IMCI/sick baby head nurse  
 
Introduce the study to the IMCI/sick baby head nurse using the information sheet & 
receive signed consent   before starting the interview 
1. Do you offer PCR testing for HIV-exposed infants at sick baby clinic?  
1=Yes 
2=No 
2.  If yes how do you identify HIV exposed infants for PCR testing? CIRCLE ALL 
THAT APPLY 
1= Symptoms of infants 
2= from clinic register 
3= from patient folder 
4= from the RTHC  
5= from mothers/caregivers report 
4= Others 
4.1= If other specify 
3. Is it a good idea to offer infant DNA PCR testing routinely as part of routine IMCI 
/sick child services  
1=Yes  
2= No 
4. If it is a good idea, do you think it is feasible to offer DNA PCR testing as part of 
routine IMCI/  ill child care??  
 
4.1. Please explain your answer 
 
 
 
 
 
 
 220 
  
 
   
 
5. Do you normally routinely ask all new mothers whether they had HIV test (& 
received their result) during their last pregnancy    
1=Yes   
2=No 
6. If yes, do you refer or provide VCT for  mothers who haven’t been  tested during 
pregnancy  
1=Yes   
2=No 
7. Do you normally routinely ask  HIV positive mothers (as identified by the 
RTHC/other registers or mothers report)  when her last CD4 count was done 
1=Yes   
2=No 
8. If yes, do you routinely  identify & provide CD4 count test for  mothers who haven’t 
been checked  for their  CD4 count  since giving birth 
1=Yes   
2=No 
9. Do you refer HIV positive infants (as identified by the RTHC , registers or mothers 
report)  for CD4 count 1=Yes   
    2=No 
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